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 The fight against tuberculosis (TB), has been further complicated by both 
the emergence of multidrug resistant strains of the organism, along with its 
coinfection with Human Immunodeficiency Virus (HIV). Since current TB regimens 
reduce the efficacy of highly active antiretroviral therapies (HAART) by cytochrome 
induction, TB and HIV cannot be treated simultaneously. With mortality rates of 
TB–HIV coinfected people rising globally, the scientific community has seen 
renewed vigor in the search for a novel, noncytochrome inducing antitubercular, 
agent. In a screen conducted at the University of Utah, the natural product amicetin 
was identified as a potential scaffold with antitubercular activity, noncytotoxicity, 
and compatibility with HAART.  
The first generation of analogs aimed to simultaneously reduce the 
complexity involved in the synthesis of the disaccharide moiety and replace the 
acid labile glycosidic linkage. It was shown with analog CZ–02–023 that despite 
the removal of eight stereocenters from amicetin, potency (IC50 of 0.98 µM 
against Mtb) and on–target selectivity (SIRR/E.coli =111) could be retained.  
          The crystal structure of Ami bound to the Peptidyl Transferase Center (PTC) 
of the T. thermophiles 70S ribosome elucidated amicetin’s important binding 
interactions, includes a cation– interaction of its terminal aminosugar with A2450 
and a Watson–Crick base pair between its cytosine portion and G2262. 
iv 
 
Additionally, hydrogen bonding of amicetin’s α–methylserine moiety with the 
phosphate backbone of G2506 and – stacking with the p–aminobenzoyl moiety 
with A2613 were observed. Not only did this data demonstrate amicetin’s binding 
to the therapeutically unexploited PTC, it served to guide intelligent SAR 
development which led to the synthesis of CZ–02033 and CZ–02039 with broad 
spectrum activity and faded on–target selectivity (SIRR/E.coli < 3).  
The loss of on–target selectivity prompted further modifications to the 
Cytosine–PABA region in a series of third generation analogs based on the 
knowledge of the crystal structure of the Ami–70S–tRNA ternary complex. The 
third generation piperazinyl urea analogs including CZ–02–117, CZ–02118, and 
CZ–02–132 increased selectivity (SIRR/E.coli >400). Efforts continue to further the 
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Tuberculosis: Cause and Spread 
Tuberculosis (TB) is an infectious disease caused by the bacterial pathogen 
Mycobacterium tuberculosis (Mtb) and is the leading cause of death among any 
single infectious pathogen. TB has been known by many aliases throughout history 
such as Consumption, Phthisis, Scrofula, Pott’s disease, and the White Plague.1, 
2, 3  It is also called Koch’s disease, which is named after the German scientist 
Robert Koch who in 1882 first discovered Mtb as the etiologic agent.4, 5 There are 
three major types of tubercle bacilli that are capable of causing TB: Mycobacterium 
tuberculosis, the most common bacilli which affects humans and is simultaneously 
spread by humans;  Mycobacterium bovis, which is spread by infected cattle and 
has the potential to affect humans as well as other mammals; Mycobacterium 
avium–intracellualare complex (MAC), which is transmitted through infected birds, 
which can cause infections in birds, pigs, and especially in immunocompromised 
individuals such as HIV patients.6 In general, TB is an airborne disease, 
transmitted from person to person by inhalation of respiratory droplets (coughs or 
sneezes) of an active TB infected (TB disease) individual. The infection primarily 
targets the lungs (pulmonary TB); when the air droplets containing Mtb bacteria 





through the blood stream to other organs of the body, including the kidney, spine, 
brain, lymphatic, and nervous systems (extrapulmonary TB). With the apparent 
ease of transmission, it is assessed that nearly one-third of the world’s population 
harbors the asymptomatic latent or dormant form of TB.7, 8, 9, 10, 11 
Not all individuals who are exposed to Mtb bacteria become symptomatic, 
and are able to transmit the disease to others; however, exposure to Mtb leads to 
two–TB related conditions; a) latent TB infection, and b) TB disease.12 
 
Latent TB Infection 
Latent tuberculosis infection (LTBI) is a condition in which a person’s 
immune system defends the body against the attack by Mtb bacteria and takes 
control over the bacteria to prevent them from developing into the active disease.  
In the latent infection, an individual is already exposed to bacteria, but it can remain 
dormant for years by forming a thick waxy coat on its cell wall. Individuals with 
latent TB infection are asymptomatic, cannot transmit TB to others, and do not fall 
ill. However, they show positive skin tests, positive blood tests, normal chest x– 
rays, and negative sputum cultures.13  
 
Mantoux Tuberculin Skin Test (TST) 
 A tuberculin skin test is a standard protocol performed to determine if a 
person is infected with Mtb bacteria.  The test is carried out by injecting 0.1 mL of 
tuberculin purified protein derivatives (PPD) under the epidermal layer of the skin 
with a syringe having the needle bevel facing upward. The test results are read by 





induration of 5 mm in diameter is considered positive in Human Immuno–
deficiency Virus (HIV) infected persons. An induration of ≥ 10 mm in individuals 
from high TB burdened countries, persons with known TB risk factors 
(mycobacteriology lab personnel), and children under 4 years of age is considered 
positive. An induration of ≥ 15 mm in any individual is considered positive. Often, 
TST can create false positive reactions in case of infections with nontuberculosis 
mycobacteria, and in individuals vaccinated with the Bacillus Calmette–Guerin 
(BCG) vaccine. In addition, the TST will not be able to differentiate between latent 
and active TB infections.14 
 
The TB blood test 
The TB blood test also known as interferon–gamma release assay (IGRA) 
while the QuantiFERON®–TB Gold in–tube test (QFT–GIT) is an alternate method 
for tuberculin skin testing performed to find out if a person has TB infection. The 
QFT–GIT measures a cell–mediated immune response using ELISA technology, 
by adding a cocktail of three mycobacterial proteins (ESAT–6, CFP–10, and TB 
7.7)15 to patients’ blood to stimulate T–cell mediate interferon–gamma (INF–) 
release. The TB blood test has improved specificity for Mtb bacteria, latent 
infection, and unaffected by prior BCG vaccination.16 
 
TB Disease 
Not all latent TB infections develop into TB disease. Individuals with LTBI 
are at lifetime risk of developing active TB and high risk in HIV patients. If a 





becomes active and starts multiplying leading to TB disease. Among the 2.3 billion 
LTB infected individuals, approximately 10.4 million people develop active TB 
symptoms annually, with 1.8 to 2 million cases in due course leading to death. 
Nearly 60% of 10.4 million new cases are from six high burden countries such as 
India, China, Russia, Indonesia, Pakistan, and South Africa.11 
Active TB disease, which is usually pulmonary TB, is accompanied by 
pertussis, chest pain, and coughing up of blood or sputum (phlegm). Unlike LTB 
infected persons, individuals with TB disease are able to spread the disease. TB 
disease can be diagnosed with positive TST, positive sputum or smear culture 
(samples are examined under a microscope for presence of Mtb bacteria), and 
abnormal chest X–rays (cavities and lesions in lungs).11, 12, 13 
 
Treatment Options for TB (LTBI and TB Disease) 
Effective antituberculosis chemotherapy was first developed in the 1940s, 
with the introduction of Streptomycin, an antibiotic from Streptomyces griseus. 
Later in the 1950s, a few other TB drugs (p–aminosalicylic acid, isoniazid, 
pyrazinamide, cycloserine) with different mechanisms of action were introduced 
into the available therapeutic portfolio. At present, the standard TB drug regimen 
consists of more than 20 drugs11 categorized under different groups. Existing 
chemotherapy for TB heavily depends on drugs that target bacterial metabolism 
and cell wall synthesis.17 Based on their mechanism of action, TB drugs (Table 
1.1) can be classified as cell wall synthesis inhibitors (isoniazide (INH), ethambutol 
(EMB), ethionamide, cycloserine), nucleic acid synthesis inhibitors (rifampicin 





(PNH)), and protein synthesis inhibitors (streptomycin, kanamycin) which bind to 
the small 16S rRNA of the 30S subunit of the bacterial ribosome, interfering with 
the binding of formyl–methionyl–tRNA to the 30S subunit (Table 1.1).18  
Treatment for LTBI involves two options: a six–month isoniazid regimen, 
where patients are asked to take isoniazid for the entire duration under the direct 
observation of a health care worker (DOTS–Directly Observed Therapy, Short 
course), or a 12–dose once–weekly drug combination of isoniazid and rifampin. 
The standard recommended treatment for drug susceptible TB (DS–TB) 
involves a cocktail of four drugs, also referred to as first line drugs. The treatment 
for DS–TB involves two phases, the initial two–month treatment phase which 
involves the administration of a cocktail of four of the first line drugs RIF, INH, PNH, 
and EMB. The continuation of the second phase involves the administration of RIF, 
and INH for the next four to seven months. The four–medicine regimen is effective 
and can cure 85% of drug sensitive TB patients when taken as prescribed. But 
when treatment is inadequate or intermittent and fails to treat DS–TB, the disease 
becomes resistant and more difficult to cure.19 
 
Recurrent TB and drug resistant strains of Mtb 
The incomplete and intermittent TB treatment therapies have resulted in the 
recurrent TB with Mtb resistance, and promoted the development of, multidrug 
resistant TB (MDR–TB) and extensively drug–resistant TB (XDR–TB).  The advent 
of drug resistant strains of TB is posing a problem for developed countries with 
successful and highly focused TB treatment strategies.20, 21, 22 





two most important first line anti–TB drugs from the core of standard treatment 
regimen, which also includes pyrazinamide (PNH), and ethambutol (EMB). XDR 
are referred to the strains of MDR, which are also resistant to fluoroquinolones and 
any of the injectable second line of anti–TB drugs like kanamycin, amikacin or 
capreomycin. In 2009 the term totally drug–resistant TB (TDR–TB) was proposed 
for the TB strains that are resistant in vitro to existing standard treatment regimen 
including all first and second line drugs.11 
According to the World Health Organization (WHO) global TB surveillance 
report 2015, there were about 480,000 reported new cases of MDR–TB.11 The 
MDR–TB treatment requires the administration of second line drugs for two years 
or longer, involving more than 14,000 pills, along with daily injections for a period 
of six months. Almost all medications are associated with side effects, and TB 
medication is no exception. Generally, compared to first line anti–TB drugs the 
second line anti–TB regimen are associated with side effects that are more 
serious. The first line drugs can cause issues related to gastrointestinal issues, 
rashes, and drug induced hepatitis, whereas the second line drugs can result in 
hearing loss, depression, and renal failure. Furthermore, the longer duration, 
intricacies and unaffordable cost of continuing to treat MDR–TB results in only a 
50% success rate in curing MDR–TB patients around the world. The rapid increase 
in TB disease burden and 50% of the world’s MDR–TB cases are accounted for 
by the two most populous countries in the world, India and China. The immense 
TB population from these two countries (around 100,000 each) increases the 





Health Organization (WHO) on drug resistance surveillance data, an estimated 
average of around 10% of MDR–TB cases have developed into XDR–TB. The 
treatment for XDR–TB is more complex, expensive, and lengthier, often impossible 
to cure and ultimately leads to death.11, 23, 24 
The XDR–TB patients who have received an erratic, intermittent and 
incorrect doses have developed TDR–TB often referred to as extremely drug 
resistant TB (XXDR–TB).24 The term extremely drug resistant was first used in 
2007 by Migliori and co–workers to describe the strains of Mtb (cases from Italy) 
that are resistant to almost all the first line and second line anti–TB drugs.25 After 
the initial reports of XXDR–TB strains, two years later in Iran, Velayati co–workers 
used the term totally drug resistant to describe the similar strains as XXDR–TB 
that are resistant to all first and second line anti–TB drugs in vitro. The patients 
affected with TDR–TB remained culture and smear positive even after 18 months 
of treatment with second line drugs.26 The alarming progress in the emergence of 
lethal resistant strains of Mtb have been reported in at least three countries. 
Although the term TDR–TB has not yet been accepted by the WHO, in 2012, an 
article on TDR–TB cases in India authenticating Mtb strains exhibiting resistance 
to every drug available to treat TB gained worldwide attention.27, 28 In spite of their 
clinical differentiations in drug–susceptibility test results, the reported cases of 
TDR–TB or XXDR–TB are officially classified under XDR–TB. While poor clinical 
and control practices result in the development of TDR–TB strains, the treatment 
options for TDR–TB remain dismal. Many factors are aggravating the spread of 





infection control; however, a key factor is its synergistic relation with HIV. 
 
TB–HIV Co–Infection 
Preliminary anecdotal evidence suggests two ways through which the 
incidence of drug resistant TB increases: acquired resistance and transmitted 
resistance as in case of HIV coinfection.29 In persons co–infected with both HIV 
and either latent or active TB, each disease speeds up the progression of the other. 
In particular, HIV in particular can facilitate the progression of latent to active TB, 
and in turn, the TB can worsen the HIV infection. In a deadly synergy of HIV and 
TB infection, TB remains the leading cause of death among persons with HIV 
coinfection. The huge upsurge in the prevalence of TB epidemic can be attributed 
to high incidence of HIV infection, collectively leading to TB–HIV synergistic 
pandemics.28 Together, these are the two deadliest infectious diseases worldwide, 
killing four million people every year. Globally, people with HIV are at higher risk 
(26 times) to develop active TB than those who are HIV–negative. According to 
global TB report by WHO in 2016, an estimated 14% (1.4 million) among the 10.4 
million people who developed active TB were HIV positive. In 2015, there were 1.8 
million deaths from TB, the toll comprised of 0.4 million (~27%) of people who were 
HIV–positive.11  
The situation was further complicated by the drug–drug interactions that 
impede the co–administration of the current regimen for TB along with anti–
retroviral therapy. The major concern in confronting global HIV (viral infection) and 
TB (bacterial infection) epidemics is developing a compatible treatment regimen. 





antiretroviral therapy (ART for HIV) and antibacterial (for TB) drugs, and 
overlapping adverse side effects. The main issue being the ART and antibacterial 
treatment regimen compatibility.30, 31 
The first line anti–TB drug RIF upregulates the expression of the hepatic 
cytochrome P450 (CYP2C9 (5.6–fold) and CYP3A4 (47–fold) oxidase system 
responsible for the metabolism of HIV protease inhibitors (PIs), thereby resulting 
in subtherapeutic plasma levels of ART medication which makes it inefficacious. 
Even so, the use of CYP450 inhibitors (for example Ritonavir) could not maintain 
and rescue the therapeutic levels of PIs, thereby impeding the co–administration 
of PIs, whether boosted or not, along with current regimen for TB (RIF). This 
situation of drug–drug interactions resulted in the only treatment option for HIV–
infected TB patients being the use of non–nucleoside–reverse–transcriptase–
inhibitors (NNRTI), leaving none for patients with NNRTI mutations. However, the 
advances in identifying new RIF analogs with minimal drug–drug interactions 
(reduced CYP induction), such as rifabutin, were in vain because the presence of 
the CYP inhibitor ritonavir in PIs cocktail regimen results in increased serum 
concentration of rifabutin, ultimately increasing its associated toxicity.32, 33, 34, 35, 36  
 
TB Pipeline 
 TB remained a neglected disease for long time, and drug discovery efforts 
toward developing antitubercular drugs remained unattended. However, significant 
progress has been made in the TB treatment pipeline with the initiatives taken by 
WHO, TB Alliance (TBA), and the Bill and Melinda Gates Foundation to fight 





Although, in the last ten years various new drug candidates have 
progressed to different phases of clinical trials, while in particular, the last year has 
been a big setback for the development of antitubercular drugs with the 
discontinuation of AZD–5847 (AstraZeneca–5847), due to its lack of in vivo 
potency against TB, and TBA–354 (signs of neurotoxicity).  
The other concerning fact is, the majority of newly approved drug 
candidates are the analogs of existing TB drugs (known drug resistance) such as, 
gatifloxacin, and moxifloxacin (fluoroquinolones) for treatment of MDR–TB as 
second line drugs. Linezolid (oxazolidinone) was introduced into TB treatment 
therapy for treating MBR and XDR–TB, albeit, it has associated side effects include 
painful nerve damage. Rifampin analogs such as rifapentine and rifabutin were 
developed to shorten the treatment for LTBI, and DS–TB in combination with 
isoniazid (Figure 1.1).30, 37, 38, 39, 40, 41, 42, 43, 44, 45  
In over 50 years, after the introduction of Rifampin (1966) the two new 
classes of drugs that were introduced into TB treatment regimen for treating DR–
TB are Delamanid and Bedaquiline. 
 
Delamanid (Deltyba®) 
 Delamanid is a nitro imidazole class of antibiotic developed by Ostuka 
pharmaceutical company for treating pulmonary MDR–TB in adults in combination 
with standard drug regimen. Delamanid was approved in early 2014 by the 
European Medical Agency (EMA), and targets the cell wall by inhibiting mycolic 







 The FDA approved Bedaquiline, a novel bi–aryl quinolone class of antibiotic 
developed by Janssen Pharmaceutica, on a fast track basis in late 2012 (in late 
2014 by EMA) for the treatment of DR–TB as part of combination therapy in adults. 
It targets ATP synthase and interferes with bacterial energy metabolism, which is 
a different mechanism of action from the existing TB drugs.  
The WHO, as last resort drugs for treating DR–TB that lacks viable 
treatment options, placed both Delamanid and Bedaquiline on the list of essential 
medicines. However, the biggest concern with these drugs is their associated side 
effects such as prolonging the QT interval (irregular heartbeat), neurological 
disturbances and hyperuricemia (excess uric acid in blood). In fact, Bedaquiline is 
marketed with a warning label of potentially increased mortality from life–
threatening abnormal heartbeats. The more concerning fact is that just a year after 
the introduction of these drugs to the TB regimen, acquired resistance was seen 
in Mtb strains causing XXDR–TB in a Tibetan refugee in Switzerland.44, 45, 46 
Even after the discovery of etiology and half a century of medical advances 
in the therapeutic area of TB, the global TB epidemic seems persistent. The 
unabated TB epidemic situation highlights the drawbacks of the existing TB 
treatment strategies. To control the global epidemic of TB there is a requirement 
for new TB drugs, which can: 1) shorten and simplify treatment duration 2) are 
effective against MDR and XDR–TB strains 3) are compatible with antiretroviral 
therapy 4) are effective against latent or dormant infection 5) minimize resistance, 





and fewer or no side effects.30 
 
University of Utah Natural Products Screening:  
Amicetin as a Viable Lead 
In the course of the search for potential TB drugs with new scaffolds 
possessing the aforementioned requirements, we revisited and screened a small 
molecule library of natural products and synthetic derivatives at the University of 
Utah for antitubercular activity and further tested for mammalian toxicity and CYP 
induction properties, in collaboration with Professor Louis R. Barrow’s group 
(Department of Pharmacology and Toxicology University of Utah). Screening has 
led to the identification of amicetin, an old under explored natural product, as a 
possible lead compound that potentially suits this profile. This natural product is 
active against the attenuated mutant strain Mtb–H37Ra with an IC50 of 0.24 µM. 
 Amicetin showed limited cytotoxicity when tested against the CEM/TART 
T–Cell leukemia cell line (IC50 of 4.4 µM). In addition, it showed negligible 
mammalian cytotoxicity: a) against human mammary epithelial cell line MCF–10A 
(EC50 of 74 µM); b) against breast cancer (MCF–7) cell line (EC50 of 84 µM); c) 
against monkey kidney epithelial cells (Vero IC50 = >100 µM); d) and against 
human liver cancer cell line (Hep–G2 IC50 = >100 µM). More importantly, it shows 
no significant activation of hepatic cytochromes (< 2–fold induction of CYP2C9 and 
CYP3A4) as measured by qPCR in the HepG2 cell line (compatible with HAART) 
compared to rifampicin (>54–fold induction).47, 48, 49 All of these properties of 
amicetin are distinct in comparison to the current drug regimen for TB and the 





amicetin (Figure 1.2).  
 
Literature Reports on Amicetin 
Upon exploring literature data on amicetin, it is reported as an amino hexose 
pyrimidine nucleoside antibiotic isolated by J. Hinman and coworkers in 1953 from 
fermentation broths of Streptomyces vinaceusdrappus.50 Amicetin was also 
isolated by various research groups from different Streptomyces species.51, 52, 53 
Stereochemistry and specific configuration of the disaccharide portion in the 
molecule was determined by NMR analysis and synthesis of hydrolysis products.54, 
55, 56, 57, 58, 59, 60, 61 Later in 1981, the crystallographic studies published by Smith et 
al. confirm the structure of amicetin.62 In the seminal isolation paper, amicetin was 
shown to be active against the virulent strain of Mtb–H37Rv with an IC100 = 0.5 
g/mL (0.81 M), against Mtb var. homonis. ATCC 607 with an IC100 = 1.0 g/mL 
(1.62 M), and Staphylococcus aureus (FDA–209) with an IC100 = 2.0 g/mL.  
Amicetin showed no significant activity against Gram (–) bacteria (Table 1.2). In 
addition, it was shown to be active in vivo against Mtb–H37Rv infected mice 
(details unpublished). Further, the reported systemic toxicity of amicetin was 
reasonable with LD50 = 200 mg/kg in rat when administered intravenously (IV), and 
the subcutaneous (SC) LD50 = 600 mg/kg.63, 64  
 
Amicetin–a known protein synthesis inhibitor 
Amicetin was known to exhibit its antibiotic activity by functioning as a 
peptidyl–transferase inhibitor to inhibit protein biosynthesis. In a report by Rychlik 





percentage adduct (CACA–AcLeu–puromycin) formation with respect to antibiotic 
concentration.  Plicacetin, cytimidine, and cytosamine (Figure 1.3) were shown to 
be ten–, fifty– and 100–fold less active than amicetin, respectively, whereas 
oxamicetin, a close structural analog to amicetin, was shown to be a more potent 
inhibitor of the overall peptidyl transferase inhibition activity than amicetin. 
Correlating the decrease in protein synthesis inhibition activity with the absence of 
certain structural features clearly emphasizes the importance of the presence of 
the aminoacyl portion, i.e., L–α–methylserine portion (Figure 1.3). 65, 66, 67 
 
Hypothetical binding site of amicetin 
While amicetin was shown to inhibit protein synthesis, its exact role in 
translation inhibition is unknown. In an effort to determine the exact binding site of 
amicetin to the ribosome, Levive et al. have performed site–directed mutations, 
and chemical foot printing experiments on the highly conserved 23S rRNA, the 
secondary structural motif of larger subunit (50S) of ribosome. The results imply a 
single point mutation in the peptidyl transferase center of domain V, U2547C, has 
shown to be responsible for resistance and has been suggested as the 
hypothetical binding site of amicetin. However, the exact working mechanism for 
amicetin with atomic resolution still remains undefined.68 Another important 
outcome of this experiment was that after 100 passages of H. halobium sp. over a 
period of 1.5 months, the resistant bacteria were sensitive to 2X MIC of amicetin 
(only 2–fold increase in MIC). This result suggests the target mutations at PTC are 






Introduction to the Ribosome 
Amicetin has long been known to inhibit protein synthesis.69 However, the 
atomic details of the mechanism of action have been unknown. Efforts were also 
focused on probing the mode of action of amicetin with molecular details by solving 
their crystal structures bound to the ribosome.70, 71, 72, 73, 74, 75, 76 
Both the prokaryotic and eukaryotic ribosomes consist of two major 
subunits, the small ribosomal subunit, and the large ribosomal subunit. However, 
the prokaryotic and eukaryotic ribosomes differ in their size, structure, and slightly 
in the translation process. These differences offer an opportunity for selectivity in 
which drugs can target the prokaryotic bacterial ribosomes over eukaryotic 
ribosomes. The bacterial 70S ribosomes consists of ~ 54 ribosomal proteins, a 
larger 50S subunit with two different types of ribosomal RNAs (rRNAs; 23S, 5S) 
with ribozyme (a sequence of RNA with enzymatic activity), and a smaller 30S 
subunit comprised of 16S rRNA. The eukaryotic 80S ribosomes composed of ~80 
ribosomal proteins and a larger 60S subunit with three rRNAs (28S, 5.8S, and 5S) 
and a smaller 30S subunit consist of 18S rRNA.77, 78, 79, 80 
 
Structure of Ribosome 
 Until recently, the complexity and dynamic nature of ribosomes made it 
difficult to understand the relationship between structure (dynamics) and function. 
Since the 1950s disclosure of the role of the ribosomes in translation a great deal 
of effort has gone into studying the translational process and how it is hindered by 
ribosomal antibiotics. The ribosome targeting antibiotics bind to specific regions in 





functions. These are used both for probing various steps involved in protein 
translation, and clinically to cure severe infections. Over time bacteria have 
developed resistance to these antibiotics. Therefore understanding the 
mechanisms of bacterial resistance is of great importance as the significance of 
developing potential therapeutics.81, 82, 83, 84, 85 
Initially, the structure of the ribosome was visualized by electron microscopy 
(EM) and advanced with cryo–EM techniques that could capture different phases 
of protein synthesis. At first, the rRNAs were regarded as scaffolding units for the 
catalytically active r–proteins. Later, the significant contributions from genetic and 
biochemical approaches have changed the perception of the ribosomal 
components and their relative roles, in which rRNAs play a vital role in ribosome 
function, and r–proteins play a supporting role.84, 85, 86 The intrinsic resolving power 
of cryo–EM results did not permit the elucidation of the different functional states 
of translation with minute details of its molecular interactions. However, at the end 
of the twentieth century, advances in the high–resolution X–ray diffraction studies 
(X–ray crystallography) of the ribosome have provided compelling pieces of 
evidence in the translational process. There were no r–proteins closer than 18 Å 
at the peptidyltransferase center (PTC) on 50S subunit, suggesting that the 
translational process is RNA–directed and ultimately based on RNA–RNA 
interactions. Given the significance of the rRNA in translation, it is anticipated that 
most of the protein synthesis inhibitors target the rRNA rich surfaces on both the 
ribosomal 30S and 50S subunits. Significant progress towards understanding the 





ribosomal crystal studies during last two decades.87, 88, 89, 90, 91, 92 
By the early 2000s, all atom crystal structures of individual small 30S and 
large 50S ribosomal subunits of bacterial ribosomes had been solved.92, 93, 94 The 
crystal structures of individual subunits allow us to infer limited information 
regarding the translational process. Since the bacteria use full–length tRNA for its 
protein biosynthesis, the atomic details (crystal structures) of intact 70S ribosome 
complex with integral tRNAs were also resolved and studied at 5 Å and 3.5 Å 
resolution.95, 96 The X–ray crystallographic model of the Thermus thermophiles 
(Tth) entire 70S ribosome embracing tRNA and messenger RNA (mRNA) at 5.5 Å 
resolution accounts for the electron densities for all the ribonucleoproteins (16S, 
23S, and 5S rRNAs and proteins), and the A–, P–, and E– site tRNAs (Figure 1.4). 
The model also provides a general description of RNA–rich interfacial core 
between the 30S and 50S ribosomal subunits where the tRNAs are bound and the 
protein rich interfacial periphery. However, because of its limited resolution, it fails 
to reveal the significance of particular atoms in ribosomal function. The full atomic 
crystal structures of the intact 70S ribosome of Escherichia coli bacteria at 3.5 Å 
resolution have provided complete atomic details, and deeper understanding of 
the interface between intraribosomal subunits, and molecular details of ribosomal 
conformational flexibility. Furthermore, the reports of X–ray crystal structures of 
the Tth intact 70S ribosome complexed with mRNA and tRNA refined to 2.8 Å 
emphasizes the fact that, though these complexes are solved in different crystal 
forms, they all demonstrate conformational similarities of the ribosome and its 





Peptidyl Transferase Center (PTC) 
After the advances in high–resolution crystallography, the mechanistic 
understanding of translation has progressed rapidly. Description of specific 
structural interactions of the ribosome with mRNA, and tRNA in the P–, and E– 
sites of the peptidyl transferase center (PTC). The A–site of PTC recognizes the 
aminoacyl–tRNA, positions it for the peptidyl transferase reaction, and monitors 
the interaction between codon and anticodon in the 30S subunit-decoding site. The 
aminoacyl–tRNA in A–site also functions as the acceptor for the growing 
polypeptide during peptide bond formation. The P–site is responsible for binding 
the initiator tRNA (fMet–tRNA) during the initiation phase. The P–site role also 
includes positioning of the translational reading frame and holding onto the nascent 
polypeptide chain. After peptide bond formation between the two adjacent amino 
acids on the P–site tRNA and A–site tRNA, the E–site acts as a host for 
deacetylated tRNA favoring the translocation from P–site to E–site.  The E–site 
also provides free energy change for the exit of deacetylated tRNA out of the 50S 
P–site. The conformational differences between the vacant and tRNA complexed 
70S ribosome, asserts the induced fit model (an active site of the ribosome, when 
makes contact with substrate, the ribosome itself adopts the shape of the 
substrate) for the ribosome in response to tRNA binding, accompanied by 
significant changes in the peptidyl–transferase catalytic site.80, 85, 99, 100 
 
The Process of Translation 
The prestigious Nobel prize–winning science by Dr. Steitz, Dr. 





ribosome” have provided unparalleled insights into the mechanism of action of 
ribosomes and the bacterial translational process. These scientific discoveries 
have not only helped a great deal in understanding binding, and mode of action of 
ribosomal antibiotics (natural and semisynthetic), but also bacterial resistance 
mechanisms, and aided in the design of more efficient ribosomal antibiotics. Each 
step of the life’s core process, translation of DNAs information to functional protein, 
has been extensively studied over the past decade; however, these studies are by 
no means exhaustive. 80, 85, 99, 100 
 
Initiation 
A schematic view of protein biosynthesis (translation) is shown in Figure 
1.5. Translation can be divided into four steps. First, initiation implicates the 
assembly of a smaller 30S subunit and larger 50S subunit to form a 70S ribosomal 
complex. This step also includes precise positioning of N–formyl methionyl (fMet)–
tRNA at the ribosomal peptidyl site (P–site) in 50S subunit to the target mRNA start 
codon (often AUG) on 30S ribosomal subunit. In prokaryotes, the three key 
initiation factors, IF1, IF2, and IF3, facilitate the efficiency and fidelity of 
translational initiation process.80  
 
Elongation 
Elongation is a three–step cyclic process. It begins with the delivery of an 
aminoacylated tRNA (aa–tRNA), facilitated by Elongation Factor–Tu (EF–Tu) in 
association with guanosine triphosphate (GTP) and dictated by the nucleotide 





between the two amino acids attached to A– and P–site tRNAs, mediated by 
peptidyl transferase located on the 50S ribosomal subunit the process of peptide 
bond formation results in migration of amino acid from P–tRNA to A–tRNA.  
 
Translocation 
The next step is translocation facilitated by Elongation Factor–G (EF–G). 
To accommodate the incoming aa–tRNA in the A–site, the tRNA of the initiator is 
ejected from the P–site to E–site. The dipeptidyl–tRNA (fMet–aa–tRNA) is moved 
to the P–site and the mRNA moves relative to the ribosome to expose a new triplet 
codon in the A–site, allowing the cycle to repeat. The translocation process runs 
in parallel with elongation of nascent polypeptide chain which exits through an exit 
tunnel into the cytoplasm and folds into a functionalized protein. In many cases, 




During the termination step, the peptide is released when the mRNA 
terminator codon is read.79 The elongation cycle continues until a stop codon on 
the mRNA is recognized by release factors (RF1 and RF2), which then hydrolyzes 
the peptidyl–tRNA bond. The result is the release of a nascent polypeptide chain. 
Therefore, recycling the disassembled post–translational complex to be available 
for the next translational initiation process.  
Translation is a multistep process involving complex structures such as 





bacterial ribosome is one of the major in vivo targets for a number of antibiotics 
such as purine nucleosides (e.g., puromycin), sparsomycin, chloramphenicol, 
streptogramins, oxazolidines, lincosamides, tetracyclines, and pyrimidine 
nucleosides (blasticidin S, gougerotin) among others.77 Each step of bacterial 
translation is targeted by at least one ribosomal antibiotic (protein synthesis 
inhibitors).  
Initially, the biochemical information, structural insights, and mode of action 
of different antibiotics were characterized by crystallizing individual 30S or 50S 
subunits of the ribosome with antibiotics. However, over the past decade the ability 
to elucidate the complexes of antibiotics bound to 70S ribosomes with high 
resolution has resulted in documentation of almost all of the major classes of 
ribosomal antibiotic complexes with ribosomes. Subsequently, collection and 
interpretation of highly resolved X–ray diffraction patterns of ribosome–antibiotic 
complexes have taken place.  
The majority of known clinically used antibiotics such as the 
aminoglycosides, chloramphenicol, fusidic acids, oxazolidinones, streptogramins, 
and tetracyclines target the elongation cycle of bacterial translation. Several other 
classes of antibiotics block the initiation, termination, and recycling phases of 
bacterial protein synthesis. However, the clinical applications of antibiotics 
targeting the initiation phase such as pactamycin, edeine, evernimicin, and 
thiopeptides are limited due to specificity (selectivity index), toxicity, and solubility 
issues associated with them. Notably, the majority of the antibiotics targeting 





chloramphenicol, puromycin, and sparsomycin, exert their significant inhibitory 
effect on the elongation phase of translation.  
 
Antibiotics Targeting the 30S Subunit of Ribosome 
In 2014, Professor Wilson, in his review on “Ribosome–targeting antibiotics 
and mechanism of bacterial resistance,” states that “despite the large size of the 
ribosome, relatively few sites are targeted by our current arsenal of antibiotics. On 
the 30S subunit, the antibiotic binding sites are clustered along the path of mRNA 
and tRNAs.” Evidence from several assays80–84 and structural studies (crystal 
structures) of these natural product ribosomal antibiotics and their synthetic 
analogs explain the way these antibiotics interact with ribosomes. They also 
suggest that antibiotics, despite considerable structural diversity, engage in 
common and only a few competitive binding sites of the ribosome. The major 
classes of antibiotics bound to the 30S ribosome subunit are fusidic acid, 
tetracyclines (tetracycline, oxytetracycline, doxycycline, tigacil, and minocycline), 
aminoglycosides (gentamycin, amikacin, tobramycin), pactamycin, and edeine 
(Figure 1.6). 80,85 
 
Antibiotics Targeting the 50S Subunit of Ribosome 
The most common binding sites on the 50S subunit targeted by current 
antibiotic regimen are grouped around PTC, especially overlaid on A–tRNA (e.g., 
chloramphenicol, lincosamides, oxazolidines, puromycin, and sparsomycin) and 
few (e.g., macrolides, and streptogramins) within the exit tunnel. Surprisingly, there 





S (BlaS) was shown to bind at P–tRNA as well as overlapping on A– and P–sites. 
However, BlaS is a universal antibiotic and is known to inhibit both prokaryotic and 
eukaryotic translation equally. It was shown to be toxic to bacteria, fungi, and 
mammals (mice and rat). While BlaS is used to control plant disease (treatment of 
rice blast disease), its associated toxicity, and lack of species specificity hinders 
the BlaS clinical use in treating human infections (Figure 1.7).101, 102, 103 
 
Blasticidin S 
Initially, the molecular details emphasizing the binding of BlaS (belongs to 
amino hexose–cytosine class of antibiotics) to the larger subunit of ribosome 50S 
of Haloarcula marismortui (Hm) was illustrated by crystallographic studies in 
Steitz’s lab. Strangely, two ligands of BlaS were reported occupying two non–
overlapping binding sites with varied strengths (Figure 1.8). First, a high–affinity 
binding site is characterized by a conserved Watson–Crick base pairing between 
BlaS cytosine and G2284 (G2251)) [Hm, (E. coli)] of the 23S rRNA, and a cation–
 interaction with A2472 (A2439). The hydrogen bonding interactions of the N–
methyl guanidine tail with the phosphates of A2472 (A2439) and A2635 (A2600) 
further stabilize the interaction. Secondly, there are low–affinity binding 
interactions involving a W–C base pairing of BlaS cytosine with G2285 (G2252) 
[Hm, (E. coli)]. Since the two bases [G2284, and G2285 (Hm)] interacting with two 
molecules of the BlaS are universally conserved and base pair with the two 
cytosine residues (C75 and C74, respectively) of the P–tRNA CCA tail, BlaS was 
thought to inhibit translation by being a competitive inhibitor of P–site binding 





Later, the exact mechanism of action for BlaSwas resolved by X–ray 
crystallographic studies of BlaS bound to 70S ribosome of Tth in presence of P–
site tRNA.33 Unlike previously reported crystal structure of the 50S subunit of Hm 
with two BlaS ligands, the 70S–tRNA complex was seen bound with only one BlaS 
ligand with its cytosine moiety W–C base paired to G2262 (G2251) [Tth, (E. coli)]. 
Moreover, it was shown to inhibit translation by stabilizing distorted P–tRNA on the 
ribosome, by displacing Watson–Crick base pairing of C75 of 3’CCA tail with 
G2262 (G2251) [Tth, (E. coli)], thereby inhibiting new peptide formation beside 
release factor–mediated peptidyl–tRNA hydrolysis (Figure 1.9). 101, 102, 103, 104 
 
Amicetin Binds to P–site of PTC Similar to BlaS 
The Looper group has succeded in solving the X–ray crystal structures of 
the natural product amicetin (Ami) (re–expressed, isolated, and purified from the 
bacteria Streptomyces vinaceousdrappus by Dr. Serrano in Looper lab),105 in 
complex with the 70S Tth ribosome within 3.5 Å resolution, in collaboration with 
Dr. Eiler of the Steitz’s lab at Yale University. 
 
Molecular mapping of amicetin and its analogs  
bound to Tth 70S ribosome 
In the crystal structure, amicetin is seen bound to the P–site of the PTC of 
23S rRNA, at the same binding site as BlaS. Critical interactions that highlight the 
binding of amicetin to the ribosome are: 1) the nucleobase cytosine of amicetin is 
engaged in a W–C base pair with G2262 (2251) [Tth (E. coli) numbering]. 2) p–





A2613 (2602). 3) The dimethylamine group of the disaccharide portion of amicetin 
participates in a (cationinteraction) with A2450 (2439), and the hydroxyl group 
is engaged in a hydrogen bonding interaction with a phosphate group of 
C2612(2601). 4) Finally, the amino acid –methylserine lies in an extremely polar 
region, exposed to a solvated front, forming a hydrogen bonding interaction with a 
phosphate group of G2506(2495) via an amine. The hydroxyl group of –
methylserine is in proximity to the glutamate (E80) of L–16 ribosomal proteins, 
which could result in a possible weak interaction via the terminal hydroxyl group 
(Figure 1.10). 104, 105 
 
Amicetin Bound to Tth 70S Ribosome in  
Presence of P–site tRNA 
All the binding interactions in Ami–70S complex, except  stacking 
interaction of p–aminobenzoate of amicetin with A2613(2602), are also seen in the 
structure of Ami–70S–P–tRNA ternary complex. Similar to BlaS, the W–C base 
pairing of the cytosine of Ami with G2262(2251) causes distortion in C75 of 3’–
CCA tail of P–tRNA. The phosphate backbone of C75 is shifted by 7Å in BlaS–
70S–tRNA ternary complex, whereas the nearby A76 and C74 are shifted by 2Å, 
4Å, respectively (Figure 1.11). 101, 102, 103, 104 
 
Mechanism of Action of Amicetin 
 The crystallographic studies of amicetin bound to 70S ribosome of Tth in 
the presence of P–site tRNA provide mechanistic insights into the mode of action 





deformed conformation of P–site tRNA of the larger ribosomal subunit similar to 
BlaS. The site where amicetin binds and involves in Watson–Crick (W–C) base 
pairing of cytosine with G2251 is also a binding site for P–site tRNA, where the 
C74 and C75 of 3’CCA tail of P–tRNA forms a W–C base pair with G2252, and 
G2251 (E. coli numbering), respectively, and positions itself in the P–site of the 
ribosome for translational elongation. During the formation of a new peptide bond, 
hydrogen bonding interactions between rRNA nucleotides constituting the PTC 
and tRNA nucleotides result in an orientation of acceptor aminoacyl–tRNA (Aa–
tRNA) and donor peptidyl–tRNA suitable for peptidyl transfer. This adjustment 
allows the attack of the –amino group of the acceptor A–site bound aminoacyl–
tRNA on to the carbonyl center of the ester bond of a P–site bound tRNA with the 
spontaneous transfer of peptidyl residue to the A–site bound aminoacyl–tRNA 
amino acid to form a new peptide bond.106, 107, 108 After peptide bond formation the 
nascent oligopeptide is transported through the exit tunnel and placed below the 
PTC. Amicetin interrupts this interaction of C75–G2251 by displacing C75 and 
forming key Watson–Crick base pair of its cytosine with G2262(2251). The 
displaced C75 results in bending of the P–tRNA toward the A–site creating an 
unproductive conformation on the ribosome thus inhibiting peptidyl tRNA 
hydrolysis (Figure 1.12). 101, 102, 103, 104 
 
Factors Governing the Selectivity of Amicetin  
Compared to BlaS 
While both Ami and BlaS bind at the same site in PTC, unlike BlaS, amicetin 





the factors governing amicetin’s selectivity are not clear, we anticipate four 
elements that seem to oversee selectivity. 1) The ability of amicetin to be involved 
in stacking interactions (note: BlaS lacks this interaction) with A2613(2602) 
[Tth, (E. coli)]. The highly conserved A2602 (E. coli) is shown to be critical for RF 
dependent peptidyl–tRNA hydrolysis.97 2) The presence of α–methylserine of 
amicetin and its interaction with ribosomal protein L16, and the universally 
conserved phosphate groups might have a part in antibiotic activity and selectivity. 
3) The absence of a guanidine moiety in amicetin (instead it has a dimethylamino 
pyranose). BlaS binds tightly in the binding pocket (Six noncovalent interactions 
vs Two in Ami) utilizing a guanidine to engage the cation–interaction and 
hydrogen bonding interactions with A2439.98, 99 4) Lastly, the magnitude of 
displacement with C75 in presence of Ami compared to BlaS in tRNA stacked 70S 


































































Figure 1.2 Structure of amicetin 
 
 
Figure 1.3 Protein synthesis inhibition assay of amicetin and congeners67 
















Figure 1.5 Translation and various steps involved in translation (Adapted from 























Figure 1.8 BlaS bound to 50S ribosomal subunit of Haloarcula marismortui 
 
 







Figure 1.10 Molecular interactions of amicetin bound to 70S Tth ribosome 
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FIRST GENEREATION ANALOGS 
 
Hydrolytic Stability of Amicetin 
Tuberculosis (TB) is a highly contagious airborne bacterial infection and is 
one of the greatest health threats to the current population as a whole.1, 2, 3 To 
address this growing public health issue, the Looper lab launched a campaign of 
small molecule screening at the University of Utah, and identified a natural product 
amicetin, a known protein synthesis inhibitor active against drug resistant Mtb 
H37Ra, as a promising lead. Apart from the promicing antimycobacterial activity 
associated with amicetin, the biggest liabilities are its structural complexicity and 
hydrolytic stability. Amicetin has also been noted to be highly unstable in acidic 
and alkaline solutions leading to degradation products cytimidine and cytosamine, 
respectively, which are 100–fold less potent than amicetin (Figure 2.1).4, 5, 6 Most 
notably, due to the presence of highly acid labile cytosine–glycol linkage, amicetin 
is chemically unstable and remains a poor drug candidate. To confer stability in 
the gut, oral bioavailability, and synthetic feasibility, redesigning and simplifying 
the complicated disaccharide portion of amicetin is required. Our quest to increase 
the potency and therapeutic properties of amicetin and synthesize more potent and 
synthetically fesible amicetin derivatives stimulated us to design a simplified 





Experimental Design of Simplified Pharmacophore 
In an effort to reorganize the disaccharide portion and design a simplified 
pharmacophore, we note that in a review by Fox and co–workers on nucleoside 
antibiotics it was stated that “for any aminoacyl nucleosides antibiotics capable of 
inhibiting protein synthesis will have an accessible amino acid moiety attached to 
a carrier nucleoside, this in turn attached to another basic center at the end of the 
molecule.”7 One basic center is the amine of the amino acid (–methyl serine), and 
the other can be a nitrogen of the nucleobase (the dimethyl amino moiety in the 
disaccharide unit in the case of amicetin). 
In addition to Fox’s statement, later in 1973 Lichtenthaler et al. in their 
studies on structural basis for inhibition of protein synthesis by the cytosine group 
of antibiotics hypothesized that the spacing of cationic amine of amino acid 
tethered to the nitrogen of nucleobase by molecular linker (hexose sugar of 
blasticidin S (BlaS) and gougerotin, and p–aminobenzoic acid of amicetin) is 
important for exhibiting translational inhibitory function.1, 2, 3 This resulted in an 
assumption that the accessible amino acid –methyl serine moiety of amicetin 
would mimic the sarcosine in gougerotin, N–methyl–guanidine unit in BlaS as 
shown in Figure 2.2. If this overlap were true, it would suggest that cytimidine that 
constitutes the requisite structural elements except the amine terminus on the 








Cytosine–based protein synthesis inhibitors 
Most of the cytosine–based antibiotics (amicetin, BlaS, gougerotin) are in 
agreement with Fox and Lichtenthaler’s statement. However, TAN–1057 A–D, a 
class of translational inhibitors isolated from flexi bacteria, in contradiction to Fox’s 
statement, lacks both a sugar moiety attached to nucleobase and a formal 
nitrogenous base. TAN 1057 A–B, however, have an isocytosine that mimics 
cytosine. In partial agreement with Fox’s statement, TAN 1057 A–B have two basic 
centers at either terminus of isocytosine (urea functionality on and an accessible 
amino acid –homoarginine).9 
In perspective of TAN 1057's simple structural features (nonglycosidic linker 
in particular), compared to other cytosine nucleoside antibiotic agents, we expect 
that the amicetin analogs with cationic amine attached to a less complex, and more 
stable alkyl linkers to show translational inhibition properties (Figure 2.3). With the 
above assumption, we focused our efforts on the design of a simplified 
pharmacophore model for the analogs synthesis.  
To address all the contradictions and assumptions we plan to synthesize 
simplified amicetin analogs based on hypothetical simplified pharmacophore 
possessing a basic group (amine) attached via a linker to one side of the 
nucleobase (cytosine core) which in turn attached to a dipeptide portion (cap 
region) with an accessible amino acid on the other side of the cytosine (Figure 2.3). 
In our approach toward the design and synthesis of amicetin analogs, we 
planned to safeguard the cytimidine segment of amicetin, which possess the 





as cationic terminus (cap region). This conceptually prompts an SAR study on the 
disaccharide portion of amicetin and synthesis of focused library of analogs, re–
engineering the sugar moiety and studying their activity against MDR–TB, 
cytotoxicity and compatibility with ART. We supplanted the disaccharide with non–
hydrolysable linkers to investigate conceivable varieties of cationic tails and spacer 
linkers. Replacing the sugar moiety with an alkyl chain also streamlines potential 
synthetic challenges.   
To test the hypothesis of a simplified pharmacophore, synthesis of dimethyl 
amino polyethylene glycol (PEG) derivatives of amicetin 11 were designed. PEG 
linkers (spacers) are the best–known substitutes for disaccharides and have 
previously been used in antiretroviral and antibacterial chemical entities.10 Also, 
the PEG derivatives designed mimic the chain length of disaccharide and position 
the cationic amine at a similar distance to diamine of the amicetin (Figure 2.4).  
 
Retrosynthetic Analysis of Simplified Amicetin Analogs 
A retrosynthetic approach of future designed analogs is depicted in Scheme 
2.1. We envisioned two different routes to access the designed amino alkyl 
cytimidine analogs, the first route being route A; the N1–alkylation of cytosine with 
alkyl halides (linker) followed by a peptide coupling reaction of N1– alkylated 
cytosine (1) with PABA derivative (2). The PABA derivative could be synthesized 
via a Buchwald amidation11 of 4–iodomethyl benzoate and protected –methyl 
serine carboxamide (3)11, 12, 13 that in turn would be synthesized from a 
commercially available serine methyl ester hydrochloride. The alternative method 





protected cytimidine (4) with requisite alkyl halides / mesylate (linker/spacer). The 
protected cytimidine can be synthesized by employing a Buchwald–Hartwig 
amidation reaction of –methylserine carboxamide (3) and aryliodide (5). The aryl 
iodide itself is a peptide coupled product of p–Iodobenzoic acid and 
aminopyrimidine (6).14  
 
Synthesis of –methylserine carboxamide 
We first focused our efforts on the synthesis of carboxamide 3, employing 
Seebach’s chemistry and improvising on a reported procedure by Dr. Serrano in 
the Looper group.12, 13 The carboxamide 3 corresponding to –methylserine 
synthesis began with condensation of commercially available L–serine methyl 
ester hydrochloride (3a) with pivaladehyde to form oxazolidine 3b which was 
further protected using Boc anhydride to give N–Boc oxazolidine 3c as a single 
diasteromer. Diastereoselective α–methylation of 3c employing Seebach’s 
memory of chirality,11 formed 3d and subsequent saponification of ester 3d yielded 
the acid 3e in excellent yield and >95:5 dr. The acid 3e was peptide coupled with 
ammonium chloride using HATU and DIPEA in DMF to form carboxamide 3 
(Scheme 2.2). 
 
Synthesis of polyethylene glycol analogs of amicetin 
The synthesis of PEG analogs began with the N1–pegylation of cytosine 
with PEG linker 8 (amino PEG chloride), which was formed by chloride 
displacement in bis(2–chloroethoxy) ethane 1a with dimethyl amine (Scheme 2.3). 





synthesized by a sequence of Buchwald amidation and saponification of the 
resultant monopeptide. The protected α–methylserine carboxamide 3 was then 
treated with 4–iodomethyl benzoate under Buchwald–Hartwig amidation 
conditions to result in the formation of monopeptide 10.11 The resultant mono–
peptide 10 was saponified to yield acid 11 (Scheme 2.3).  
With both alkylated cytosine 9 and acid 11 in hand, we proceeded to setup 
a peptide coupling reaction to synthesize the dipeptide 12. The peptide coupling 
of amine 9 and acid 11 provided protected PEG derivative 12, which on final global 
de–protection with trifluoro acetic acid (TFA) yielded the analog HKR–01–084 
(12L) (Scheme 2.3). 
 
Biological evaluation of PEG analogs of amicetin 
Both enantiomers (D and L) of –methyl serine were successfully 
synthesized using the similar protocol (Scheme 2.3) and tested for their activity 
against Mtb–H37Ra. The analog of natural enantiomer (S)– (–) HKR–01–084 
showed 43% of growth inhibition at 100µg/mL and the other enantiomer (R)– (+) 
HKR–01–090 showed 49% of inhibition at 100µg/mL. More importantly, both the 
compounds were more active than cytimidine (inactive at 100 µg/mL) which lacks 
any kind of substitution on N1–cytosine. With these encouraging results, our 
immediate plan was to synthesize similar analogs devoid of amine (cationic tail), 
and analogs with short linkers to clearly understand the importance of amine and 
the linker length.  
The compounds shown in Figure 2.5 were synthesized using a protocol 





To strengthen our hypothesis of the simplified pharmacophore model, the 
analog HKR–01–180 without a pendent amine was inactive (no measurable 
activity at 100 g/mL) when tested against Mtb–H37Ra. Similarly, the analog 
HKR–01–186 where the amine is positioned six atoms (compared to nine atoms 
in active analog) apart from N1 of cytosine is slightly less active (34% inhibition 
compared to 49%), suggesting the importance of cationic amine tether, linker 
length, and position of amine for biological activity. 
 
Altering the length of the linker in amicetin analogs 
At this point, we were unsure about the optimum length for the linker to be 
an effective protein synthesis inhibitor. Our plan was to synthesize a set of analogs 
with different linker lengths with different functional groups and investigate their 
role in biological activity. For quick access to the analogs with a diverse a set of 
linkers, our strategy was to synthesize the common intermediate cytimidine and 
exploit the acidic nature of N1–cytosine proton (pKa = ~12.2) for alkylations and 
propargyl cytimidine 12 as a common precursor for diversity generating reactions 
(A3 –coupling, and N1–cytosine alkylations). 
Note: All the first generation analogs are synthesized and tested in one lot 
except HKR–02–058, HKR–02–059, and HKR–02–061.  
 
Synthesis of Protected Cytimidine and Propargyl Cytimidine 
The protected cytimidine was synthesized through a sequence of reactions 
on readily available 4–amino–2–chloro pyrimidine. Nucleophilic displacement of 





pyrimidine 13. Reaction of 13 with in situ generated 4–iodobenzoylchloride 
resulted in the formation of monopeptide 14, which was further reacted with 
carboxamide 3 under Buchwald amidation conditions to form fully protected 
cytimidine 15. Careful debenzylation results in protected cytimidine 16. 
Propargylation of protected cytimidine 16 with propargyl bromide yielded the 
common intermediate propargyl cytimidine 17 (Scheme 2.4).13,15 
 
Alternate synthetic procedure for protected cytimidine 
After gaining a better understanding of the nature and solubility of the 
cytosine, and cytosine derivatives (propargyl cytosine), the synthesis of the 
protected cytimidine and propargyl cytimidine was achieved in an expedient and 
efficient manner using feed stock chemicals with fewer steps by deploying 
alternative peptide coupling reactions and saponification.  The PABA adduct 11 
was synthesized via a sequence of peptide coupling reaction of p–aminomethyl 
benzoate and carboxylic acid 3e, which gives ester 10. Hydrolysis of 10 produces 
acid 11. The propargyl cytosine is prepared from cytosine using tetrabutyl 
ammoniumhydroxide and propargyl bromide in dichloromethane as shown in 
Scheme 2.5.16 The cytosine or propargyl cytosine dissolved in DMSO (only solvent 
that dissolves cytosine or propargyl cytosine at higher temparatures) is peptide 
coupled with the –methylserine coupled PABA adduct (11) to form protected 









With the key precursor propargyl cytimidine 17 in hand, we proceeded to 
explore the utility of 17 to carry out multicomponent coupling reactions, such as 
A3– coupling (A3= alkyne/aldehyde/amine). It is noteworthy that all the efforts to 
carry out three components coupling reaction using regular protocol by employing 
(Cu(I)) salts failed with our substrates (alkyl alkyne). Adapted reaction conditions 
of a reported protocol by Cravotto et al. in their synthesis of umbelliferon 
aminoalkyl derivatives using Cu(OAc)2 under microwave conditions were 
successful and resulted in the formation of A3– coupled products in good yields 
(Scheme 2.6).17  
Three component coupling of propargyl cytimidine 17, paraformaldehyde, 
and N,N,N’–trimethyl ethylenediamine (A3 –coupling) resulted in the formation of 
18 (Scheme 2.5). Global deprotection of A3 –coupled product 18 using TFA in 
dichloromethane yielded amino alkyl derivative of amicetin 19 (scheme 2.6). 
Compounds shown in Figure 2.6 with different tethered amines were synthesized 
following a protocol similar to that shown in Scheme 2.6.  
 
Synthesis of analogs with increased cLogP 
Efforts are being focused on incresing the cLogP and reducing the number 
of basic amines of the amicetin analogs. We also plan to synthesize tethered 
carboxylic acids and amines on cytimidine, and derivetize them to peptides as in 
gougerotin. The next set of analogs synthesized were envisioned to have two basic 
amines (cationic cap and tail) at either termini of the molecule. 





Boc–L–proline and bromopropylamine hydrobromide via a carbonic acid anhydride 
formation on Boc–L–proline, which resulted in tethered alkyl bromide 20. Cytosine 
N1–alkylation with the resultant alkyl bromide 20 gave alkylated cytosine 21. 
Peptide coupling reaction between alkylated cytosine 21 and N–acyl PABA 11 
resulted in protected tripeptide 22 formation. Global deprotection yields the analog 
HKR–02–014 (23) as trifluoroacetate salt (Scheme 2.7).18 
The alanyl amide analogs of amicetin (Figure 2.10) was synthesized using 
a protocol similar to that shown in Scheme 2.7. The synthesized analogs were 
tested for their protein synthesis inhibition activity.  
With the aim of reducing the number of basic amines and having diverse 
class of linker (length / amine) the amide derivatives of amicetin were targeted and 
synthesized via alkylation on N1 of cytosine in protected cytimidine with an 
activated alkyl halide methyl bromoactate. It’s important to note that the alkylations 
on protected cytimidine with activated alkyl halides result in better yields with fewer 
byproducts compared to nonactivated alkyl halides. Also, the unactivated alkyl 
halides required harsh conditions (heating >80 oC) which eventually results in 
unwanted products in the reaction.  
The synthesis of targeted analogs began with alkylation of cytimidine with 
an bromo ester followed by saponification of resultant ester 23 afforded the acid 
24 in acceptable yields, along with cleaving the base labile amide bond to give 
byproducts acid 11, and cytosine acetic acid. The resultant carboxyllic acid was 
peptide coupled with N,N’,N’–trimethylethylenediamine resulting in tripeptide 25, 





Analog HKR–02–020 was synthesized using the similar protocol shown in 
HKR–02–019 (Scheme 2.8), using 3–aminomethyl–Boc–piperidine as peptide 
coupling partner. Having worked on SAR studies on dibasic (cationic cap and tail 
regions) amine derivatives and their associated protein synthesis inhibition 
activities, more efforts are focused on increasing the linker length and cLogP of 
the analogs limiting the number of basic amines. 
For increasing the spacer length consisting of only two basic amines, we 
thought of synthesizing aryl amides. For the synthesis of aryl amides with pendant 
amines, the two key reactions employed were peptide coupling and Sonogashira 
cross coupling using propargyl alcohol.  
The targeted analogs synthesis began with a peptide coupling reaction of 
p–iodobenzoic acid with 4–N–Boc–amino–piperidine resulting in arylamide 26, 
which under Sonogashira cross coupling conditions with propargyl alcohol 
produced the coupled product alcohol. The alcohol was activated as mesylate 27 
and used in the alkylation of the N1–of cytosine in protected cytimidine 16 yielded 
the protected aryl amide 28, which upon global deprotection produced alkynylaryl 
amide analog of amicetin as trifluoroacetate salt HKR–02–056 (28F) (Scheme 
2.9). Prolyl arylamide HKR–02–057 was synthesized using a similar protocol with 
the exception of the first step. The 4–iodoaniline was coupled to an activated mixed 
anhydride of Boc–L–proline to form amide 29 (Figure 2.9).   
In view of biological activity of HKR–02–018, the synthesis of HKR–02–059 
with tertiary amine as cationic tail was targeted. The amino alkynyl derivatives of 





of alkyne to alkane to increase the flexibility of the linker and reach of amine 
cationic tail. The reduced analogs will give an idea of activity of flexible and 
elongated amicetin derivatives (Scheme 2.10). 
Compounds shown in Figure 2.10 were synthesized using a similar protocol 
to HKR–02–058 and tested for their proposed biological activity. 
 
Results and Discussion 
Advancing with a simplified pharmacophore model, with an emphasis on 
simplifying the disaccharide portion (linker region) and supplementing it with a 
methylene group on the cytosine to impart hydrolytic stability, we worked out the 
SAR on amicetin analogs, which led to the synthesis of a focused library of ~15 
compounds. 
The compounds synthesized were screened against Mtb H37Ra for their 
antitubercular activity using the MTT assay and translational inhibition activity 
using the E. coli S30 extract T/T assay. Out of the 15 analogs tested, the ones 
lacking an amine tether (cationic tail) did not show any detectable activity at 100 
M (inactive against Mtb–H37Ra, inactive in protein synthesis inhibition assay). 
This result clearly emphasizes the importance of the presence of basic amines at 
either terminus of the molecule (cationic tail, and cationic cap region) and 
strengthens our hypothesis of simplified pharmacophore. 
The analogs with shorter linker length wherein the basic amine is positioned 
at distance of ≤ six atoms from N1 of cytosine, displayed a negligible 10% to 35%) 
protein synthesis inhibition (on target) activity at 100 M.  





at distance of ≥ ten atoms from N1 of Cytosine were also shown to have negligible 
effect on target (protein synthesis inhibition) activity. Most of the analogs with linker 
length of ≥ ten atoms from N1 of Cytosine were also dibasic amines. The only 
dibasic amine–containing analog that showed appreciable activity was HKR–02–
014, which has the amine positioned at seven atoms distant from N1 of Cytosine. 
Out of all the 15 analogs, five (Figure 2.7) were active and showed good 
activity against Mtb–H37Ra, and most importantly, they were active against protein 
synthesis inhibition (on target activity). Interestingly, an observable structure– 
activity relationship can be drawn based on the set of active compounds.  
The five active amicetin analogs possess either a fully saturated alkyl chain 
(a four–carbon aliphatic n–butyl as in HKR–02–058 / 61 or a three–carbon aliphatic 
n–propyl as in HKR–02–014) or an unsaturated alkynyl chain (2–butynyl as in 
HKR–02–018 / 59) as a linker (spacer) between the N1 of cytimidine and the amine 
group (cationic tail), which mimics the sugar portion in amicetin. Four among five 
active analogs are tribasic, whereas the proline substituted amide HKR–02–014 is 
dibasic, and is the least active analog among the set of five (80 times less active 
than amicetin), followed by the alkynes HKR–02–059 with a tertiary amine as 
cationic tail, and HKR–02–018 with a primary amine as cationic tail. The more 
flexible saturated alkyl amine linker containing compounds are the most potent, 
with a tertiary amine as a cationic tail as in HKR–02–061 with an IC50 = 7.40 M 
against Mtb–H37Ra, and the most active analog being HKR–02–058 consisting of 






As expected and hypothesized, all these analogs were also effective in 
protein synthesis inhibition (on–target activity) similar to amicetin. They displayed 
dose dependent protein synthesis inhibition, when evaluated for luciferase 
expression in the Promega E. coli S30 Extract System. Protein synthesis inhibition 
activity was directly proportional to their antitubercular activity with the most active 
analog HKR–02–58 having an IC50 = 3.8 M (amicetin, IC50 = 1.6 M). Analog 
HKR–02–058 results in 98% protein synthesis inhibition at 50 M concentration 
(compared to amicetin inhibits 100% at 50 M). 
Having seen the antitubercular activity and on–target protein synthesis 
inhibition activity of these compounds, we wanted to confirm the lack of 
cytotoxicity. Much to our delight, they exhibited no measurable cytotoxicity against 
the immuno–compromised CEM/TART T–leukemia cell line up to 100 M. In 
addition, the compounds are further tested in Vero cell line cell line (no cytotoxicity 
observed at 100 M). Given this lack of toxicity, these compounds were also tested 
for their effects on cytochrome activation (CYP induction) properties and shown to 
have no measurable CYP induction at 100 M (Table 2.1). 
 The SAR on amicetin analogs and the biological data associated with these 
analogs supports our initial hypothesis of simplified pharmacophore and simpler 
scaffolds could preserve the protein synthesis inhibition. The complex 
disaccharide portion (8–stereo centers) of amicetin can be streamlined with a 
linear flexible alkyl molecular spacer (0–stereo centers) tethered to a cyclic amine 
(4–aminopiperidine) that acts as a cationic tail, while maintaining  the comparable 





amicetin). Noncytotoxicity and non–CYP inducing properties are the significant 
features of this class of compounds. More importantly, the analogs are 
synthetically easily accessible compared to amicetin (no reported total synthesis). 
 Out of 15 analogs synthesized, HKR–02–058, which has more flexible alkyl 
linker and charged amines at either terminii of the molecule and an amine in the 
linker tether, turned out to be the active in protein synthesis inhibition assays and 
against MDR–TB/H37Ra. More material was needed for profiling this analog 
(ADME toxicity testing and in vivo studies). Following a convergent synthetic route 
depicted in Scheme 2.10, we could synthesize enough material for all the biological 
profiling studies.  
The convergent approch begins with N1 alkylation of acetylcytosine with 
1,4–dibromobutane followed by a SN2 displacement of the resultant alkylbromide 
31 with 4–Boc–aminopiperidine to yield acetylcytosine alkylamine 32. 
Deacetylation of 32 using excess ammonium hydroxide followed by a peptide 
coupling between resultant aminoalkyl cytosine 33 and PABA derivative 11 gave 
the dipeptide. Global deprotection using methanolic HCl results in HKR–02–058 
as hydrochloride salt. Adopting this convergent protocol, we were able to 
synthesize (~100 mg) enough material for biological studies (Scheme 2.11).  
 
Similarities in amicetin and its analogs binding interactions 
to Tth 70S ribosome 
The Looper group has succeeded in solving the X-ray crystal structures of 
the natural product amicetin (Ami) (re-expressed, isolated, and purified from the 





of the synthesized analogs (HKR-02-014, HKR-02-18) in complex with the 70S 
Thermus thermophiles ribosome within 3.5 Å resolution, in collaboration with 
Steitz’s lab at Yale University.19  
Analogs HKR–02–014 and HKR–02–018 also bind to the ribosome in a 
similar fashion as amicetin, involving similar molecular interactions. They share a 
common binding site in a stretched conformation, albeit with minor disagreements. 
Each of these structures preserves the WC base pairing of the nucleobase 
cytosine and guanine G2262 (2251) [Tth, (E. coli)]. All three structures have p–
aminobenzoate motif positioned to –stack with A2613 (A2602). The only 
discrepancies that were seen among the three structures are at the ends of the 
molecules. The –methylserine fragment’s hydrogen bond interactions in the 
western portion of the binding pocket of the ribosome vary, and differences in the 
effectiveness of cation–interaction of charged terminus with A2450 (2439) are 
also noted (Figure 2.12 & 2.13). 
 
Differences in binding interactions of HKR–02–014 bound to 
Tth 70S ribosome 
 In the crystal structure of HKR–02–014–70S complex compared to 70S–
Ami complex, the propylprolyl amide deviates significantly from amicetin, and 
extends into the hydrophobic region leading to the exit tunnel, failing to involve in 
a cation–interaction with A2450(2439). We assume that the linker length with 
attached cationic amine (2o amine in proline) in HKR–02–014 is short enough to 
engage in a cation–interaction with A2439 (A2450). The –Methylserine in a 





bonding interaction. First, the carbonyl of the amide interacts with the arginine 
(R82) of the ribosomal protein L16. Second, the amine of the –Methylserine 
hydrogen bonds with the phosphate of G2506 (2495) as shown in Figure 2.9. We 
assume the lack of cation–interaction with A2450 (2439) is responsible for the 
reduced protein synthesis inhibition activity of HKR–02–014 (Figure 2.12).  
 
Differences in binding interactions of HKR–02–018 bound to 
Tth 70S ribosome 
 The –Methylserine surrounded by various polar hydrogen bond donors 
and acceptors can prompt hydrogen bond formation either through the amine 
group or via the amide carbonyl or with both as in the case of HKR–02–018 (see 
Figure 2.10). Furthermore, the disaccharide region in amicetin protrudes into the 
helix, with the hexose (amicetose) attached to N1 of cytosine blocking the exit 
tunnel through which nascent polypeptide chain egresses into the cytoplasm. In 
the analog HKR–02–018 the butynyl amino–piperidine aligns with the amicetine 
disaccharide and manages to engage in cation–interactions with A2439(A2450). 
While the analog HKR–02–018 has similar binding interactions to Ami, the reduced 
translation inhibition activity of analog HKR–02–018 (compared to Ami) could be 
a result of weaker binding interactions (Figure 2.13). 
 
Conclusion 
In summary, amicetin is a ribosomal antibiotic shown to inhibit protein 
synthesis. This is significantly active against drug resistant strains of TB, non–





reengineer the acid labile disaccharide portion of amicetin and synthesized a 
library of analogs adopting a simplified pharmacophore. We identified a set of 
simplified amicetin analogs with comparable antitubercular activity, on–target 
translational inhibition activity. Lack of cytotoxicity (against mammalian cells) and 
CYP inducing properties is the best feature of these amicetin analogs. The active 
analog HKR–02–058, is only 4–fold less active against (3–fold more on–target 
activity), and comparable selectivity (SIRR/E.coli = 125, amicetin SI = 87) compared 


































































































Amicetin 0.24 ± 1.2 0.82 ± 0.079 71.0 ± 6.5 87 4.40 ~70 
Cytimidine >100 –– –– –– >100 >100 
HKR–02–014 22.0 ± 1.2 –– –– –– >100 >100 
HKR–02–059 19.0 ± 1.2 33.6 ± 3.2 >100 >3 >100 >100 
HKR–02–018 8.20 ± 1.2 14.8 ± 3.2 >100 >7 >100 >100 
HKR–02–061 7.40 ± 1.2 2.43 ± 0.132 >100 >40 >100 >100 
















Figure 2.2 Superimposable confirmations of inverted cytosine portion of amicetin 







































Figure 2.6 Compounds synthesized using a protocol similar to HKR–02–018 and 










Figure 2.7 Compound synthesized using a protocol similar to HKR–02–014 
 
 
Figure 2.8 Compounds synthesized using a protocol similar to HKR–02–019 
 
 







Figure 2.10 Compound synthesized using a protocol similar to HKR–02–058 
 
 






Figure 2.12 Analog HKR–02–014 bound to 70S Tth ribosome 
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General experimental considerations 
All reactions requiring anhydrous conditions were conducted in flame–dried 
glassware under a positive pressure of either nitrogen or argon. Commercially 
available reagents were used as received; otherwise, materials were purified 
according to Purification of Laboratory Chemicals.1 Acetonitrile (CH3CN), N,N’–
dimethylformamide (DMF), dichloromethane (CH2Cl2), toluene (PhCH3), and 
tetrahydrofuran (THF) were degassed with nitrogen and passed through a solvent 
purification system (Innovative Technologies Pure Solv). Dry 1,4–dioxane was 
purchased from Acros Organics in a Acros Seal™ bottle. Copper iodide (CuI) was 
purchased from Acros Organics. Microwave reactions were done in CEM Discover 
System Model 908005.  
Melting points were determined using Mel–Temp® Capillary Melting Point 
Apparatus. Infrared spectra were obtained using Nicolet 380–FT IR spectrometer 
fitted with a Smart Orbit sample system. Optical rotations were obtained at ambient 
temperature on a Perkin Elmer Model 343 polarimeter (Na D line) using a microcell 
with a 1 decimeter path length. Mass spectra were determined on a Micromass 
Quattro II (ESI/APCI–TOF) for HRMS at the University of Utah Mass Spectrometry 
Facility. 1H NMR and 13C NMR spectra were recorded at 300 MHz, 400MHz, 500 
MHz, and 13C NMR spectra were recorded at 75 MHz, 100 MHz, 125 MHz, 
respectively. Proton resonances were reported relative to the deuterated solvent 
peak: 7.26 ppm for CDCl3 and 3.31 ppm (center line signal) for CD3OD, 4.80 ppm 





road singlet, d= doublet, dd= doublet of doublet, t= triplet, q= quartet, m= multiplet), 
coupling constant(s) J in Hz, integration].2 Carbon resonances were reported as 
chemical shifts (δ) in parts per million, relative to the center line signal of the 
respective solvent peak: 77.23 ppm for CDCl3 and 49.00 ppm for CD3OD. All the 
commercially available chemicals are purchased from Sigma–Aldrich, Acros, TCI 
America, Combi–Blocks, and Chem–Impex. 
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Experimental procedures: Procedure for synthesis of  




–oxazolidine–3–carboxylate was synthesized according to reported literature. 






Scheme 1. Preparation of propargyl cytimidine. 
 
 2–(benzyloxy)pyrimidin–4–amine (S1).  Benzyl alcohol (2.81 mL, 26.0 
mmol) was added dropwise to a stirring suspension of 60% NaH in mineral oil (1.0 
g, 26 mmol) in dry THF (60 mL) at 0 °C, under a nitrogen atmosphere. The mixture 
was allowed to stir for a further 30 min until it formed a clear solution. 
aminochloropyrimidine S (3.30 g, 25.4 mmol) was dissolved in THF was added 
dropwise at 0 °C and then was refluxed for 12 hrs.  The reaction mixture was 
concentrated under reduced pressure, and purification using flash 
chromatography (60% EtOAc/Hexanes) afforded the title compound (3.70 g, 71%) 






 Rf= 0.28 (5% MeOH/CH2Cl2). M.p. 76–78 °C (lit. 80–81 °C).  
 1H NMR (400 MHz, CDCl3):  δ 7.82 (d, J= 5.6 Hz, 1H), 7.36 (d, J= 6.8 Hz, 
2H), 7.25–7.21 (m, 3H), 5.95 (d, J= 5.6 Hz, 1H), 5.89 (brs, 2H), 5.28 (s, 2H). 13C 
NMR (100 MHz, CDCl3); δ 165.1, 164.7, 156.5, 136.7, 128.2, 127.6, 127.5, 99.7, 
68.1 ppm. IR (neat) 3465, 3324, 3034, 3034, 1635, 1559, 1455, 1352, 1292 cm–1. 
HRMS (ESI) Calculated for C11H12N3O m/z (M+) 202.0980, Obsd 202.0977.  
 
 N–(2–(benzyloxy)pyrimidin–4–yl)–4–iodobenzamide (S2). A 0.5 M 
solution of KHMDS in toluene (5.95 mL, 2.98 mmol), was added to a stirring 
solution of the amino pyrimidine S1 (0.50 g, 2.48 mmol) in dry toluene (15 mL) at 
0 °C under a nitrogen atmosphere. The reaction was left stir for 30 min. In a second 
flask, 4–iodobenzoic acid (1.85 g, 7.44 mmol) was dissolved in dry CH2Cl2 (20 mL) 
under an atmosphere of nitrogen. The solution was cooled to 0 °C, after which 
oxalylchloride (0.65 mL, 5.16 mmol) was added drop wise followed by the addition 
of two drops of DMF. The reaction was allowed to stir for 30 min, until the solution 
became clear. The acid chloride formed was concentrated and dissolved in a 
minimum amount (6 mL) of toluene and added dropwise using cannula into the 
deprotonated amino pyrimidine. The reaction was allowed to warm to room 
temperature and was stirred overnight. The reaction was quenched with a 
saturated solution of NH4Cl (15 mL), extracted with EtOAc (3 x 50 mL). The 





anhydrous Na2SO4, filtered and concentrated under reduced pressure. Purification 
on silica gel using flash chromatography (10% EtOAc/Hexanes) afforded the title 
compound (0.54 g, 50%) as a white solid.   
 Rf= 0.30 (30% EtOAc/hexanes). Mp. 110 –112 °C.  
 1H NMR (500 MHz, CDCl3); δ 8.50 (d, J= 5.2 Hz, 1H), 8.48 (brs, 1H), 7.96 
(d, J= 6.0 Hz, 1H), 7.88 (d, J= 8.0 Hz, 2H), 7.60 (d, J= 8.0 Hz, 2H), 7.47 (d, J= 7.6 
Hz, 2H), 7.38 (t, J= 6.8 Hz, 2H), 7.34 (t, J= 7.3 Hz, 1H), 5.43 (s, 2H) ppm.  13C 
NMR (125 MHz, CDCl3); δ 165.4, 164.7, 161.0, 159.2, 138.5, 136.4, 132.8, 128.9, 
128.6, 128.2, 128.0, 104.4, 100.6, 69.3 ppm. IR (neat); 3303, 3061, 1695, 1585, 
1516, 1402, 1288 cm–1. HRMS (ESI) Calculated for C18H14N3O2NaI m/z (M+Na) 
454.0028, Obsd. 454.0030.  
 
 (2R,4S)–tert–butyl4– ((4– ((2– (benzyloxy) pyrimidin–4–yl) carbamoyl) 
phenyl)carbamoyl)–2–(tert–butyl)–4–methyloxazolidine–3–carboxylate (S3). 
An oven dried pressure tube equipped with a magnetic stir bar was charged with 
CuI (0.01 g, 0.05 mmol), anhydrous K2CO3 (1.44 g, 1.04 mmol), and coupled 
pyrimidine S2 (0.23 g, 0.52 mmol).  The pressure flask was then quickly fitted with 
a rubber septum.  A solution of amide oxazolidine (0.29 g, 0.52 mmol) in dry 1, 4–
dioxane (5 mL) was added to the reaction flask via syringe under a positive 
pressure of nitrogen.  The reaction mixture was degassed and purged with nitrogen 





(20 µL, 0.05 mmol) was then added into the reaction mixture via syringe.  The 
rubber septum was replaced with the sealed tube cap.  The reaction was stirred 
and heated at 110 °C for 24 hrs.  The reaction mixture was then diluted with EtOAc 
(20 mL), filtered through a pad of Celite® and concentrated under reduced 
pressure.  Purification on silica gel using flash chromatography (50% 
EtOAc/hexanes) afforded title compound (0.25 g, 80%) as a white solid. 
 Rf= 0.20 (50% EtOAc/hexanes). Mp. 152 – 154 °C. [α]20D = –53 (c = 0.20, 
CHCl3).  
 1H NMR (400 MHz, CDCl3); δ 8.48 (t, J = 5.6 Hz,2H), 
7.98 (d, J = 5.4 Hz, 1H), 7.89 (d, J = 8.5 Hz, 2H), 7.70 (d, J = 8.9 Hz, 2H), 
7.48 (d, J = 7.4 Hz, 1H), 7.39–7.27 (m, 3 H), 5.45 (s, 2H), 5.22 (s, 1H), 4.82 (d, J 
= 8.8 Hz, 1 H), 3.82 (d, J = 8.8 Hz, 1H), 1.74 (s, 3H), 1.55 (s, 9H), 0.93 (s, 9H) ppm. 
13C NMR (100 MHz, CDCl3); δ 171.7, 165.0, 164.5, 160.5, 159.2, 155.9, 142.5, 
136.3, 128.5, 128.4, 128.2, 127.9, 127.8, 119.4, 104.2, 97.9, 82.9, 76.0, 69.0, 68.0, 
38.1, 28.1, 26.1, 22.0 ppm.  IR (neat); 2967, 2210, 1976, 1691, 1591, 1493, 1460, 
1365 cm–1.  HRMS (ESI) Calculated for C32H39N5O6Na m/z (M+Na) 612.2798, 









mmol) was evacuated and backfilled with nitrogen gas, and 10% palladium (Pd) 
on activated carbon (0.02 g, 10% wt) was transferred into the reaction flask under 
nitrogen atmosphere. Small amounts of EtOAc (1mL) were added to submerge the 
Pd/C followed by the careful addition of methanol by creating a stream down the 
side of the flask wall (8 mL). The reaction mixture was evacuated and purged with 
hydrogen gas three times, and then the reaction mixture was left to react for 20 
min under hydrogen atmosphere, after which, the reaction mixture was filtered 
through a pad of Celite® and washed with hot methanol. Then the filtrate was 
concentrated under reduced pressure to yield cytimidine (S4) as white solid (0.12 
g, 70%).   
Rf= 0.30 (15% CH2Cl2/MeOH). Mp 206 – 208 °C. [α]20D = –10 (c = 0.12, 
MeOH).  
1H NMR (400 MHz, DMSO–d6): δ 8.03 (d, J = 8.20 Hz, 2H), 7.85 
(d, J = 6.6 Hz, 1H), 7.69 (d, J = 8.20 Hz, 2H), 7.17 (brs, 1H), 5.07 (s, 1H), 4.41(d, 
J = 8 Hz, 1H), 4.40 (brs, 1H), 3.85 (d, J = 8 Hz, 1H), 1.64 (s, 3H), 1.46 (s, 9H), 0.90 
(s, 9H) ppm. 13C NMR (125 MHz, CDCl3) δ 170.6, 163.7, 154.4, 147.0, 141.9, 
129.5, 128.6, 128.4, 119.3, 96.8, 95.5, 81.3, 79.1, 75.8, 67.6, 38.0, 27.7, 25.9, 21.1 
ppm. IR (neat) 2972, 1691, 1594, 1493, 1459 cm–1.  HRMS (ESI) Calculated for 







2–yn–1–yl)–1,2–dihydropyri–midin–4–yl) carbamoyl) phenyl) carbamoyl) 
oxazolidine–3–carboxylate (S5). To a solution of S4 (0.04 g, 0.08 mmol) in 
CH3CN (2 mL), Cs2CO3 (33 mg, 0.10 mmol) and propargylbromide (12 mg, 0.10 
mmol) were added under a positive pressure of nitrogen.  The reaction mixture 
was stirred for 0.4 hrs at 50 °C, and then concentrated under reduced pressure.  
Purification on silica gel using flash chromatography (1.5% CH2Cl2/MeOH) 
afforded the title compound (40 mg, 85%) as a colorless sticky solid. 
Rf= 0.30 (5% CH2Cl2/MeOH). [α]20D = –87 (c = 1.00, CHCl3). 
1H NMR (400 MHz, CDCl3): δ 8.01(d, J = 7.6 Hz, 1H), 7.90 (d, J = 8.4 Hz, 
2H), 7.69 (d, J = 8.4 Hz, 2H), 7.55 (bs, 1H), 5.20 (s, 1H), 4.79 (d, J = 9.2 Hz, 1H), 
4.72 (d, J = 2.8 Hz, 2H), 3.79 (d, J = 9.2 Hz, 1H), 2.59 (t, J = 2.8 Hz, 1H), 1.71 (s, 
3H), 1.53 (s, 9H), 0.90 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 171.7, 162.5, 155.8, 
146.6, 142.8, 128.9, 119.3, 97.9, 97.1, 82.9, 76.0, 75.7, 68.0, 44.6, 38.8, 38.1, 
28.1, 26.1, 22.0.  IR (neat) 3260, 2971, 2130, 1663, 1625, 1597, 1482, 1359 cm–







D. General procedure for three component coupling reaction.   
 





carboxylate (S6): In a 10 ml borosilicate glass vessel equipped with a magnetic 
stir bar the following were added: dry 1,4–dioxane (2.5 mL), paraformaldehyde 
(15.0 mg, 0.39 mmol, 4.0 equiv.), copper(II) acetate (2.30 mg g, 13.0 µmol, 0.1 
equiv.) and the amine (4–NHBoc–aminopiperidine) (27.0 mg, 0.04 mmol 1.1 
equiv.). The mixture was irradiated with microwave (200 W) for 10 min at 80 °C, 
after cooling down to 25 °C, the propargyl cytimidine S5 (70.0 mg, 0.04 mmol, 1.0 





irradiated further (200 W) for 10 min at 80 °C. The reaction was monitored by TLC 
using CHCl3/CH3OH (97:3) as eluent. The reaction mixture was diluted with ethyl 
acetate (5mL x 2) and filtered through a pad of Celite® and concentrated under 
reduced pressure. Purification on silica gel using flash chromatography (3% 
MeOH/CHCl3) afforded the A3–coupled product S6 (70mg, 75%) as yellow colored 
solid.  
Rf = 0.30 (3% MeOH/CH2Cl2). Mp 126 – 128 °C. [α]20D = –53 o (c = 0.10, 
CHCl3).  
1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 7.2 Hz, 1H), 7.89 (d, J = 8.4 Hz, 
2H), 7.70 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 7.2 Hz, 1H), 5.21 (s, 1H), 4.82 (d, J = 8.8 
Hz, 1H), 4.76 (s, 1H), 4.14 (brs, 1H), 3.82 (d, J = 8.8 Hz, 1H), 3.48–3.43 (m, 1H), 
3.35 (s, 2H), 2.87 (d, J = 10.8 Hz, 2H), 2.26 (t, J = 10.8 Hz, 2H), 1.98 (d, J = 11.6 
Hz, 2H), 1.73 (s, 3H), 1.54 (s, 9H), 1.47 (d, J = 11.6 Hz, 2H), 1.44 (s, 9H), 0.92 (s, 
9H). 13C NMR (100 MHz, CDCl3); δ 171.5, 166.4, 162.8, 156.0, 155.1, 146.9, 
142.3, 131.1, 129.2, 127.8, 118.9, 97.8, 97.1, 83.9, 82.8, 82.6, 79.0, 77.4, 75.9, 
67.9, 51.4, 47.1, 39.2, 38.0, 32.0, 28.3, 28.0, 26.0, 21.9. IR (neat) 3258, 2974, 
2135, 1696, 1600, 1559, 1489 cm–1. LRMS Calculated for C39H56N7O8 m/z (M+H) 









Compound S10 was synthesized following similar procedure as S6 using 
Cu(OAc)2 (4.00 mg g, 21.3 µmol), paraformaldehyde (34.0 mg, 0.86 mmol), N,N–
dimethylpiperidin–4–amine (27.0 mg, 0.21 mmol), propargylcytimidine (115 mg, 
0.21 mmol) and 1,4–Dioxane (2.5 mL) to afford the title compound (98mg, 68%) 
as colorless solid. 
 Rf = 0.30 (MeOH/CH2Cl2/ NH4OH (3:7:0.1). Mp 120 – 122 °C. [α]20D = –39 o 
(c = 0.10, CHCl3).  
1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 7.6 Hz, 1H), 7.87 (d, J = 8.4 Hz, 
2H), 7.65 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 7.6 Hz, 1H), 5.17 (s, 1H), 4.77 (d, J = 8.8 
Hz, 1H), 4.73 (s, 2H), 3.77 (d, J = 8.8 Hz, 1H), 3.33 (s, 2H), 2.92 (d, J = 11.2 Hz, 
2H), 2.26 (s, 6H), 2.15 (t, J = 11.6 Hz, 3H), 1.82 (d, J = 12.4 Hz, 2H), 1.69 (s, 3H), 
1.59–1.50 (m, 2H), 1.49 (s, 9H), 0.89 (s, 9H). 13C NMR (100 MHz, CDCl3); 171.8, 
166.0, 162.5, 156.0, 155.2, 147.0, 142.9, 129.0, 128.0, 119.4, 98.0, 97.0, 84.6, 
83.1, 76.0, 68.1, 61.7, 52.2, 47.2, 41.6, 39.4, 38.2, 28.2, 28.1, 26.2, 22.1. IR (neat) 
3258, 2973, 2131, 1743, 1598, 1412 cm–1. LRMS Calculated for C36H52N7O6 m/z 






E. General procedure for reduction of Alkyne to Alkane 
 




carbamoyl)–4–methyloxazolidine–3–carboxylate (S8): A dried round bottom 
flask equipped with a stir bar was evacuated and backfilled with nitrogen gas, and 
10% palladium (Pd) on activated carbon (14 mg, 20% by weight) was transferred 
into the reaction flask under nitrogen atmosphere. EtOAc (4mL) was added to 
submerge the Pd/C followed by the addition of alkyne S6 (68 mg, 92.0 µmol, 1.0 
equiv.). The reaction mixture was evacuated and purged with hydrogen gas three 
times, and then the reaction mixture was left to react for 8 hrs under hydrogen 





eluent.  The TLC shows progressive conversion of alkyne to alkene and then the 
more polar alkane. The reaction mixture was diluted with ethyl acetate (5mL) and 
filtered through a pad of Celite® and washed with hot MeOH (3 ml x 2). The solvent 
was concentrated under reduced pressure affording the reduced products as 





carbamoyl)–4–methyloxazolidine–3–carboxylate (S12): Compound S12 was 
synthesized following a procedure similar to S8, using alkyne S10 (70 mg, 93.0 
µmol, 1.0 equiv.), Palladium, 10% on activated carbon (14 mg, 20% by weight), 
and ethyl acetate (3mL) to afford the alkane S12 as yellow colored sticky solid. 






F. General procedure for global deprotection 
 




benzamide (S7): Compound S6 (70 mg, 93.0 µmol) was dissolved in methanolic 
HCl (3 mL) and stirred at room temperature for three hrs. The reaction mixture was 
concentrated under reduced pressure. The residue was basified with Et3N and 
purified using Isco–Combiflash® and MeOH: CHCl3:NH4OH (2.8:7:0.2) as eluting 
solvent to yield the title compound as freebase (31 mg, 69%) as yellow colored 
solid.  





°C(decomposed). [α]20D = –8 (c = 0.10, H2O).  
1H NMR (500 MHz, CD3OD) δ 8.18 (d, J = 7.5 Hz, 1H), 7.94 (d, J = 8.5 Hz, 
2H), 7.78 (d, J = 8.5 Hz, 2H), 7.54 (d, J = 7.5 Hz, 1H), 4.76 (s, 2H), 3.95 (d, J = 
11.0 Hz, 1H), 3.44 (d, J = 10.5 Hz, 1H), 3.35 (s, 2H), 2.89 (d, J = 12.0 Hz, 2H), 
2.70–2.64 (m, 1H), 2.25 (t, J = 11.5 Hz, 2H), 1.85 (d, J = 11.5 Hz, 2H), 1.47–1.38 
(m, 2H), 1.31 (s, 3H). 13C NMR (125 MHz, CD3OD) δ 177.4, 168.2, 165.0, 157.9, 
149.7, 143.9, 130.3, 129.4, 120.4, 98.8, 83.0, 79.4, 69.7, 60.6, 52.2, 47.5, 40.6, 
34.8, 23.4. IR (neat) 3726, 3265, 2962, 2138, 1683, 1605, 1546, 1476 cm–1. 




(S9): Compound S9 was prepared following a procedure similar to S7 using fully 
protected S8 (68 mg, 90.0 µmol) dissolved in methanolic HCl (3 mL)  followed by 
column purification to yield the title compound as free base (18.0 mg, 42%) as 
yellow colored solid.  
Rf = 0.30 (MeOH:CHCl3:NH4OH (2.8:7:0.2), Mp 190 – 192 °C, 
(decomposed). [α]20D = –10 (c = 0.20, H2O). 
1H NMR (400 MHz, D2O) δ 8.07 (d, J = 7.2 Hz, 1H), 7.97 (d, J = 8.8 Hz, 2H), 





Hz, 1H), 3.43 (d, J = 10.4 Hz, 1H), 2.92 (d, J = 11.6 Hz, 1H), 2.71–2.63 (m, 1H), 
2.94 (t, J = 10.4 Hz, 2H), 2.05 (t, J = 11.6 Hz, 2H), 1.87–1.75 (m, 4H), 1.62–1.54 
(m, 2H), 1.49–1.29 (m, 2H) 1,31 (s, 2H). 13C NMR (100 MHz, D2O) δ 177.5, 168.3, 
164.8, 158.8, 151.1, 144.0, 130.3, 129.6, 120.5, 98.5, 79.5, 69.7, 60.6, 58.9, 53.4, 
51.7, 34.9, 28.0, 24.7, 23.3. IR (neat) 3847, 2930, 1642, 1482, 1406, 1302, 1242 





din–4–yl)benzamide (S11): Compound S11 was prepared following a procedure 
similar to S7 using fully protected S10 (34 mg, 50 µmol) dissolved in methanolic 
HCl (2 mL) followed by column purification to yield the title compound as free base. 
The free base was then dissolved in a minimal amount of MeOH.  Then 1M HCl in 
diethyl ether was added and a solid crashed out. The solid was triturated with 
diethyl ether and the solvent was decanted.  The solid was dried under high 
vacuum to yield the hydrochloride salt of the title compound as a colorless solid 
(16 mg, 50%).  
Rf = 0.30 (MeOH/CHCl3/NH4OH (2.8/7.0/0.2), Mp 194 – 196 °C 





1H NMR (500 MHz, D2O) δ 8.22 (d, J = 7.0 Hz, 1H), 7.90 (d, J = 7.5 Hz, 2H), 
7.63 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 7.0 Hz, 1H), 4.82 (s, 2H), 4.13 (s, 2H), 4.12 
(d, J = 12.0 Hz, 1H), 3.89 (d, J = 12.0 Hz, 1H), 3.83 (d, J = 12.0 Hz, 2H), 3.64–
3.55 (m, 1H), 3.22 (t, J = 12.0 Hz, 2H), 2.89 (s, 6H), 2.44 (d, J = 12.5 Hz, 2H), 
2.04–1.98 (m, 2H), 1.66 (s, 3H). 13C NMR (125 MHz, D2O) δ 171.4, 170.6, 164.5, 
156.9, 152.8, 143.1, 131.4, 130.8, 123.6, 100.3, 85.5, 76.1, 66.1, 64.1, 61.6, 52.2, 
47.8, 42.5, 42.0, 26.0, 20.0. IR (neat) 3740, 3662, 2945, 2136, 1691, 1600, 1530, 




benzamide (S13): Compound S12 was prepared following a procedure similar to 
S7 using fully protected S12  (34.0 mg, 50 µmol) dissolved in methanolic HCl 
followed by column purification to yield the title compound as free base. The free 
base was then dissolved in a minimal amount of MeOH.  Then 1M HCl in diethyl 
ether was added and a solid crashed out. The solid was triturated and the solvent 
was decanted and residue was dried under high vacuum to yield the title 
compound as hydrochloride salt (12 mg, 38%). 
Rf = 0.30 (MeOH/CHCl3/NH4OH (2.8/7/0.2), Mp 198 – 200 °C 





 1H NMR (500 MHz, D2O) δ 8.24 (d, J = 7.5 Hz, 1H), 7.94 (d, J = 8.5 Hz, 
2H), 7.66 (d, J = 8.5 Hz, 2H), 7.16 (d, J = 7.5 Hz, 1H), 4.14 (d, J = 12.5 Hz, 1H), 
4.00 (brs, 2H), 3.91 (d, J = 12.5 Hz, 1H), 3.78 (d, J = 12.5 Hz, 1H), 3.64–3.55 (m, 
1H), 3.20 (t, J = 7.0 Hz, 2H), 3.11 (t, J = 12.5 Hz, 2H), 2.89 (s, 6H), 2.41 (d, J = 
12.5 Hz, 2H), 2.06–1.95 (m, 2H), 1.86–1.75 (m, 4H), 1.67 (s, 3H). 13C NMR (125 
MHz, D2O) δ 169.4, 168.8, 161.0, 153.2, 152.8, 141.4, 129.5, 128.3, 121.6, 97.4, 
64.0, 62.1, 59.7, 56.1, 50.6, 50.3, 40.0, 39.9, 25.0, 23.9, 20.6, 17.7. IR (neat) 3723, 
3260, 2943, 1692, 1600, 1536, 1486, 1410, 1367, 1245 cm–1. HRMS (ESI) 




dihydropyrimidin–4–yl)benzamide trifluoroacetate salt: Orange colored solid. 
mp. 108–110 °C, [α]20D = –2.8 (c = 2.00, CHCl3). 1H NMR (400 MHz, CDCl3); 
δ ppm 8.06 (d, J = 7.2 Hz, 1H), 7.91 (d, J = 8.4 Hz, 2H), 7.71 (d, J = 8.4 Hz, 2H), 
7.58 (d, J = 7.2 Hz, 1H), 4.75 (s, 1H), 4.17 (d, J = 10.4 Hz, 1H), 3.48 – 3.44 (m, 
3H), 2.56 (t, J1 = 6.4, J2 = 7.2 Hz, 2H), 2.42 (t, J1 = 6.4, J2 = 7.2 Hz, 2H), 2.33 (s, 3 
H), 2.26 (s, 6H), 1.35 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3) δ ppm 175.7, 
162.6, 155.5, 146.8, 142.1, 129.1, 127.8, 119.2, 97.2, 84.3, 69.2, 64.2, 59.8, 57.2, 
53.6, 46.2, 45.8, 42.2, 39.5, 29.7, 23.7. IR (neat) 2920, 2850, 1733, 1683, 1674, 







HKR-01-143:4–amino–1–(4–((2–(dimethylamino)ethyl) (methyl) amino) 
but–2–yn–1–yl)pyrimidin–2(1H)–one  
Brick red solid. Mp 150–153 °C. 1H NMR (400 MHz, CDCl3) δ ppm 7.48 (d, J = 7.2 
Hz, 1H), 5.92 (d, J = 6.9 Hz, 1H), 4.54 (bs, 2H), 3.34 (bs, 2H), 2.47 (t, J = 6.3 Hz, 
2H), 2.34 (t, J = 6.3 Hz, 2H), 2.24 (s, 3H), 2.19 (s, 3H). 13C NMR (100 MHz, CDCl3) 




1H NMR (300 MHz, CDCl3) δ ppm 8.26 (d, J = 8.7 Hz, 2H), 8.24 (d, J = 7.8 
Hz, 1H), 8.17 (d, J = 8.7 Hz, 2H), 8.01 (d, J = 7.8 Hz, 1H), 4.68 (bs, 2H), 3.41 (bs, 
2H), 2.49 (t, J = 6.9 Hz, 2H), 2.35 (t, J = 6.3 Hz, 2H), 2.27 (s, 3H), 2.22 (s, 3H). 13C 
NMR (100 MHz, CDCl3) δ ppm 167.8, 162.6, 153.9, 150.3, 146.9, 139.4,130.8, 
123.9, 98.5, 84.5, 76.7, 57.3, 53.6, 46.3, 45.8, 42.3, 39.4 ppm.  







late: Under a nitrogen atmosphere ethylchloroformate (0.29 mL, 3.11 mmol) was 
added to a cold (–20 °C) solution of N–Boc L–proline (0.64 g, 3.00 mmol) and N–
Methylmorpholine (0.32 mL, 4.50 mmol) in dry THF (5 mL). After 5 min 3–
bromopropylamine hydrobromide dissolved in THF: DMF (1:4 v/v) was added to 
the above mixture followed by the addition of N–Methylmorpholine (0.53 mL, 7.8 
mmol). After stirring the mixture at –20 °C for 10 min, it was warmed to room 
temperature and stirred for 4 hrs. The reaction mixture was diluted with ethyl 
acetate (25 mL) and washed with water followed by brine. The organic layer was 
dried over Na2SO4 and concentrated under reduced pressure. Purification on silica 
gel using flash chromatography (30% EtOAc:Hexanes) afforded the desired 
product (0.60 g, 58%) as a white solid.  
 
tert–butyl(S)–2–((3–(4–amino–2–oxopyrimidin–1(2H)–yl)propyl) 
carbamoyl) pyrrolidine–1–carboxylate: To a stirred solution of cytosine (0.22 g, 
2.00 mmol) in CH3CN (12 mL), Cs2CO3 (0.65 g, 2 mmol) and tert–butyl (S)–2–((3–
bromopropyl)carbamoyl)pyrrolidine–1–carboxylate (0.67 g, 2.00 mmol) was added 
under an atmosphere of nitrogen. The reaction mixture was heated to reflux for 2 
hrs. After which, mixture was concentrated under reduced pressure. Purification 
on silica gel using flash chromatography (10% CH2Cl2/MeOH, 1% NH4OH) 









carboxylate: To a solution of 4–((2R,4S)–3–(tert–butoxycarbonyl)–2–(tert–butyl)–
4–methyloxazolidine–4–carboxamido)benzoic acid (102 mg, 0.25 mmol) in 
dichloromethane (12 mL), was added EDC.Cl (110 mg, 0.5 mmol), HOBt (70 mg, 
0.50 mmol), NEt3 (137 µL, 1.00 mmol) and stirred at room temperature  for 5 min. 
tert–Butyl(S)–2–((3–(4–amino–2–oxopyrimidin–1(2H)–yl)propyl)carbamoyl)pyrol-
edine–1–carboxylate (116 mg, 0.25 mmol) was added to this mixture and stirring 
continued for an additional 2 hrs. The reaction was quenched with a saturated 
NaHCO3 (3 mL) aqueous solution and diluted with 3 mL of dichloromethane. The 
phases were separated and the organic phase was washed with water (2 X 2 mL) 
followed by a brine wash (1 X 2 mL). The organic layer was dried (Na2SO4), filtered 
and concentrated under reduced pressure.  The crude product was purified by 
flash chromatography (5% MeOH/CHCl3) to afford desired compound (98 mg, 







propanamido) benzamido)–2–oxopyrimidin–1 (2H)–yl) propyl) pyrrolidine–
2–carboxamide trifluoroacetate salt: tert–butyl (2R,4S)–4–((4–((1–(3–((S)–1–
(tert–butoxycarbonyl)pyrrolidine–2–carboxamido)propyl)–2–oxo–1,2–dihydropyri-
midin–4–yl) carbamoyl) phenyl) carbamoyl)–2–(tert–butyl)–4–methyloxazolidine–
3–carboxylate (76.0 mg, 0.10 mmol) was  dissolved in 30% TFA in 
dichloromethane (4 mL)  and stirred at room temperature for 12 hrs. The reaction 
mixture was concentrated, dissolved in water and washed with ether (2 X 2 mL) to 
remove the organic impurities. The aqueous layer was diluted with aq. NaHCO3 
and the compound was extracted with dichloromethane (2 X 4 mL) dried over 
anhydrous Na2SO4, filtered and concentrated, and the residue was dissolved in 
30% TFA in dichloromethane and stirred for 0.5 h. Then, the solvent was 
evaporated and triturated with diethyl ether followed by filtration affording the title 
compound HKR–02–014 (42 mg, 53%). 
Rf = 0.30 (MeOH/CHCl3/NH4OH (2.8/7.0/0.2), Mp 130–132 °C, [α]20D = – 6 
o (c = 0.1, H2O). 
  1H NMR (400 MHz, D2O) δ 8.12 (d, J = 7.2 Hz, 1H), 7.98 (d, J = 8.0 Hz, 2H), 
7.70 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 7.2 Hz, 1H), 4.38 (t, J = 6.8 Hz, 1H), 4.18 (d, 
J = 13.2 Hz, 1H), 4.01 (t, J = 6.4 Hz, 2H), 3.95 (d, J = 12.8 Hz, 2H), 3.50–3.32 (m, 
4H), 2.50–2.43 (m, 1H), 2.12–2.02 (m, 5H), 1.72 (s, 3H). 13C NMR (100 MHz, D2O) 
δ 169.4, 162.9, 157.7, 150.9, 140.8, 129.2, 121.9, 117.8, 110.0, 98.5, 64.1, 62.1, 
59.8, 48.5, 46.4, 36.7, 29.6, 27.4, 23.7, 17.8 ppm. IR (neat); LC–MS Calculated for 







In an oven dried sealed tube, 4–Amino–1–(2–(2–(2–chloroethoxy)ethoxy)ethyl) 
pyrimidin–2(1H)–one (24 mg, 0.09 mmol), K2CO3 (14 mg, 0.09 mmol) and a 2 M 
solution of dimethylamine in methanol (1 mL) was added under an atmosphere of 
nitrogen.  The reaction mixture was heated for 2 hrs at 70 °C. The solvent was 
evaporated and the residue was purified on silica gel using flash chromatography 
(15% CH2Cl2/MeOH) affording the desired product (36 mg, 85%) as a colorless oil. 
1H NMR (400 MHz, CDCl3); δ ppm 7.37 (d, J = 6.8 Hz, 1H), 
5.92 (d, J = 6.8 Hz, 1H), 3.86 (t, J = 4.20 Hz, 2H), 3.62 (t, J = 4.2 Hz, 2H), 
3.54 (t, J = 4.20 Hz, 2H), 3.49 (bs, 6H), 2.70 (t, J = 4.2 Hz, 2H), 2.39 (s, 6H). 13C 
NMR (100 MHz, CDCl3); δ ppm 166.2, 157.1, 146.8, 94.7, 70.3, 70.2, 68.8, 67.8, 
58.1, 49.5, 45.1.  IR (neat) 3326, 3184, 2867, 1645, 1520, 1489, 1385 cm–1.  
HRMS (ESI) Calculated for C12H23N4O3 m/z (M+H) 271.1770, Obsd. 271.1770. 
 
(2R,4S) –tert–butyl2– (tert – butyl) –4– ((4– ((1– (2– (2–(dimethylamino) 
ethoxy)ethyl)–2–oxo–1,2–dihydropyrimidin–4–yl)carbamoyl)phenyl)carbam-
oyl)–4–methyloxazolidine–3–carboxylate:  





methyloxazolidine–4–carboxamido)benzoic acid (20 mg, 0.04 mmol) in 
dichloromethane (2 mL), was added EDCI (11 mg, 0.05 mmol), HOBt (7 mg, 0.05 
mmol), NEt3 (20 µL, 0.14 mmol) and stirred at room temperature for 5 min. 4–
Amino–1–(2–(2–(dimethylamino)ethoxy)ethyl)pyrimidin–2(1H)–one (12 mg, 0.04 
mmol) was added to this mixture, and stirring continued for an additional 2 hrs. The 
reaction mixture was quenched with a saturated NaHCO3 solution and diluted with 
3 mL of dichloromethane. The organic layer was separated and washed with water 
(2 X 2 mL) followed by a brine wash (1 X 2 mL). The organic layer was dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure.  The crude 
product was purified by flash chromatography (5% MeOH/CHCl3, 1% Et3N) 
afforded the desired compound (15 mg, 54%) as a yellow sticky solid. [α]20D = –2.8 
(c = 2, CHCl3). 1H NMR (300 MHz, CDCl3): δ ppm 7.90 (d, J = 9.0 Hz, 2H), 
7.82 (d, J = 7.2 Hz, 1H), 7.69 (d, J = 9.0 Hz, 2H), 7.40 (d, J = 7.2 Hz, 1H), 5.21 (s, 
1H), 4.82 (d, J = 9.6 Hz, 1H), 4.11 (t, J = 5.4 Hz, 2H), 3.84 –3.76 (m, 3H), 3.62 – 
3.54 (s, 6H), 2.52 (t, J = 5.4 Hz, 2H), 2.28 (s, 6H), 1.73 (s, 3H), 1.54 (s, 9H), 0.91 
(s, 9H).  IR (neat) 2961, 1733, 1683, 1653, 1635, 1598, 1521, 1481 cm–1.  HRMS 








midin–4–yl)benzamide trifluoroacetate salt: brick red colored solid. [α]20D = –
2.8 (c = 2.00, CHCl3). 1H NMR (400 MHz, D2O); δ ppm 8.10  (d, J = 7.2 Hz, 2H), 
7.98 (d, J = 8.8 Hz, 1H), 7.70 (d, J = 8.8 Hz, 2H), 7.47 (d, J = 6.8 Hz, 1H), 
4.19 (d, J = 12.0 Hz, 1H), 4.18–3.94 (m, 2H), 3.93 (d, J = 12.0, 1H), 3.90 (t, 
, J = 5.2, 2H), 3.82 – 3.79 (m, 2H), 3.75 – 3.68 (m, 4H), 3.37–3.33 (m, 2H), 
2.91 s, 6H), 1.73 (s, 3H) 13C NMR (100 MHz, D2O ); δ ppm.169.5, 168.7, 163.1, 
157.8, 151.5, 140.9, 129.2, 121.8, 117.8, 114.9, 98.1, 69.7, 67.5, 63.9, 62.1, 56.7, 
50.3, 46.6, 42.7, 22.4, IR (neat) 2924, 2854, 1699, 1669, 1652, 1635, 1558, 1506, 





benzamide trifluoroacetate salt: 
White solid. 1H NMR (400 MHz, D2O); δ ppm 8.04 (d, J = 7.2 Hz, 1H), 
7.91 (d, J = 8.0 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 7.2 Hz, 1H), 
4.19 (d, J = 12.4 Hz, 1H), 4.10 (bs, 2H), 3.97(d, J = 12.4, 1H), 3.84 (bs 2H), 3.74 
– 3.65 (m, 8H), 1.73 (s, 3H) 13C NMR (100 MHz, D2O); δ ppm.171.9, 170.6, 165.2, 
159.5, 154.4, 143.6, 131.7, 131.4, 123.9, 100.3, 73.3, 72.2, 71.9, 69.8, 66.7, 64.7, 








benzamide trifluoroacetate salt: 
White solid. 1H NMR (400 MHz, D2O) δ ppm 8.17 (d, J = 5.6 Hz, 1H), 8.02 
(d, J = 6.8 Hz, 2H), 7.74 (d, J = 6.4 Hz, 2H), 7.54 (d, J = 5.6 Hz, 1H), 4.19 (d, J = 
12.4 Hz, 1H), 4.16 (bs, 2H), 4.03 (d, J = 12.4 Hz, 1H), 3.96 (bs, 2H), 3.88 (bs, 2H), 







SECOND GENERATION AMICETIN ANALOGS 
 
Background  
Our first generation analogs were targeted at removal of the acid labile 
glycosidic (cytosine–acetal) linkage and replacing the complex disaccharide with 
a stable alkyl group. In doing so, we synthesized ~15 analogs, and identified a set 
of five simplified analogs that retained activity including our first lead analog HKR–
02–058 / CZ–02–023.1 The analog CZ–02–023 has shown to be active against 
Mtb H37Ra with an IC50 of 0.98 M (amicetin H37Ra IC50 = 0.24 M) only 4–fold 
less active than the natural product amicetin. Moreover, the analog CZ–02–023 
has 3–fold higher on–target activity (E. coli S30 IC50 = 0.261 M) compared to 
amicetin (E. coli S30 IC50 = 0.851 M), with no measurable cytotoxicity against 
CEM/TARTs and no CYP induction at 100 M. One of the biggest assets of the 
first generation analogs is that they are easily accessible and simple in structure 
with only one stereocenter, that of the –methyl serine (compared to amicetin with 
9–stereocenters).  
 
Hydrolytic Stability of First Generation Analogs 
The biggest concern associated with the first generation analogs is their 





formed between cytosine and the p–aminobenzoate fragment is not only base 
labile but also acid sensitive. The Boc–protected first generation analogs under 
deprotection reaction conditions (TFA or Methanolic–HCl for >4h) result in 
hydrolysis of the amide bond. The hydrolytic decomposition of purified final 
compounds largely through the amide bond is seen, when stored in methanol (t1/2 
= 72h). The acid sensitivity of these compounds is attributed to the strong electron 
withdrawing nature of cytosine that results in increased electrophilicity of the 
carbonyl of the amide thereby making this bond vulnerable to hydrolysis (Figure 
3.1. (b)). 
  
Solvolysis and half–life of CZ–02–023 
 The half–life of CZ–02–023 (both freebase and HCl salt) was determined 
under different conditions at 25 oC using proton nuclear magnetic resonance 
(NMR) spectroscopy. The measured half–life under different conditions are 
reported in Figure 3.1(b). (See supporting information for experimental procedure).  
 
Replacement of p–Aminobenzoate with 2–Aminopyridines 
In our second generation analog synthesis, our efforts were focused on 
optimizing CZ–02–023 derivatives to improve stability, and potency retaining the 
selectivity. Advanced SAR on CZ–02–023 stems from the inputs provided by 
docking studies of newly designed bi–aryl amine analogs on to the X–ray crystal 
structure of amicetin bound to the ribosome. The docking studies confirm that the 
replacement of p–amino benzoate with 2–aminopyridines would preserve all the 





 Accordingly, our next strategy was complete removal of hydrolytically labile 
p–amino benzoate and replacing it with 2–aminopyridine while still preserving the 
essential structural features (including charged amine termini) to retain amicetin–
like ribosomal binding. Presumably, the co–planarity of two aromatic rings in the 
proposed bi–aryl amine will allow the flanked amine to be able to base pair with 
G2251, preserving a donor–acceptor–acceptor pattern. The  interaction with 
A2602 involving p–amino benzoate will be accomplished by pyridine / phenyl ring 
in these newly designed analogs. The flexible n–butyl–(4–amino)–piperadinyl 
linker with primary amine terminus will continue to engage in a cation –  
interaction with A2439 and the amine of 1,3–diamine will form a hydrogen bonding 
interaction with the western portion of binding pocket with the phosphate of G2495 
(Figure 3.2).  
In this chapter, we describe the synthesis and biological evaluation of 
different bi–arylamines (pyridyl–cytosine / phenyl–cytosine) with varied charged 
terminus in the solvent front (western portion of the binding pocket).  
 
Synthesis of Pyridyl–Cytosine Analogs 
 We envisioned the synthesis of designed bi–aryl amine analogs by 
employing a Buchwald–Hartwig amination of N1–alkylated cytosine 4 and 
substituted aryl halides 4a.2, 3, 4, 5, 6 The synthesis of substituted aryl halides could 
be achieved from corresponding aldehydes and acids via a reductive amination or 
peptide coupling with N–Boc–1,3–diamino propane, respectively (Figure 3.3). 
The forward synthesis of pyridyl–cytosine analogs began with the 





3.1, the reductive amination of 2–bromo–4–formyl pyridine 2a with N–Boc–1,3–
diamino propane and followed by Boc protection of resultant 2o amine afforded di–
amino halo pyridine 2. The amide 3 was synthesized via a peptide coupling 
reaction of N–Boc–1,3–diaminopropane and 2–bromo–pyridine–4–carboxylic acid 
3a. The hydroxy methyl 1a was protected using TBS and the resultant TBS 
protected alcohol 1 was used in next step. The prepared substituted 2–
halopyridines (1, 2, and 3) were individually reacted in different reaction sequences 
with an alkylated cytosine 4 under Buchwald–Hartwig amination conditions 
followed by global deprotection yielded bi–aryl amine analogs as shown in section 
D Scheme 3.1.  
The pyridyl–cytosine analogs that we synthesized were tested against Mtb 
H37Ra / Mtb H37Rv and for protein synthesis inhibition assays. As expected, the 
analog with terminal alcohol (no interactions in the western portion of the binding 
pocket in docking studies) CZ–02–024 was inactive at 50 M (MTT assay). The 
analog with the diamine amine CZ–02–025 (western half) showed improved 
activity against Mtb H37Ra over the PABA derivatives of amicetin CZ–02–023 (IC50 
= 0.98 M) and is equipotent with amicetin (IC50 = 0.24 M). The 3–pyridylamide 
substituted analog CZ–02–026 was 2–fold more active than the natural product 
amicetin itself. More importantly, both the analogs (CZ–02–025 / 026) have shown 
excellent on–target potency (E. coli S30), and are noncytotoxic to mammalian cell 







Synthesis of Pyridyl–Cytosine and Phenyl–Cytosine 
Analogs 
The potential biological activities of newly synthesized pyridyl–cytosine 
analogs encouraged us to synthesize phenyl pyridyl C4 & C5–substidtuted, and 
C3 & C4–substidtuted 1,3–diamino propane amide and amine variations of biaryl 
analogs (suggestions from docking studies), and tested for their antitubercular, and 
protein synthesis inhibition properties. 
During the synthesis of phenyl–cytosine derivatives, the general Buchwald–
Hartwig amination reaction conditions that worked with activated aryl halides (2–
halopyridines) and weak nucleophile (N1–alkylated cytosine) did not work for halo 
benzenes (Bromo benzene or Iodo benzene). Through the screening of various 
ligands, palladium catalysts and bases we identified a set of optimized reaction 
conditions with Xantphos/Pd(dba)2/Cs2CO3 shown in Scheme 3.2 to couple halo 
benzene 6 to alkylated cytosine 4.2, 3, 4, 5, 6 
Employing optimized amination conditions, we synthesized the phenyl 
cytosine analogs with substitutions on C3 & C4 of phenyl ring (amides and amines 
with 1,3–diaminopropane) as shown in Scheme 3.2. The synthesis of the C3/C4–
substituted halo benzenes was accomplished in a similar fashion following similar 
protocols to those described in Scheme 3.1. 
 
Biological Evaluation of Pyridyl–Cytosine and 
Phenyl–Cytosine Analogs 
Biological evaluation of these meta or para substituted phenyl/pyridyl–





or 2– to 3–fold more active than amicetin against Mtb H37Ra. As expected, 
pyridyl–cytosine derivatives were more active than the phenyl–cytosine derivatives 
(activity is attributed to the planarity of pyridyl–cytosine derivatives). However, the 
most concerning factor with these new analogs is the loss of selectivity for 
prokaryotic translation over eukaryotic protein synthesis inhibition. In fact, m–
substituted pyridyl–cytosine derivatives inhibit eukaryotic translation (Rabbit 
Reticulocyte Lysate) at lower concentrations than prokaryotic translation (E. coli 
S30) in vitro. The p–substituted phenyl / pyridyl–cytosine derivatives are slightly 
selectivity for prokaryotic translation inhibition (Figure 3.2). These compounds 
show no measurable toxicity to Vero cells (nontoxic, IC50s > 100 M at 24 hrs). 
Much to our excitement, the p–substituted derivatives HKR–02–033 / 039 have 
shown to be active against Gram (–) bacteria (whole cell activity) with MIC’s 1–8 
g/mL against E. coli , WT K. pneumoniae (wild type Klebsiella pneumonia), CRE 
K. pneumoniae (Carbapenem–Resistant Enterobacteriaceae) and moderately 
active against P. aeruginosa (>64 g/mL). The broad–spectrum activity of p–
substituted derivatives opens up new avenues of developing broad spectrum 
antibiotics (Table 3.2). 
 
Synthesis of RX–P792 for Internal Reference7 
Encouraged by the activity profiles of p–substituted derivatives, and upon 
further developments, we were hoping to optimize these molecules to create 
selective and more potent broad spectrum antibiotics. As addressed briefly by 
Melinta therapeutics in an ASM (American Society for Microbiology) microbe 





Nobel Prize– winning science. Most importantly, BlaS served as an inspiration for 
their program to develop novel broad–spectrum pyrrolocytosine containing protein 
synthesis inhibitors.7, 8, 9 Toxicity of the pyrrolocytosine class of compounds has 
been one of the major issues they have yet to address.  Before proceeding with 
further SAR on bi–aryl amine derivatives, we targeted the synthesis of Melinta’s 
active compound RX–P792 as an internal reference to gain insights into the factors 
governing the Gram (–) penetrance, potency, and toxicity. The convergent 
synthesis of RX–P792 was achieved by improvising a reported protocol shown in 
Scheme 3.3.  
 
Retrosynthetic analysis of RX–P7927 
 The reported convergent synthetic procedure for RX–P792 employs a key 
Sonogashira cross–coupling reaction of N1–arylated–5–Iodocytosine 9 
intermediate with substituted phenyl acetylene 8, followed by an intramolecular 
cyclization reaction to produce the pyrrolocytosine. The eastern half of the 
molecule N1–arylated–5–Iodocytosine 9 was synthesized by employing a Chan–
Lam coupling reaction of iodo cytosine and boronic acid 11. The phenyl acetylene 
8 is synthesized via a sequence of reactions from fluoro, chloro–substituted aniline 
10. Installation of guanidine on the 1o amine of the eastern half was carried out in 
the penultimate step of the synthesis. The optimized synthetic route for the western 
half of the molecule (substituted phenyl acetylene) followed a different synthetic 







Reported synthetic procedure of substituted  
phenylacetylene 
 The reported synthetic procedure for substituted phenylacetylene 8 involves 
a six longest–linear step sequence of reactions beginning from a commercially 
available starting material 4–Chloro–3–fluoroaniline 10. The 4–Chloro–3–
fluoroaniline subjected to ortho–iodination followed by ortho–bromination using the 
amine as a strong o–directing group, resulted in 2–bromo–4–Chloro–3–fluoro–6–
Iodo–aniline 12. Deamination of the aniline was accomplished by Knoevenagel 
diazotization followed by 1N NaOH workup to afford 1–bromo–3–Chloro–2–fluoro–
5–Iodo–benzene 13. The reactivity of aryl Iodide was utilized in regio–selective 
Suzuki–Miyaura cross–coupling reaction with N–cbz–butyl amino boronate to yield 
alkylated aryl bromide 14. The reactive bromide was then used in the Sonogashira 
cross–coupling reaction with trimethylsilyl acetylene, followed by base mediated 
desilylation of the resultant TMS alkyne 15 to afford the desired product [4–(4–
Chloro–3–ethynyl–5–fluoro–phenyl)–butyl]–carbamic acid benzyl ester 8. The 
synthetic sequence involves a couple of low yielding steps (47–55%), and also 
other industrious reaction conditions and expensive reagents as shown in Scheme 
3.4.10 
An efficient convergent synthetic route to RX–P792 followed an initial 
synthesis of coupling partners, and late stage installation of guanidine functionality 







Modified synthetic procedure for substituted phenyl 
acetylene 
 Our expedient synthesis of the substituted phenyl acetylene (western half) 
involved a short sequence of three simple steps as shown in Scheme 3.5 
(compared to six steps in a reported procedure in Scheme 3.4). The optimized 
route begins with Iodination of the cheap feedstock chemical 2–Chloro–3–fluoro–
benzaldehyde (25G–34$) using aldehyde as the m–directing group resulted in 2–
Chloro–3–fluoro–5–Iodo–benzaldehyde 16. The aryl iodide was subjected to 
Suzuki–Miyaura cross–coupling reaction conditions with in situ generated N–Cbz–
butyl amino boronate to afford alkylated benzaldehyde 17. The terminal alkyne 18 
was generated from aldehyde using Ohira–Bestman reagent in high yields as 
shown in Scheme 3.5.7, 11, 12 
 
Synthesis of N1–arylated–5–iodocytosine 
The coupling partner to create the pyrrolo–cytosine (N1–arylated–5–
Iodocytosine) fragment 9 was synthesized following a reported protocol, albeit 
some modified workup procedures for few reactions. The synthesis commences 
with iodination of cytosine to give 5–Iodo cytosine as shown in section (E) Scheme 
3.6.13 In another reaction sequence (F), reductive amination of 4–formyl 
phenylboronic acid with N–Boc–1,3–diaminopropane followed by Boc protection 
of resultant 2o amine produced amino alkyl phenylboronic acid 18. The resultant 
phenylboronic acid was oxidatively coupled to 5–iodocytosine under Chan–Lam 
cross–coupling conditions to form the new N–C bond, resulting in N1–arylation of 





benzoic anhydride to afford the eastern half 9 of the pyrrolocytosine as depicted in 
Scheme 3.6.  
 
Regioselective guanylation and synthesis of RX–P792 
Having both coupling partners in hand, we went on to synthesize RX–P792. 
The pyroolocytosine 20 was prepared from the Sonogashira cross–coupling 
reaction of the two coupling partners’ phenyl acetylene 8 and iodo cytosine 9, 
followed by in situ cyclization and debenzoylation. Later, Boc–deprotection of the 
resultant pyrrolocytosine 20 derivative and subsequent regioselective guanylation 
of the 1o amine in the presence of the 2o amine in diamine 21 using a bulky 
guanylating reagent N, N–bis–Boc–guanylpyrrazole resulted in the formation of 
guanidino–pyrrolocytosine 22. One pot deprotection of Cbz and Boc groups using 
thioanisole and trifluoroacetic acid followed by column purification afforded desired 
product RX–P792 as a yellow colored fluffy solid as illustrated in Scheme 3.7. 
 
Biological Evaluation of RX–P792 and Comparison with 
CZ–02–039 
The compound RX–P972 was screened for its antibacterial activity and 
protein synthesis inhibition activity. RX–P972 was active against a number of Gram 
(+) and Gram (–) bacteria with high nanomolar IC50. Though the SAR and synthesis 
of RX–P792 are inspired from BlaS, this compound is capable of engaging in a 
 stacking with A2602 like amicetin. We believe the ability of amicetin to  
stack with A2602 (compared to BlaS) is responsible for the selectivity for 





Surprisingly, the compound RX–P792 showed no selectivity when tested in 
translational inhibition assays. In fact, it was more potent against eukaryotic 
translation compared to prokaryotic translation (27 nM vs 37 nM). Both RX–P972, 
and CZ–02–039 being capable of engaging a  stacking interaction with A2602, 
are nonselective. This observation precludes the role of a  stacking interaction 
with A2602 in selectivity that we witnessed with amicetin and CZ–02–023. We 
assume the guanidine moiety is responsible for the broad-spectrum activity and 
lack of selectivity of RX–P792 similar to BlaS. The strong interactions (cation– ) 
involving guanidine with A2439, and hydrogen bonding interactions with the 
phosphate backbone of A2439 could contribute to the associated toxicity and non–
selective nature of BlaS analogs.  
Further, compared to RX–P792 (37 nM), CZ–02–039 (52 ± 13 nM) exhibits 
comparable E.coli protein synthesis inhibition, but minimal whole cell activity. We 
attribute the broad spectrum whole cell activity of RX–P792 to its high CLogP (3.35 
compared to 0.03 of CZ–02–039), and maybe the presence of guanidine on 1,3–
diamine. Having linked the whole cell activity (partially), and lack of selectivity to 
guanidine fragment present in RX–P972, we were keen to realize the biological 
profile of des–guanyl RX–P792 compared to RX–P792. We synthesized des–
guanyl RX–P792 employing a thioanisole, TFA–mediated one pot deprotection of 
di–Boc amine 20 (Scheme 3.8) and screened for antibacterial and translational 
inhibition activities. Surprisingly, des–guanyl RX–P792 continued to display broad 
spectrum activity, and was moderately selective for prokaryotic translational 





shown to be cytotoxic against Vero cell line with an IC50 of 18 M (Table 3.3). 
These results imply that the lack of cytotoxicity with CZ–02–039 could be a 
consequence of its physiochemical properties, restricting both bacterial and 
mammalian cell wall penetrance. It further suggests that SAR focusing on altering 
the physiochemical properties (cLogP, tPSA, MWt) of CZ–02–039 will enhance 
penetrance and potency. Further, all the three analogs RX–P972, des–guanyl RX–
P792, and CZ–02–039 have a primary amine as an electrostatic anchor in the 
western portion of the binding pocket (assuming they bind in a the similar fashion) 
attached to a 4– and 5–atom linker, respectively. We suspect the flexible linker 
with an attached primary amine is capable of engaging in off–target interactions, 
thereby resulting in loss of selectivity.  
 
Strategies for Increasing On–target Potency 
 while Retaining Selectivity 
With the inputs provided by RX–P792, and des–guanyl RX–P792 we aim 
to design our next set of analogs with an increased cLogP (hydrophilicity) for better 
permeability, and reduced degrees of freedom in the solvated front for selectivity. 
In addition, we preferred not to have a guanidine in our designed analogs to avoid 
the general toxicity issues associated with it. Our idea was to synthesize phenyl–
cytosine analogs with fluoro–and chloro–substitutions (the similar to RX–P792) on 
the phenyl rings, and reducing the number of basic amines (replace with a carbon 







Synthesis of CZ–02–033 analogs with increased cLogP 
All newly proposed analog synthesis involved a penultimate Buchwald–
Hartwig amination reaction of two essential coupling partners (amine 4 /aryl halide) 
followed by a global deprotection using methanolic HCl. The synthesis of designed 
analogs was pursued with the preparation of requisite western halves, followed by 
a Buchwald–Hartwig amination reaction using our optimized conditions with the 
eastern half 4. The fluoro–chloro–substituted phenyl derivatives were synthesized 
via an m–directed iodination9 of corresponding carboxylic acid and aldehydes 
followed by peptide coupling of 23 or reductive amination of 25 with N–Boc–1,3–
diaminopropane, respectively, to form iodo aryl amide 24 and iodo aryl amine 26 
as shown in Scheme 3.9. The amide 24 and amine 26 were reacted individually 
with alkylated cytosine 4 under Buchwald –Hartwig amination conditions followed 
by Boc deprotection resulting in CZ–02–037 and CZ–02–038, respectively 
(Scheme 3.9). 
 The synthesized analogs screened for their potential biological activities. 
Surprisingly, the newly synthesized fluoro–chloro– substituted phenyl derivatives 
have shown a substantial loss in activity across the spectrum (> 32–64 M) 
compared to 1–32 M (except P. aerugunosa >64) for unsubstituted counterpart 
CZ–02–033. We were unsure of the reason for the observed loss of activity (Table 
3.4). 
Since substitutions on the aryl ring did not help us in imparting potency and 
selectivity, we thought of varying the chain length and the nature of the linker in 





SN2 reaction of a cyclopropyl amine onto 4–bromo–1–butanol, followed by Boc 
protection of secondary amine 28 resulting in the formation of alcohol 29. Another 
SN2 reaction of the alcohol 29 onto 4– (bromomethyl)–2–bromopyridine afforded 
bromo pyridine 30. The western halves with variable alkyl linkers synthesized by 
employing Suzuki–Miyaura cross– coupling reaction of aryl boronic acid 31 or alkyl 
borane 37 with aryl halide 1–Bromo–2–fluoro–4–iodobenzene. The alkyl borane 
was prepared by the hydroboration of the corresponding terminal alkene (34 or 
36).7 The alkene 36 was prepared from 1–Boc–4–piperadone via a Wittig 
olefination reaction as shown in Scheme 3.10. 
The western halves synthesized above were reacted with alkylated cytosine 
4 under Buchwald–Hartwig amination conditions following a  protocol similar to that 
reported in Scheme 3.9 followed by Boc deprotection resulted in CZ–02–029 and 
CZ–02–040 / 41 / 42, respectively, as shown in Figure 3.5.     
The prepared analogs with diversified linkers in western half targeting 
increase in cLogP were tested in on–target protein synthesis inhibition assays. The 
analogs have shown a considerable loss in activity in translational inhibition. They 
were inactive against Gram (–) and Gram (+) bacteria and showed good activity 
against acid–fast Mycobacterium smegmatis (4–32 M). The analogs with ether 
linkages were shown to be active against the virulent strain of Mtb H37Rv with an 






Synthesis of CZ–02–039 analogs with reduced 
conformational freedom in linker region 
In an attempt to identify a lead compound with on–target potency and 
selectivity for bacterial translation inhibition, we focused on reducing the 
conformational freedom of the linker in the western portion of the binding pocket. 
The rationale for tweaking the amine linker stems from an assumption that the 
flexible linker engaging in off–target interactions could be the reason for the loss 
of selectivity. In order to reduce the conformational freedom, we thought of 
replacing 1,3–diamine with cyclic amines, and chiral tethered amine terminus on 
western halves. These designed linkers are synthesized from corresponding 
aldehydes, or acids, via a reductive amination or a peptide coupling reactions 
respectively as shown in Scheme 3.11. Reductive amination of aldehyde 39 with 
2o amine (4–Boc amino piperadine) was achieved under sodium triacetoxy 
borohydride conditions to give 3o amine 40, whereas for 1o amines, a conventional 
NaBH4 reduction was used to access 2o amine followed by Boc protection resulting 
in amine 41. To access benzyl amide 42, the benzyl amine 41 was used as a 
precursor in peptide couplings with acids (e.g., Boc–Ala), whereas the benzamide 
44 was synthesized via a peptide coupling reaction of carboxylic acid 43 and amine 
(N–Boc–azitidine–3–amine) using HATU as the peptide coupling reagent. The 
synthesis of ether linker 47 was accessed via an SN2 reaction of alcohol (L–prolinol) 
on to benzyl chloride 46. Using the reported protocols in Scheme 3.11, several 
amines, benzamides, benzyl amides were prepared and used in Buchwald–





amines with various rigid linkers in the western portion of the binding pocket. 
The compounds synthesized were screened for activity against M. 
smegmatis and translational inhibition, and the results are shown in Table 3.6. 
Most of these compounds have submicromolar on–target potency and good 
activity against M. smegmatis (2–32 g/mL). Since Mtb is hard and slow to grow 
in vitro, these compounds are tested against M. smegmatis (acid–fast bacteria). 
The activity profile against M. smegmatis correlates to Mtb. Compounds with MIC’s 
≤8 against M. smegmatis were further screened for activity against the virulent 
strain of Mtb (H37Rv) in collaboration with NIAID (National Institute of Allergy and 
Infectious Diseases), as shown in Table 3.7, and on–target protein synthesis 
inhibition activities but unfortunately none of these analogs retained selectivity.   
 
CZ–02–039 analogs with varied linkers in the 
eastern portion of the binding pocket 
Compared to amicetin (SI RR/E.Coli = 98), CZ–02–023 (SI RR/E.Coli = 111), 
where disaccharide of amicetin is replaced with butylamino piperadine has a better 
selectivity index. Assuming that the linker portion in the eastern half of the molecule 
has a role to play in the translational selectivity, we pursued modification in the 
cation– region in the eastern portion of the binding pocket. Expanding the 
optimized route to N1–butylaminopiperadine cytosine, we synthesized variable 
linker substitutions on N1–cytosine (eastern fragments) and subjected them to 
Buchwald–Hartwig amination conditions with the western half of the potent 
compound (CZ–02–039) in the synthesis of bi–aryl amine analogs (Scheme 3.3).  





–methyl (CZ–02–084) and N–methyl–4–aminopiperidene (CZ–02–085) showed 
comparable activity. The –methyl containing analog showed slightly better 
selectivity (E. coli /R. ret = 3.77) compared to CZ–02–039 (E. coli /R. ret = 1.6). 
 The two analogs were further screened against Mtb H37Rv and the results 
are shown in Table 3.9. 
 
Conclusion 
The second generation analogs synthesized by far replacing the p–amino 
benzoate with an amine functionality resulted in nonselective broad–spectrum 
antibacterial compounds (CZ–02–033, and 039), and nonselective anti–
mycobacterial compounds (CZ–02–026, 029, 048, 049, 050, 054) with 
submicromolar IC50s. The lode of translational selectivity of the second generation 


























Scheme 3.4 The reported synthetic sequence for substituted phenylacetylene 
 
 
















































Scheme 3.12 (S) Optimized protocol for cytosine–butyl amino piperadine, and (T) 















































































































































Table 3.6 Protein synthesis inhibition and MIC evaluation of CZ–02–compounds 





































Table 3.8 Biological evaluation of CZ–02–039 analogs with varied linkers in the 
eastern portion of the binding pocket 
 
    
 ** = @ 0.25 M, * = @ 0.1 g/mL 
 













Figure 3.1 Design of second generation amicetin analogs. (a) Strategies.  





















Figure 3.3 Retrosynthetic analysis of second generation amicetin analogs 
 
 
Figure 3.4 Cytosine–pyridyl/phenyl derivatives synthesized using a protocol 














Figure 3.6 Analogs with conformational rigid linkers in the western part of the 
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 Supporting Information 
General experimental considerations 
All reactions requiring anhydrous conditions were conducted in flame–dried 
glassware under a positive pressure of either nitrogen or argon. Commercially 
available reagents were used as received; otherwise, materials were purified 
according to Purification of Laboratory Chemicals. Acetonitrile (CH3CN), N,N’–
dimethylformamide (DMF), and tetrahydrofuran (THF) were degassed with 
nitrogen and passed through a solvent purification system (Innovative 
Technologies Pure Solv). Dry 1,4–dioxane was purchased from Acros Organics in 
a Acros Seal™ bottle. Microwave reactions were done in CEM Discover System 
Model 908005.  
Melting points were determined using a Mel–Temp® Capillary Melting Point 
Apparatus. Infrared spectra were obtained using Nicolet 380–FT IR spectrometer 
fitted with a Smart Orbit sample system. Optical rotations were obtained at ambient 
temperature on a Perkin Elmer Model 343 polarimeter (Na D line) using a microcell 
with a 1 decimeter path length. Mass spectra were determined on a Micromass 
Quattro II (ESI/APCI–TOF) for HRMS at the University of Utah Mass Spectrometry 
Facility. 1H NMR and 13C NMR spectra were recorded at 300 MHz, 400MHz, 500 
MHz and 13C NMR spectra were recorded at 75 MHz, 100 MHz, 125 MHz, 
respectively. Proton resonances were reported relative to the deuterated solvent 
peak: 7.26 ppm for CDCl3 and 3.31 ppm (center line signal) for CD3OD, 4.80 ppm 
for D2O using the following format: chemical shift (δ) [multiplicity (s= singlet, bs= 





multiplet), coupling constant(s) J in Hz, integration]. Carbon resonances were 
reported as chemical shifts (δ) in parts per million, relative to the center line signal 
of the respective solvent peak: 77.23 ppm for CDCl3 and 49.00 ppm for CD3OD. 
All the commercially available chemicals are purchased from Sigma–Aldrich, 
Acros, TCI America, Combi–Blocks, and Chem–Impex. 
 
Half–life of CZ–02–023 
CZ–02–023 freebase or salt was dissolved in CD3OD and D2O, 
respectively, (5 mM solution) and an array of proton NMR experiments are run with 
a 1-hr interval for 72-96 hrs. The solvolysis of CZ–02–023 was monitored by the 
formation of N1-alkylated cytosine (fragment B in Figure 3.1(b)). [Note: a distinct 
peak for cytosine C5-H was seen around  6 ppm]. The integral value for newly 
formed fragment B cytosine C5-H proton was calculated with respect to solvent 
peak. A plot of ln [Integral cyt-5H] vs Time in hrs gives a straight line, form that the 
half–life is calculated using the slope of the curve employing the first–order kinetics 
equation. 




 CZ–02–023 free base in CD3OD: 𝑡1/2  =  
0.693
0.009
= 77 (3.2) 
 
CZ–02–023 free base in CD3OD + 5% TFA: 𝑡1/2  =  
0.693
0.022
= 31.5 (3.3) 
 
CZ–02–023 free base in CD3OD + 5% TEA: 𝑡1/2  =  
0.693
0.042
= 16.5 (3.4) 
 
CZ–02–023–HCl salt in D2O: 𝑡1/2  =  
0.693
0.01














































































CZ-02-023-FB + 5% TEA

























Example for Buchwald-Hartwig amination 
 




oven dried microwave reaction tube was charged with 2–bromo–4–(((tert–
butyldimethylsilyl)oxy)methyl)pyridine (75 mg, 0.25 mmol), tert–butyl (1–(4–(4–
amino–2–oxopyrimidin–1(2H)–yl)butyl)piperidin–4–yl)carbamate (92 mg, 0.25 
mmol), NaOtBu (48 mg, 0.50 mmol), Pd3(dba)2 (23 mg, 25.0 µmol), rac–BINAP (23 
mg, 37. µmol) and dry toluene (1 mL). The reaction mixture was degassed and 
purged with nitrogen three times and stirred and heated in a focused CEM 





reaction mixture was diluted with EtOAc (3 mL) and filtered through a pad of 
Celite® and concentrated under reduced pressure. Purification on silica gel using 
flash chromatography (2% MeOH/CHCl3) afforded the desired product (55 mg, 




yl)amino)–2–oxopyrimidin–1(2H)–yl)butyl)piperidin–4–yl)carbamate (50 mg, 85.0 
µmol) was dissolved in 50% TFA in dichloromethane (1 mL) and stirred for 16 hrs 
at room temperature. The solvent was evaporated and the reaction was 
neutralized with Et3N. The compound was purified using MPLC to afford title 
compound 1–(4–(4–Aminopiperidin–1–yl)butyl)–4–((4–(hydroxymethyl)pyridin–2–
yl)amino)pyrami-din–2(1H)–one (25 mg, 79%) as a brown colored solid. Mp 174–
176 °C. 
1H NMR (500 MHz, CD3OD) δ ppm 8.23–8.19 (m, 2H), 7.75 (d, J = 7.0 Hz, 
1H), 7.08 (t, J1 = 1.5, J1 = 4.5 Hz, 1H), 6.51 (bs, 1H), 4.67 (s, 2H), 3.86 (t, J1 = 7.0, 
J1 = 7.5 Hz, 2H), 2.90 (d, J = 12.0 Hz, 2H), 2.65–2.60 (m, 1H), 2.39–2.37 (m, 2H), 
2.04–1.98 (m, 2H), 1.83–1.79 (m, 2H), 1.76–1.70 (m, 2H), 1.57–1.51 (m, 2H), 
1.44–1.36 (m, 2H). δ 13C NMR (125 MHz, CD3OD) δ ppm 163.9, 158.9, 155.0, 
153.8, 148.7, 147.9, 118.0, 113.7, 97.7, 79.5, 63.8, 59.0, 53.5, 51.1, 35.3, 28.1, 







CZ–02–025: Mp 174–176 °C. 
NMR (400 MHz, D2O) δ ppm 8.50 (d, J = 6.0 Hz, 1H), 8.13 (d, J = 7.6 Hz, 
1H), 7.52 (br s 1H), 6.47 (d, J1 = 6.8, 1H), 4.45 (s, 2H), 4.00 (br s, 2H), 3.73 (d, J 
= 12.8, 2H), 3.61–3.44 (m, 1H), 3.32–3.28 (m, 2H), 3.22 (br s, 2H), 3.17–3.11 (m, 
2H), 2.35 (d, J = 13.2, 2H), 2.21–2.12 (m, 2H), 1.20–1.92 (m, 2H), 1.90–1.84 (m, 
4H). HRMS Calculated for m/z, 429.3090 Obsd.429.3096 
 
CZ–02–026: Mp 194–196 °C. 
1H NMR (500 MHz, CD3OD) δ ppm 8.59 (br s, 1H), 8.31 (d, J = 8.0 Hz, 1H), 
7.71 (d, J1 = 7.5, 1H), 7.37 (d, J1 = 5.0, 1H), 6.29 (d, J1 = 4.0, 1H), 3.79 (t, J = 7.0, 
2H), 3.42–3.38 (m, 2H), 2.82 (d, J1 = 11.0, 2H), 2.69–2.65 (m, 2H), 2.57–2.51 (m, 
1H), 2.29 (t, J = 7.5, 2H), 1.93 (t, J = 12.0, 2H), 1.76–1.70 (m, 4H), 1.69–1.63 (m, 
2H), 1.49–1.43 (m, 2H), 1.36–1.27 (m, 2H). 13C NMR (120 MHz, CD3OD) δ ppm 
167.9, 163.8, 159.0, 154.3, 149.9, 148.1, 144.8, 118.3, 113.0, 97.8, 59.0, 53.5, 








Optimized Buchwald–Hartwig amination procedure 
CZ–02–030:4–((1–(4–(4–aminopiperidin–1–yl)butyl)–2–oxo–1,2–dihyd-
ropyrimidin–4–yl)amino)–N–(3–aminopropyl)benzamide: An oven dried 
pressure flask was charged with tert–butyl (3–(4–
bromobenzamido)propyl)carbamate (1.0 equiv.), tert–butyl (1–(4–(4–amino–2–
oxopyrimidin–1(2H)–yl)butyl)piperidin–4–yl)carbamate (1.01 equiv.), cesium 
carbonate  (2 equiv.), Pd(dba)2 (0.1 equiv.), Xantphos (0.2 equiv.) and dry dioxane 
(12 mL). The reaction mixture was degassed and purged with nitrogen three times 
and stirred at 105 °C for 16 hrs, after which the reaction mixture was diluted with 
CHCl3 (25 mL) and filtered through a pad of Celite® and concentrated under 
reduced pressure. Purification on silica gel using flash chromatography (2% 
MeOH/CHCl3) afforded the Boc protected product, which was further dissolved in 
methanolic HCl and stirred for 4 hrs. The methanol was evaporated after the 
completion of reaction (monitored by TLC), and the resultant solid was triturated 
with ether to remove miscellaneous organic impurities and dried over vacuum to 





1H NMR (500 MHz, D2O) δ 8.00 (d, J = 7.5 Hz, 1H), 7.95 (d, J = 9.0 Hz, 2H), 
7.60 (d, J = 9.0 Hz, 2H), 6.35 (d, J = 7.5 Hz, 2H), 3.99 (bs, 2H), 3.79 (d, J = 13.0 
Hz, 2H), 3.66–3.60 (m, 1H), 3.58 (t, J = 7.0 Hz, 2H), 3.27 (bs, 2H), 3.21–3.14 (m, 
4H), 2.41 (d, J = 13.0 Hz, 2H), 2.10–1.97 (m, 4H), 1.87 (bs, 4H). 13C NMR (125 
MHz, D2O) δ 171.9, 170.0, 158.3, 150.4, 137.0, 133.3, 129.0, 125.0, 94.9, 56.3, 




CZ–02–028: Mp 252–254 °C. 
1H NMR (500 MHz, CD3OD) δ 8.77 (d, J = 1.5 Hz, 1H), 8.35 (bs, 1H), 8.17 
(dd, J1 = 2.0 Hz, J2 = 7.5 Hz, 1H), 7.85 (d, J = 7.0 Hz, 1H), 6.56 (d, J = 3.5 Hz, 1H), 
3.89 (t, J = 7.0 Hz, 2H), 3.50 (t, J = 7.5 Hz, 2H), 2.96 (d, J = 12.0 Hz, 2H), 2.92 (t, 
J = 7.0 Hz, 2H), 2.89–2.84 (m, 1H), 2.41 (t, J = 8.0 Hz, 2H), 2.07 (t, J = 10.0 Hz, 
2H), 1.92–1.89 (m, 4H), 1.78–1.70 (m, 2H), 1.59–1.47 (m, 4H). 13C NMR (125 
MHz, CD3OD) δ 168.3, 164.0, 158.9, 156.1, 149.0, 148.6, 138.2, 125.9, 115.1, 
98.1, 58.9, 53.1, 51.3, 49.6, 39.0, 37.9, 33.3, 30.7, 28.2, 24.8 ppm. Observed LC–








CZ–02–029: Mp 256–258 °C. 
1H NMR (500 MHz, D2O) δ 8.29 (d, J = 6.0 Hz, 1H), 8.04 (d, J = 7.5 Hz, 1H), 
7.42 (d, J = 6.0 Hz, 1H), 7.40 (s, 1H), 6.40 (d, J = 7.5 Hz, 1H), 4.76 (s, 2H), 3.96 
(t, J = 6.5 Hz, 2H), 3.75–3.67 (m, 4H), 3.57–3.51 (m, 1H), 3.29 (t, J = 7.0 Hz, 2H), 
3.19 (t, J = 6.5 Hz, 2H), 3.09 (t, J = 13.5 Hz, 2H), 2.74 (t, J = 6.5 Hz, 2H), 2.32 (d, 
J = 13.5 Hz, 2H), 2.09–2.01 (m, 2H), 1.97–1.87 (m, 2H), 1.80 (bs, 4H). 13C NMR 
(125 MHz, D2O) δ 161.9, 158.0, 155.4, 150.1, 148.9, 137.5, 117.7, 112.9, 97.1, 
70.0, 68.2, 56.2, 50.6, 50.0, 45.8, 45.3, 30.0, 27.0, 25.4, 25.1, 20.6, 2.9 ppm. 
Observed LC–MS [M+H]+ 470.3 
 
CZ–02–037:  Mp 283 °C. (decomposition) 
1H NMR (500 MHz, D2O) δ 8.45 (d, J = 3.5 Hz, 1H), 7.63 (d, J = 7.0 Hz, 1H), 
7.51 (d, J = 4.0 Hz, 1H), 6.08 (d, J = 7.5 Hz, 1H), 3.69 (t, J = 7.5 Hz, 2H), 3.29 (t, 
J = 6.5 Hz, 2H), 2.76 (t, J = 10.5 Hz, 2H), 2.71 (d, J = 7.0 Hz, 2H), 2.66–2.59 (m, 
1H), 2.17 (t, J = 10.5 Hz, 2H), 1.88 (t, J = 10.5 Hz, 5H), 1.71 (d, J = 7.5 Hz, 2H), 
1.55 (d, J = 7.5 Hz, 2H), 1.38–1.30 (m, 4H). 13C NMR (125 MHz, D2O) δ 167.8, 





122.9, 122.2 (d, JC–F = 17), 97.4, 58.8, 53.1, 51.5, 49.4, 39.0, 38.2, 33.6, 30.7, 
28.1, 24.6 ppm. Observed LC–MS [M+H]+ 494.2 
 
CZ–02–038. 
1H NMR (500 MHz, D2O) δ 7.95 (d, J = 7.5 Hz, 1H), 7.76 (bs, 1H), 7.65 (bs, 
1H), 6.26 (bs, 1H), 4.29 (s, 2H), 3.91 (bs, 2H), 3.71 (d, J = 13.0 Hz, 2H), 3.58–3.53 
(m, 1H), 3.32–3.17 (m, 4H), 3.09 (t, J = 8.5 Hz, 2H), 2.34 (d, J = 13.0 Hz, 2H), 
2.15–2.08 (m, 2H), 1.98–1.90 (m, 2H), 1.80 (bs, 4H). 13C NMR (125 MHz, D2O) δ 
160.0, 153.1 (d, JC–F = 250), 149.7, 131.3, 128.0, 127.1, 124.1, 122.6, 122.4, 
94.95, 56.2, 50.7, 50.0, 49.4, 46.6, 45.3, 44.2, 36.5, 27.05, 25.03, 23.65, 20.61 
ppm. Observed LC–MS [M+H]+ 480.3 
 
CZ–02–039: Mp 182–184 °C. 
1H NMR (500 MHz, CD3OD) δ 8.26 (s, 1H), 8.23 (bs, 1H), 7.78 (d, J = 8.0 
Hz, 2H), 6.50 (bs, 1H), 3.87 (t, J = 7.0 Hz, 2H), 3.75 (s, 2H), 2.94 (d, J = 12.0 Hz, 
2H), 2.84 (t, J = 7.0 Hz, 2H), 2.75–2.66 (m, 3H), 2.40 (t, J = 7.0 Hz, 2H), 2.06 (t, J 
= 12.0 Hz, 2H), 1.86 (d, J = 12.0 Hz, 2H), 1.79–1.71 (m, 4H), 1.59–1.53 (m, 2H), 





148.1, 139.8, 131.7, 116.2, 97.9, 59.1, 53.5, 51.3, 51.2, 49.6, 46.7, 40.4, 34.7, 
31.3, 28.3, 24.8 ppm. Observed LC–MS [M+H]+ 429.3 
 
CZ–02–041. 
1H NMR (500 MHz, CD3OD) δ 8.19 (bs, 1H), 7.72 (d, J = 7.0 Hz, 1H), 7.60 
(d, J = 8.0 Hz, 2H), 7.45–7.36 (m, 4H), 6.18 (d, J = 7.0 Hz, 1H), 3.83 (t, J = 7.0 Hz, 
2H), 3.80 (s, 2H), 2.93 (d, J = 11.5 Hz, 2H), 2.89 (t, J = 7.0 Hz, 2H), 2.80 (p, J1 = 
3.0 Hz, J2 = 7.0 Hz, 1H), 2.72 (t, J = 7.0 Hz, 2H), 2.38 (t, J = 7.5 Hz, 2H), 2.05 (t, J 
= 11.5 Hz, 2H), 1.88 (d, J = 13.5 Hz, 2H), 1.80 (p, J = 7.0 Hz, 2H), 1.71 (p, J = 7.0 
Hz, 2H), 1.56–1.45 (m, 4H). 13C NMR (125 MHz, CD3OD) δ 165.0, 159.3, 156.6 
(d, JC–F = 247.4 Hz), 147.8, 140.1, 139.6, 130.4, 128.0, 127.0, 126.7 (d, JC–F = 11.4 
Hz), 123.6, 114.7 (d, JC–F = 19.9 Hz), 97.2, 59.0, 54.0, 53.2, 51.1, 49.7, 47.6, 40.3, 
33.7, 29.7, 28.3, 24.8 ppm. Observed LC–MS [M+H]+ 522.3 
 
CZ–02–048: Mp 277–279 °C. 
1H NMR (500 MHz, D2O) δ 8.61 (s, 1H), 8.27 (d, J1 = 8.5 Hz, 1H), 8.17 (d, 
J = 8.0 Hz, 1H), 7.47 (d, J = 8.5 Hz, 1H), 6.50 (d, J = 7.5 Hz, 1H), 4.49 (s, 2H), 
4.04 (t, J = 6.5 Hz, 2H), 3.80–3.55 (m, 6H), 3.30–3.11 (m, 6H), 2.53 (d, J = 13.0 





158.8, 151.1, 150.9, 144.5, 143.6, 123.9, 116.0, 115.8, 96.2, 56.1, 52.6, 50.7, 50.0, 
45.4, 45.0, 42.3, 27.1, 26.9, 25.1, 25.0, 20.6 ppm. Observed LC–MS [M+H]+ 455.3 
 
CZ–02–049: Mp 284–196 °C. 
1H NMR (500 MHz, D2O) δ 8.58 (s, 1H), 8.22 (dd, J1 = 2.0 Hz, J2 = 8.5 Hz, 
1H), 8.16 (d, J = 7.5 Hz, 1H), 7.43 (d, J = 8.5 Hz, 1H), 6.46 (d, J = 7.5 Hz, 1H), 
4.48 (s, 2H), 4.00 (t, J = 6.5 Hz, 2H), 3.70 (t, J = 12.5 Hz, 4H), 3.59–3.53 (m, 2H), 
3.27–3.20 (m, 4H), 3.12 (t, J = 13.0 Hz, 2H), 2.33 (d, J = 13.0 Hz, 4H), 1.94 (q, J 
= 13.0 Hz, 4H), 1.83 (bs, 4H). 13C NMR (125 MHz, D2O) δ 158.5, 151.6, 151.2, 
150.2, 146.2, 144.4, 121.7, 115.9, 115.8, 96.2, 56.5, 56.1, 50.7, 50.4, 49.9, 45.4, 
45.3, 27.0, 26.9, 25.0, 20.6 ppm. Observed LC–MS [M+H]+ 455.3 
 
CZ–02–050: Mp 284–286 °C. 
1H NMR (500 MHz, D2O) δ 8.59 (s, 1H), 8.23 (dd, J1 = 2.0 Hz, J2 = 8.5 Hz, 
1H), 8.17 (d, J = 7.5 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 6.47 (d, J = 7.5 Hz, 1H), 
4.62 (p, J = 7.0 Hz, 1H), 4.50 (d, J = 7.0 Hz, 4H), 4.42 (bs, 2H), 4.01 (t, J = 6.5 Hz, 
2H), 3.73 (d, J = 13.0 Hz, 2H), 3.61–3.54 (m, 1H), 3.22 (t, J = 6.5 Hz, 2H), 3.14 (t, 
J = 13.0 Hz, 2H), 2.35 (d, J = 13.0 Hz, 2H), 1.96 (dq, J1 = 4.0 Hz, J2 = 13.0 Hz, 





150.3, 145.0, 143.3, 123.2, 116.0, 96.1, 56.1, 50.7, 49.9, 48.8, 47.5, 45.9, 45.3, 
27.0, 25.0, 20.6 ppm. Observed LC–MS [M+H]+ 427.3 
 
CZ–02–051: Mp 249–251 °C. [α]20D = –5 (c = 0.10, H2O). 
1H NMR (500 MHz, D2O) δ 8.33 (s, 1H), 8.19 (d, J = 8.5 Hz, 1H), 8.09 (d, J 
= 7.0 Hz, 1H), 7.44 (d, J = 8.5 Hz, 1H), 6.43 (d, J = 7.0 Hz, 1H), 4.56 (d, J = 4.5 
Hz, 2H), 4.22 (t, J = 4.5 Hz, 1H), 4.05–3.97 (m, 4H), 3.73 (d, J = 13.0 Hz, 2H), 3.58 
(t, J = 11.5 Hz, 1H), 3.22 (t, J = 8.0 Hz, 2H), 3.14 (t, J = 11.5 Hz, 2H), 3.36 (d, J = 
13.0 Hz, 2H), 2.01–1.92 (m, 2H), 1.84 (bs, 4H). 13C NMR (125 MHz, D2O) δ 168.1, 
160.8, 154.0, 150.3, 148.7, 143.7, 137.8, 130.5, 116.1, 96.8, 60.1, 56.2, 54.5, 50.7, 
50.0, 45.4, 39.8, 27.1, 25.1, 20.7 ppm. LC–MS [M+H] 459.3 
 
CZ–02–052: Mp 223 – 225 °C. [α]20D = –6 (c = 0.10, H2O). 
1H NMR (500 MHz, D2O) δ 8.29 (s, 1H), 8.13 (dd, J1 = 2.0 Hz, J2 = 8.5 Hz, 
1H), 8.05 (d, J = 7.5 Hz, 1H), 7.47 (d, J = 8.5 Hz, 1H), 6.42 (d, J = 7.5 Hz, 1H), 
4.72 (s, 2H), 4.15 (q, J = 7.0 Hz, 1H), 3.98 (bs, 2H), 3.73 (d, J = 13.0 Hz, 2H), 3.58 
(t, J = 13.0 Hz, 1H), 3.22–3.16 (m, 2H), 3.14 (t, J = 13.0 Hz, 2H), 1.96 (q, J = 13.0 





161.0, 154.3, 150.0, 148.8, 143.1, 138.7, 130.4, 116.1, 96.8, 56.2, 50.7, 49.9, 49.0, 
45.4, 39.8, 27.1, 25.1, 20.7, 16.4 ppm. LC–MS [M+H] 443.3 
 
CZ–02–054: Mp 301–303 °C.  
1H NMR (500 MHz, CD3OD) δ 8.72 (bs, 1H), 8.42 (d, J = 5.0 Hz, 1H), 7.82 
(d, J = 7.5 Hz, 1H), 7.47 (d, J = 5.0 Hz, 1H), 6.40 (bs, 1H), 4.95–4.89 (m, 1H), 
4.00–3.83 (m, 6H), 2.97 (d, J = 12.0 Hz, 2H), 2.90–2.85 (m, 1H), 2.42–2.10 (m, 
2H), 2.08 (t, J = 12.0 Hz, 2H), 1.91 (d, J = 13.0 Hz, 2H), 1.78–1.72 (m, 2H), 1.58–
1.49 (m, 4H). 13C NMR (125 MHz, CD3OD) δ 167.7, 164.0, 159.2, 154.4, 150.1, 
148.3, 144.5, 118.5, 113.5, 98.0, 58.9, 54.2, 53.1, 51.3, 45.8, 33.2, 28.2, 24.8 ppm. 
Observed LC–MS [M+H]+ 441.3 
 
CZ–02–060: Mp 265 – 270 °C. [α]20D = –5 (c = 0.10, H2O). 
1H NMR (500 MHz, D2O) δ 8.37 (d, J = 2.0 Hz, 1H), 8.23 (dd, J1 = 2.0 Hz, 
J2 = 8.5 Hz, 1H), 8.15 (d, J = 7.0 Hz, 1H), 7.49 (d, J = 8.5 Hz, 1H), 6.49 (d, J = 7.0 
Hz, 1H), 4.61 (s, 2H), 4.07–4.02 (m, 3H), 3.92 (d, J = 12.5 Hz, 1H), 3.79 (d, J = 
13.0 Hz, 2H), 3.64 (p, J1 = 3.0 Hz, J2 = 8.0 Hz, 1H), 3.28 (t, J = 8.0 Hz, 2H), 3.20 





J2 = 13.0 Hz, 2H), 1.90 (d, J = 3.0 Hz, 4H), 1.65 (s, 3H). 13C NMR (125 MHz, D2O) 
δ 171.1, 160.8, 154.0, 150.3, 148.7, 143.7, 137.8, 130.7, 116.2, 96.9, 64.4, 61.4, 
56.3, 50.8, 50.0, 45.5, 40.0, 27.1, 25.2, 20.7, 18.1 ppm. Observed LC–MS [M+H]+ 
473.3 
 
CZ–02–062: Mp 190 – 194 °C. 
1H NMR (500 MHz, D2O) δ 8.36 (s, 1H), 8.26 (d, J = 9.0 Hz, 1H), 8.09 (d, J 
= 7.0 Hz, 1H), 7.45 (d, J = 9.0 Hz, 1H), 6.42 (d, J = 7.0 Hz, 1H), 4.67 (s, 2H), 3.99 
(bs, 2H), 3.73 (t, J = 6.0 Hz, 2H), 3.58 (t, J = 12.5 Hz, 1H), 3.22 (bs, 1H), 3.17–
3.10 (m, 4H), 2.35 (d, J = 14.0 Hz, 2H), 2.04–1.92 (m, 4H), 1.84 (bs, 4H). 13C NMR 
(125 MHz, D2O) δ 160.9, 154.2, 150.3, 148.9, 144.4, 137.9, 130.3, 116.0, 96.8, 
68.5, 67.9, 56.2, 50.7, 50.0, 45.3, 37.4, 27.1, 26.6, 25.1, 20.6 ppm. Observed LC–
MS [M+H]+ 473.3 
 
CZ–02–063: Mp 218 – 220 °C. [α]20D = –5.0 (c = 0.10, H2O). 
1H NMR (500 MHz, D2O) δ 8.37 (s, 1H), 8.24 (d, J = 8.5 Hz, 1H), 8.05 (d, J 
= 7.0 Hz, 1H), 7.44 (d, J = 8.5 Hz, 1H), 6.40 (d, J = 7.0 Hz, 1H), 4.69 (s, 2H), 3.96 





3.31 (t, J = 12.5 Hz, 2H), 3.19 (bs, 2H), 3.10 (t, J = 12.5 Hz, 2H), 2.32 (d, J = 13.5 
Hz, 2H), 2.16–2.05 (m, 2H), 2.04–1.96 (m, 2H), 1.95–1.86 (m, 2H), 1.81 (bs, 4H). 
13C NMR (125 MHz, D2O) δ 160.7, 153.9, 150.0, 148.7, 144.0, 137.6, 129.8, 115.8, 
96.6, 68.6, 68.5, 58.9, 55.9, 50.4, 49.8, 45.4, 45.1, 26.8, 25.6, 24.8, 23.0, 20.4 
ppm. Observed LC–MS [M+H]+ 456.3 
 
CZ–02–067: Mp 265 – 267 °C. 
1H NMR (500 MHz, D2O) δ 8.84 (d, J = 20 Hz, 1H), 8.41 (dd, J1 = 2.0 Hz, J2 
= 6.5 Hz, 1H), 8.19 (d, J = 6.5 Hz, 1H), 7.43 (d, J = 8.5 Hz, 1H), 6.49 (d, J = 8.5 
Hz, 1H), 4.98–4.91 (m, 1H), 4.46 (t, J = 11.5 Hz, 2H), 4.37 (t, J = 11.5 Hz, 2H), 
4.02 (t, J = 5.5 Hz, 2H), 3.73 (d, J = 13.0 Hz, 2H), 3.60–3.54 (m, 1H), 3.22 (t, J = 
8.0 Hz, 2H), 3.13 (t, J = 13.0 Hz, 2H), 1.20–1.90 (m, 2H), 1.85 (bs, 4H). 13C NMR 
(125 MHz, D2O) δ 166.4, 158.5, 152.6, 151.4, 150.1, 143.8, 140.3, 125.9, 115.3, 
96.1, 56.2, 52.0, 50.7, 50.0, 45.3, 42.3, 27.1, 25.0, 20.6 ppm. Observed LC–MS 
[M+H]+ 441.3 
 
CZ–02–068: Mp 264 °C. (decomposition)  





1H), 7.84 (d, J = 5.5 Hz, 1H), 7.02 (d, J = 7.5 Hz, 1H), 4.56 (t, J = 10.5 Hz, 2H), 
4.50 (t, J = 10.5 Hz, 2H), 4.26 (bs, 2H), 3.56 (d, J = 10.5 Hz, 2H), 3.74 (t, J = 10.5 
Hz, 1H), 3.40–3.35 (m, 1H), 3.28–3.20 (m, 4H), 2.34 (d, J = 12.5 Hz, 2H), 2.16–
2.09 (m, 2H), 1.98 (bs, 2H). 13C NMR (125 MHz, CD3OD) δ 166.8, 157.6, 152.0, 
147.4, 146.3, 140.6, 138.7, 134.0 (d, JC–F = 228.8 Hz), 130.0 (d, JC–F = 12.4 Hz), 
123.0, 118.9, 97.4, 57.4, 53.4, 51.9, 50.7, 46.9, 43.4, 28.5, 27.0, 22.0 ppm. 
Observed LC–MS [M+H]+ 459.3 
 
CZ–02–069: Mp 264–266 °C. [α]20D = –7.0 (c = 0.10, H2O). 
1H NMR (500 MHz, D2O) δ 8.66 (s, 1H), 8.19 (d, J = 8.5 Hz, 1H), 8.10 (d, J 
= 7.0 Hz, 1H), 7.37 (d, J = 9.5 Hz, 1H), 6.41 (d, J = 7.0 Hz, 1H), 4.16 (d, J = 12.0 
Hz, 1H), 3.99 (bs, 2H), 3.92 (d, J = 12.0 Hz, 1H), 3.72 (d, J = 13.0 Hz, 2H), 3.57 (t, 
J = 11.5 Hz, 2H), 3.21 (bs, 2H), 3.12 (t, J = 12.0 Hz, 2H), 2.34 (d, J = 13.0 Hz, 2H), 
1.99–1.89 (m, 2H), 1.83 (bs, 4H), 1.70 (s, 3H). 13C NMR (125 MHz, D2O) δ 169.6, 
158.3, 150.7, 150.5, 147.3, 136.3, 135.8, 131.0, 115.8, 96.1, 64.1, 62.1, 56.2, 50.7, 
49.8, 45.3, 27.1, 25.0, 20.6, 17.8 ppm. Observed LC–MS [M+H]+ 459.3 
 





1H NMR (500 MHz, D2O) δ 8.37 (s, 1H), 8.25 (d, J = 9.0 Hz, 1H), 8.08 (d, J 
= 7.5 Hz, 1H), 7.45 (d, J = 9.0 Hz, 1H), 6.43 (d, J = 7.5 Hz, 1H), 4.67 (s, 2H), 3.99 
(t, J = 6.5 Hz, 2H), 3.72 (d, J = 13.5 Hz, 2H), 3.57 (t, J = 12.5 Hz, 1H), 3.52 (s, 2H), 
3.21 (t, J = 7.5 Hz, 2H), 3.13 (d, J = 12.5 Hz, 2H), 3.09 (s, 2H), 2.67 (s, 3H), 2.35 
(d, J = 13.5 Hz, 2H), 1.99–1.88 (m, 2H), 1.83 (d, J = 3.5 Hz, 4H), 0.70 (q, J1 = 8.0 
Hz, J2 = 7.5 Hz, 4H). 13C NMR (125 MHz, D2O) δ 161.0, 154.2, 150.2, 149.0, 144.3, 
137.9, 130.3, 116.1, 96.9, 75.4, 68.5, 56.2, 55.3, 50.7, 50.0, 45.3, 33.3, 27.1, 25.1, 
20.6, 17.5, 9.6 ppm. Observed LC–MS [M+H]+ 470.3 
 
CZ–02–071: Mp 226–231 °C. 
1H NMR (500 MHz, D2O) δ 8.39 (d, J = 2.0 Hz, 1H), 8.26 (dd, J1 = 2.0 Hz, 
J2 = 6.5 Hz, 1H), 8.07 (d, J = 7.5 Hz, 1H), 7.45 (d, J = 9.0 Hz, 1H), 6.42 (d, J = 7.5 
Hz, 1H), 4.70 (s, 2H), 3.98 (t, J = 6.5 Hz, 2H), 3.84 (t, J = 5.0 Hz, 2H), 3.71 (d, J = 
13.5 Hz, 2H), 3.56 (p, J1 = 4.0 Hz, J2 = 8.0 Hz, 1H), 3.33 (t, J = 5.5 Hz, 2H), 3.20 
(t, J = 7.5 Hz, 2H), 3.14–3.08 (m, 2H), 2.96 (d, J = 7.5 Hz, 2H), 2.34 (d, J = 13.5 
Hz, 2H), 1.98–1.89 (m, 2H), 1.88–1.80 (m, 4H), 1.08–1.04 (m, 1H), 0.66 (q, J1 = 
6.5 Hz, J2 = 8.0 Hz, 2H), 0.33 (q, J1 = 5.0 Hz, J2 = 5.0 Hz, 2H). 13C NMR (125 MHz, 
D2O) δ 160.9, 154.1, 150.3, 149.0, 144.3, 138.1, 130.0, 116.1, 96.9, 68.7, 65.1, 
56.2, 52.3, 50.7, 50.0, 46.2, 45.3, 27.1, 25.1, 20.6, 6.4, 3.3 ppm. Observed LC–








1H NMR (500 MHz, D2O) δ 8.40 (s, 2H), 8.27 (d, J = 8.5 Hz, 1H), 8.07 (d, J 
= 7.5 Hz, 1H), 7.47 (d, J = 8.5 Hz, 1H), 6.43 (d, J = 7.5 Hz, 1H), 4.72 (s, 2H), 3.99 
(bs, 2H), 3.82 (t, J = 5.0 Hz, 2H), 3.72 (d, J = 13.0 Hz, 2H), 3.60–3.52 (m, 1H), 
3.26 (bs, 2H), 3.21 (bs, 2H), 3.12 (t, J = 8.0 Hz, 2H), 3.34 (d, J = 13.0 Hz, 2H), 
1.98–1.90 (m, 2H), 1.83 (bs, 2H). 13C NMR (125 MHz, D2O) δ 161.0, 154.3, 150.2, 
144.2, 138.0, 130.1, 116.1, 96.9, 68.6, 66.0, 56.2, 50.7, 50.0, 45.3, 39.0, 27.1, 







THIRD GENERATION AMICETIN ANALOGS 
 
Background 
So far, our efforts to design and synthesize selective prokaryotic 
translational inhibitors were focused on modifications of eastern (cation– region) 
and western halves (solvent front) of bi–aryl analogs. The SAR on bi–aryl analogs 
(second generation analogs) by synthesizing a wide range of structurally and 
functionally diverse compounds were unsuccessful in retaining selectivity. We 
appreciate the fact that these compounds could not advance unless we achieved 
selective prokaryotic translation inhibition. Initially, during the synthesis of second 
generation analogs we hypothesized that the ability of Ami to participate in  
stacking interaction with A2602 and its –methylserine motif’s interaction with L16 
ribosomal protein, unlike BlaS (universal translationa inhibitor), is responsible for 
the observed selectivity of Ami toward prokaryotic translation. However, the 
second generation Ami analogs synthesized (bi–aryl amines) demonstrated that 
the ability of engaging A2602 in a  stacking interaction and hydrogen bonding 
interactions in solvent front are not sufficient to confer the selectivity. Inability to 
identify a selective translational inhibitor, in spite of the considerable number of 
endeavors leads us to focus on the approaches to mitigate the hydrolytic stability 





by supplanting the amide with a sulfonamide a urea functionality (bio–isostere of 
amide). Focus on stabilizing the amide bond in CZ–02–023 series originates from 
key perceptions of the crystal structures of the ternary complex (amicetin/70S 
ribosome and P–tRNA) and an in depth analysis of crystal structures of BlaS bound 
to prokaryotic (70S) and eukaryotic (80S) ribosomes. 
 
X–ray Crystal Structure Inputs for Selectivity and  
Synthesis of Third Generation Analogs 
 The X–ray crystal structure of amicetin bound to the ribosome in the 
presence of P–site tRNA shows two asymmetric ribosome units, each displaying 
a distinct binding pattern of amicetin (exclusively the –methyl serine unit) in the 
solvent front. In one of the structures the –methyl serine amide rests in S–cis 
confirmation (Figure 4.1, colored in Orange) and exposes the amine to a set of 
most conserved (both in prokaryotes and eukaryotes) rRNA phosphate backbone 
which we named the “Ring of Fire” via a hydrogen bonding interaction with the 
phosphate of G2506, whereas, in the other conformer the –methyl serine unit of 
amicetin adopts S–tans amide (Figure 4.1, colored in gray) positioning the amine 
away from the ring of fire and toward the tRNA involving in a hydrogen bonding 
interaction with the C74–phosphate of tRNA. We hypothesize that the conformer, 
which can place the cationic amine away from the conserved chain of phosphates, 







Comparison of both the prokaryotic and  
eukaryotic ribosomal P-site 
To gain further insights into the factors governing the selectivity of amicetin 
toward prokaryotic translation inhibition, we analyzed the key structural similarities 
and differences in the prokaryotic 70S ribosome in comparison with the eukaryotic 
80S ribosome. Further hypothetical evidence for the selectivity of Ami arises from 
the docking studies of Ami on to the eukaryotic 80S ribosome.  
In the P–site of the prokaryotic ribosome (binding pocket of BlaS, and Ami), 
the closest distance between the amino acid E80 (where –methylserine of Ami 
interacts) of the ribosomal protein L16 and the WC donor G2262 (where is cytosine 
of Ami, and BlaS binds) is approximately 11.4Å (Figure 4.3), whereas in the 
eukaryotic ribosome (saccharomyces cerevisiae), the distance between the 
ribosomal protein L10 (analogous to L16 in prokaryotes) and WC donor G2619 is 
significantly ~ 3Å shorter (7.8Å) compared to 70S ribosome (Figure 4.4). BlaS 
(lacking the p–aminobenzoate tether attached to cytosine in Ami) being short, can 
be accommodated both in prokaryotes and eukaryotes hence nonselective. We 
hypothesize that the shorter binding pocket in eukaryotes fail to accommodate 
larger compounds like Ami in the binding pocket and hence Ami is selective toward 
prokaryotic translational inhibition.  Both the prokaryotic and eukaryotic ribosomes 
have a conserved chain of phosphates right above the ribosomal protein. The 
interaction on compounds with phosphate chain as in second generation analogs 
fail to confer the selectivity.2, 3 Advancing with the above hypothesis for selectivity 





ring of fire), we identified the piperazinyl ureas as replacements of p–
aminobenzoate in first generation Ami analogs (Figure 4.5). 
 
Synthesis of Piperazinyl Urea Derivatives of Amicetin 
One of the strategies to mitigate the hydrolytic liability of amide bond is to 
chemically modify it to urea functionality. Most importantly, the opposing dipole 
moments of carbonyl groups in piperazinyl ureas orients the amine away from the 
“ring of fire” and toward the C74 phosphate of tRNA. Docking studies of designed 
piperazinyl ureas onto the crystal structure of ternary complex confirm the anti–
conformation of two carbonyls positioning the tethered cationic amine away from 
the “ring of fire” (Figure 4.5). 
As demonstrated in Scheme 4.1, the designed urea analogs synthesis 
commenced with a peptide coupling reaction of the 3–Boc–amino butyric acid with 
Cbz–piperazine followed by Cbz de–protection of the resultant amide 50 to afford 
the piperazine derivative 51. In another reaction sequence, the reaction of carbonyl 
di–imidazole (CDI) with alkylated cytosine 4 resulted in an imidazole carboxamide 
52, which was further reacted with the preformed piperazine amide 51 to form the 
urea 53. Finally, Boc de–protection of urea 53 using methanolic HCl resulting in 
the urea derivative.4 
 The N1–Phenyl cytosine was synthesized by employing Chan–Lam 
coupling reaction of cytosine and phenyl boronic acid followed by reductive 
amination of resultant aldehyde 55 to give 3o amine 56. The N1–aryl cytosine 56 
was reacted with carbonyl di–imidazole (CDI) to form imidazole carboxamide 57 





cytosine urea derivatives follows the similarly reported protocols in Scheme 14.5 
Synthesis of N1–phenethyl amino cytosine 60 began with an SN2 reaction 
of Boc–amino piperadine onto bromoethyl bromo benzene to give bromo benzene 
58. The bromobenzene 58 was converted to boronate ester 59, which was 
subsequently reacted with cytosine under Chan–Lam conditions to yield N1–
phenethyl amino cytosine 60 (Scheme 4.3). The conversion of cytosine 60 to CZ–
02–132 follows the similarly reported protocol in Scheme 4.1.5 
Using similar procedures listed in Scheme 4.1 and 4.2 following compounds 
shown in Figure 4.6 were synthesized and tested for translational inhibitory activity. 
As shown in Table 4.1, these compounds exhibited a selectivity window of 
~34–580 (SIRR/E. coli). Some of these initial compounds further tested for their 
antimycobacterial activity and the results are shown in Table 4.2.  
Excited with the selectivity window these compounds offer, we decided to 
work out an SAR on urea derivatives to develop a broad–spectrum and selective 
translational inhibitor. For quick access to these urea derivatives, our strategy is to 
develop a unified approach (Scheme 4.4) employing a common intermediate as 
described in Scheme 4.1.6  
The synthesis of the common amine intermediate began with the 
trifluoroacetamide formation of Cbz–piperazine, which upon hydrogenolysis gave 
the piperazine trifluoroacetamide. The free amine is treated with CDI to produce 
the Imidazole carboxamide, which is further activated with methyl iodide and 
reacted with cytosine butyl amino piperadine to yield the urea. Finally, base 





intermediate free amine. We have synthesized ~25 urea derivatives by exploiting 
the common amine intermediate. 
 
Conclusion 
With important learning from the crystal structure of amicetin ternary 
complex, we were able to develop a class of compounds with high nanomolar on–
target potency, and good antimycobacterial activity, modest Gram (+) activity and 
more importantly, retained the translational selectivity (SI 34580) (CZ–02–107, 117, 
118, 132). Efforts are being continued to alter the physiochemical properties for 






























Scheme 4.2 Synthesis of N1–aryl cytosine imidazole carboxamide 
 
 



















Table 4.1 Evaluation of piperazinyl ureas in translational inhibition 
 
 











Figure 4.1 Overlay of two conformations of amicetin in Ami–70S–tRNA ternary 
complex1–2 
 







Figure 4.3 Blasticidin S and amicetin overlay in Tth 70S ribosome 
 


















Figure 4.6 Urea derivatives synthesized using a protocol similar to those reported 
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General experimental considerations 
All reactions requiring anhydrous conditions were conducted in flame–dried 
glassware under a positive pressure of either nitrogen or argon. Commercially 
available reagents were used as received; otherwise, materials were purified 
according to Purification of Laboratory Chemicals. Acetonitrile (CH3CN), N,N’–
dimethylformamide (DMF), and tetrahydrofuran (THF) were degassed with 
nitrogen and passed through a solvent purification system (Innovative 
Technologies Pure Solv). Dry 1,4–dioxane was purchased from Acros Organics in 
a Acros Seal™ bottle. Microwave reactions were done in CEM Discover System 
Model 908005.  
Melting points were determined using a Mel–Temp® Capillary Melting Point 
Apparatus. Infrared spectra were obtained using Nicolet 380–FT IR spectrometer 
fitted with a Smart Orbit sample system. Optical rotations were obtained at ambient 
temperature on a Perkin Elmer Model 343 polarimeter (Na D line) using a microcell 
with a 1 decimeter path length. Mass spectra were determined on a Micromass 
Quattro II (ESI/APCI–TOF) for HRMS at the University of Utah Mass Spectrometry 
Facility. 1H NMR and 13C NMR spectra were recorded at 300 MHz, 400MHz, 500 
MHz and 13C NMR spectra were recorded at 75 MHz, 100 MHz, 125 MHz, 
respectively. Proton resonances were reported relative to the deuterated solvent 
peak: 7.26 ppm for CDCl3 and 3.31 ppm (center line signal) for CD3OD, 4.80 ppm 
for D2O using the following format: chemical shift (δ) [multiplicity (s= singlet, bs= 





multiplet), coupling constant(s) J in Hz, integration]. Carbon resonances were 
reported as chemical shifts (δ) in parts per million, relative to the center line signal 
of the respective solvent peak: 77.23 ppm for CDCl3 and 49.00 ppm for CD3OD. 
All the commercially available chemicals are purchased from Sigma–Aldrich, 
Acros, TCI America, Combi–Blocks, and Chem–Impex. 
 
Experimental procedures 
Synthesis of Piperazinyl ureas 
Scheme 3 
 
Reagents: Step 1) HATU, DIPEA, DMF, rt, 4h, 2) 10% Pd/C, H2, MeOH, rt, 6h. 
 
tert–Butyl(2–methyl–4–oxo–4–(piperazin–1–yl)butan–2–yl)carbamate: 
Step 1: To a suspension of 3–((tert–butoxycarbonyl)amino)–3–methylbutanoic 
acid (0.96 g, 4.40 mmol) and HATU (2.01g, 5.30 mmol) in dry CH2Cl2 (20mL), N,N–
diisopropylethylamine (0.92 ml, 5.30 mmol) was added at room temperature. The 
suspension was stirred for 10 min. A solution of benzyl piperazine–1–carboxylate 
(0.97 g, 4.40 mmol) in CH2Cl2 (1.5 ml) was added. The solution was stirred at room 
temperature for 16h and the solvent evaporated under reduced pressure. Water 
was added to the reaction vessel and the resulting solid was collected by filtration. 
Purification via flash chromatography yielded benzyl 4–(3–((tert–butoxycarbonyl) 






Step 2: To a round bottom flask containing benzyl 4–(3–((tert–
butoxycarbonyl)amino)–3–methylbutanoyl)piperazine–1–carboxylate (1.40 g, 3.33 
mmol) and 10% Pd/C (140 mg, 1.3 mmol), was added MeOH (15 mL) and the 
suspension stirred at room temperature for 12 hrs under an atmosphere of 
hydrogen. The reaction mixture was filtered through a bed of celite, and the filtrate 
was concentrated under reduced pressure to afford tert–butyl (2–methyl–4–oxo–
4–(piperazin–1–yl)butan–2–yl)carbamate (0.795 g, 97%) as a sticky yellow solid.  
 
tert–Butyl (4–oxo–4–(piperazin–1–yl)butan–2–yl)carbamate: Prepared 
as in scheme 1 from 3–Boc–amino butanoic acid (0.50 g, 2.49 mmol) and 1–Cbz–
piperazine (0.55 g, 2.49 mmol) to afford the desired product as a tan solid (0.42 g, 
62%). 1H NMR (500 MHz, CDCl3): δ 4.94 (br s, 1H), 4.05 (br s, 1H), 2.56 (s, 2H), 













Synthesis of CZ–02–104 
 
 
Example 1 CZ–02–104: 4–(3–Amino–3–methylbutanoyl)–N–(1–(4–(4–
aminopiperidin–1–yl)butyl)–2–oxo–1,2–dihydropyrimidin–4–yl)piperazine–
1–carboxamide trihydrochloride salt:  Step 1: To a preheated suspension at 50 
°C under a nitrogen atmosphere of N–(2–oxo–1,2–dihydropyrimidin–4–
yl)acetamide (10.0 g, 65.3 mmol), sodium iodide (9.79 g, 65.3 mmol) and 
potassium carbonate (13.5 g, 98.0 mmol) in dry DMF (150 mL) was added 1,4–
dibromobutane (17.0 g, 98.0 mmol). After 16h, the reaction mixture was cooled 





Purification via flash chromatography (0–2% MeOH/CHCl3) afforded N–(1–
(bromomethyl)–2–oxo–1,2–dihydropyrimidin–4–yl)acetamide (7.40 g, 46%) as a 
colorless solid. 1H NMR (500 MHz, CDCl3): δ 10.50 (s, 1H), 7.60 (d, 1H), 7.42 (d, 
1H), 3.90 (q, 2H), 3.18 (t, 2H), 2.29 (s, 3H), 1.89 (t, 2H), 1.85 (t, 2H). 
Step 2: A mixture of N–(1–(bromomethyl)–2–oxo–1,2–dihydropyrimidin–4–
yl)acetamide (4.00 g, 13.9 mmol), 4–(N–Boc–amino)piperidine (2.75 g, 13.9 mmol) 
and potassium carbonate (2.85 g, 20.9 mmol) was suspended in dry CH3CN (100 
mL) at 70 °C under a nitrogen atmosphere. The reaction was stirred 4h before 
cooling, filtered and washed with chloroform (3 X 15 mL). The filtrate was 
concentrated under reduced pressure to yield tert–butyl (1–(4–(4–acetamido–2–
oxopyrimidin–1(2H)–yl)butyl)piperidin–4–yl)carbamate (5.28 g, 93%) as a 
colorless solid. 1H NMR (400 MHz, CDCl3): δ 9.56 (br s, 1H), 7.64 (d, 1H), 7.39 (d, 
1H), 4.51 (s, 1H), 3.89 (t, 2H), 2.92 (s, 2H), 2.46 (m, 2H), 2.29 (s, 3H), 2.17 (m, 
2H), 2.96 (d, 2H), 1.78 (m, 2H), 1.57 (m, 2H), 1.44 (s, 12H). 
Step 3: tert–Butyl(1–(4–(4–acetamido–2–oxopyrimidin–1(2H)–yl)butyl)pip–
eridin–4–yl)carbamate (5.26 g, 14.4 mmol) was dissolved in MeOH (100 mL) and 
ammonium hydroxide (10 mL) was added. The vessel was placed in a preheated 
oil bath at 50 °C and stirred for 2h. After cooling, the solution was evaporated to 
dryness under reduced pressure. It was recrystallized from ethanol to yield tert–
butyl (1–((4–amino–2–oxopyrimidin–1(2H)–yl)methyl)piperidin–4–yl)carbamate 
(3.26 g, 70%) as a colorless solid.  
Step 4: To a 100 mL round bottom flask containing tert–butyl (1–((4–amino–





and CDI (0.20 g, 0.84mmol) was added dry CH2Cl2 (30 mL) and the mixture was 
stirred for 16h under a nitrogen atmosphere. The solvent was evaporated under 
reduced pressure and tert–butyl (1–((4–(1H–imidazole–1–carboxamido)–2–
oxopyrimidin–1(2H)–yl)methyl)piperidin–4–yl)carbamate was collected as a 
colorless solid. 
Step 5: To a round bottom flask containing tert–butyl (1–((4–(1H–
imidazole–1–carboxamido)–2–oxopyrimidin–1(2H)–yl)methyl)piperidin–4–
yl)carbamate (0.24 g, 0.48 mmol) and tert–butyl (2–methyl–4–oxo–4–(piperazin–
1–yl)butan–2–yl)carbamate (0.13 g, 0.48 mmol), was added. dry THF (10 mL). The 
reaction mixture was heated to reflux and stirred for 16h. The solvent was 
evaporated under reduced pressure. The residue was dissolved in EtOAc and 
partitioned between water. The organic layer was washed with water (3X 10 mL), 
and brine. The organic layer was dried over Na2SO4, filtered and concentrated 
under reduced pressure. Purification via flash chromatography yielded the tert–
butyl(1–((4–(4–(3–((tert–butoxycarbonyl)amino)butanoyl)piperazine–1–carbox–
amido)–2–oxopyrimidin–1(2H)–yl)methyl)piperidin–4–yl)carbamate as a light 
brown solid. 
Step 6: tert–Butyl (1–((4–(4–(3–((tert–butoxycarbonyl)amino)butanoyl) 
piperazine–1–carboxamido)–2–oxopyrimidin–1(2H)–yl)methyl)piperidin–4–yl) 
carbamate (0.10 g, 0.16 mmol) was dissolved in a solution of methanolic HCl (10 
mL, 2 M). The reaction mixture was stirred for 4h. The solvent was removed under 
reduced pressure. The resultant solid was triturated with diethyl ether and dried 





1–yl)butyl)–2–oxo–1,2–dihydropyrimidin–4–yl)piperazine–1–carboxamide as a 
color less solid. (67 mg, 90%).  
CZ–02–104: 1H NMR (500 MHz, CD3OD): δ 8.50 (br s, 1H), 6.80 (br s, 1H), 
4.08 (s, 2H), 3.98-3.43 (m, 11H), 3.42-3.12 (m, 4H), 2.86 (br s, 2H), 2.31 (br s, 2H), 
2.10 (br s, 2H), 1.91 (br s, 4H), 1.45 (s, 6H). 13C NMR (125 MHz, CD3OD): δ 169.5, 
159.8, 153.8, 152.6, 119.2, 94.7, 56.2, 52.5, 49.9, 45.6, 44.8, 40.8, 39.4, 27.2, 
25.4, 25.0, 20.9. LC–MS [M+H] 477.3 
 
CZ–02–089: 1H NMR (500 MHz, D2O): δ 8.08 (d, 1H), 6.52 (s, 1H), 3.84 (s, 
2H), 3.73–3.47 (m, 10H), 3.20–3.02 (m, 4H), 2.81–2.72 (m, 1H), 2.68–2.57 (m, 
1H), 2.04–1.91 (m, 4H), 1.66 (br s, 4H), 1.38 (s, 2H), 1.19 (s, 3H). 13C NMR (125 
MHz, D2O): δ 170.1, 159.4, 152.9, 152.5, 148.9, 95.6, 57.0, 51.6, 51.0, 46.2, 45.5, 
45.2, 41.8, 37.0, 28.0, 25.8, 21.5, 18.6. LC–MS [M+H] 463.4. 
 
CZ–02–101: 1H NMR (500 MHz, D2O) δ 8.05 (d, J = 7.5 Hz, 1H), 7.55 (d, J 
= 8.0 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 7.66 (d, J = 7.5 Hz, 1H), 4.28 (s, 2H), 3.56–
3.50 (m, 10H), 3.40 (t, J = 10.0 Hz, 1H), 3.06 (t, J = 13.0 Hz, 2H), 2.70 (s, 2H), 





D2O) δ 170.4, 160.6, 153.3, 151.2, 138.9, 132.6, 130.0, 127.0, 126.9, 96.5, 59.3, 
52.5, 50.1, 45.1, 44.4, 40.7, 39.2, 26.7, 24.9. LC–MS [M+H] 511.3 
 
CZ–02–103: 1H NMR (500 MHz, CD3OD): δ 8.35 (s, 1H), 7.78 (br s, 2H), 
7.59 (br s, 2H), 6.79 (s, 1H), 4.44-4.41 (m, 2H), 3.76–3.57 (m, 7H), 3.42 (d, 2H), 
3.20 (s, 2H), 2.75 (s, 2H), 2.24–1.95 (m, 4H), 1.49 (s, 2H), 1.34 (s, 8H). 13C NMR 
(125 MHz, CD3OD): δ 169.5, 159.7, 153.6, 152.6, 146.6, 94.6, 69.9, 55.8, 52.6, 
50.5, 49.8, 44.5, 40.6, 39.3, 32.2, 25.2, 25.0, 20.8, 19.6. LC–MS [M+H] 491.3. 
 
 
CZ–02–107: 1H NMR (500 MHz, D2O): δ 8.06 (d, J = 7.5 Hz, 1H), 6.50 (br 
s, 1H), 4.78 (s, 2H), 3.85 (br s, 2H), 3.72 (d, J = 13.0 Hz, 1H), 3.63–3.53 (m, 10H), 
3.45–3.37 (m, 1H), 3.05 (br s, 2H), 2.97 (t, J = 13.0 Hz, 1H), 2.18 (d, J = 13.0 Hz, 
1H), 1.83–1.65 (m, 2H), 1.67 (br s, 4H), 1.51 (s, 3H). 13C NMR (125 MHz, CD3OD): 
δ 169.2, 161.1, 155.7, 153.8, 147.7, 95.8, 65.3, 64.6, 57.5, 52.1, 51.4, 50.0, 47.0, 






CZ–02–117: 1H NMR (500 MHz, CD3OD): δ 7.73 (d, J = 7.5 Hz, 1H), 6.58 
(d, J = 7.5 Hz, 1H), 3.91 (br s, 2H), 3.86–3.82 (m, 4H), 3.76 (d, J = 11.0 Hz, 1H), 
3.64 (br s, 4H), 3.47 (d, J = 11.0 Hz, 1H), 2.53 (br s, 2H), 2.44–2.39 (m, 4H), 
1.74–1.68 (m, 2H), 1.61–1.54 (m, 6H), 1.33 (s, 3H), 1.14 (s, 3H). 13C NMR (125 
MHz, CD3OD): δ 176.1, 163.0, 159.6, 155.3, 148.0, 99.9, 71.1, 60.8, 59.1, 50.9, 
50.7, 50.0, 48.5, 46.2, 45.3, 39.7, 28.2, 24.7, 23.2. LC–MS [M+H] 493.3 
 
CZ–02–132: 1H NMR (500 MHz, CD3OD): δ 7.70 (d, J = 8.0 Hz, 1H), 7.37 
(d, J = 8.5 Hz, 2H), 7.34 (d, J = 8.5 Hz, 2H), 6.64 (br s, 1H), 3.91 (br s, 2H), 3.89–
3.82 (m, 4H), 3.79 (d, J = 11.5 Hz, 1H), 3.70–3.64 (m, 4H), 3.50 (d, J = 11.5 Hz, 
1H), 3.07 (d, J = 11.5 Hz, 2H), 2.98–2.93 (m, 1H), 2.89 (t, J = 11.5 Hz, 2H), 2.22–
2.14 (m, 2H), 1.96 (d, J = 11.5 Hz, 2H), 1.62–1.54 (m, 2H), 1.36 (s, 3H), 1.14 (s, 
3H). 13C NMR (125 MHz, CD3OD): δ 175.6, 162.8, 160.1, 154.5, 147.6, 142.5, 
139.2, 130.9, 127.7, 100.5, 706, 61.1, 61.0, 53.0, 49.7, 46.2, 45.3, 33.9, 32.8, 30.9, 







ANTIBIOFILM ANTIMICROBIAL AGENTS  
 
Planktonic Bacteria vs Biofilm 
The surface attached aggregate of lively reproducing bacteria encased in a 
self–produced matrix is referred to as a biofilm, whereas the isolated free–floating 
bacteria are referred to as planktonic bacteria. The adherent bacteria defend 
themselves from external threats by constructing an impermeable slimy layer 
called extracellular polymeric substance (EPS) consisting of their extracellular 
DNA/RNA, proteins, and polysaccharides around them. The EPS layer anchors, 
harbors, and shields the bacterial communities and renders bacterial resistance 
(Figure 5.1).1 
 
Phases of Biofilm Life Cycle Attachment 
The life cycle of planktonic bacteria’s transition into a biofilm phenotype 
begins with its attachment to a surface via reversible weak Van der Waals forces. 
This initial attachment stage of life cycle is aided by the slimy material produced 
and excreted by the bacteria itself. According to J. W. Costerton et al., “Thus, it 
appears that attachment itself can initiate the synthesis of the extracellular matrix 
in which the sessile bacteria (biofilm) are embedded.”1 If the pioneer bacteria 





such as protein surfaces and pili. The anchored bacteria enable the adhesion of 
other bacteria by providing additional attachment sites (Figure 5.2).2  
 
Development of mature biofilm 
In the development step, the bacteria adopt two different ways to colonize: 
a) by bacterial cell division, b) by recruiting other bacteria and starting to produce 
EPS to embrace the growing biofilm. Throughout the creation of biofilm, the 
microbes bounded inside the EPS matrix can connect and talk to each other largely 
through a communication process called “quorum sensing.” Quorum sensing 
mainly serves as communication network both within single bacterial species and 
also between distinct bacterial species. A common phenomenon, where typically 
two different species of bacteria coalesce and live together as one entity, called 
“mixed–species” biofilms are seen in the lungs of patients with cystic fibrosis (CF) 
as well as in dental cavities (Figure 5.2). 3  
Another interesting aspect of a matured biofilm is that it is often equipped 
with water/nutrient channels for nutrient circulation to cells in different regions of 
biofilm. The bacteria living in deeper regions of biofilm often suffer from oxygen 
gradient and adapt to live a life of anaerobic bacteria. The biofilm lifestyle of 
planktonic bacteria helps to evolve and adapt the extreme environmental 
conditions such as nutrient gradient, pH, oxygen, temperature, and salinity 







Disintegration of saturated biofilm 
The critical phase of the biofilm life cycle is the spread and dispersal. Once 
biofilm matures and reaches saturation in density, the planktonic bacteria are 
forced to come out of EPS periodically, in search of required nutrients. J.W. 
Costerton refers to this process as “natural pattern of programmed detachment.” 
The bacteria that come out of biofilms can swiftly multiply, disperse, and invade a 
new surface and repeat the process of biofilm formation (Figure 5.2).1, 4, 5 
 
Biofilm and its Implications in Chronic  
Infections and Biofouling 
Planktonic bacteria are responsible for a majority of acute infections, 
whereas chronic infections are the consequences of biofilms.2, 6 The chronic 
infections caused by biofilm phenotype are tough to treat. Depending on the type 
of bacteria, the biofilm phenotype can be >10 to 1000-times resistant to trivial 
antimicrobial agents compared to planktonic bacteria of a similar kind. The EPS 
around bacterial communities help biofilm to combat innate immune responses of 
the host system, and also enable resilience to environmental dangers which 
include chemical attack (conventional antibiotics), thereby causing persistent 
infections. Also, the proximity of bacteria in biofilms facilitates gene exchange 
which ultimately leads to mutations and results in the transfer of acquired antibiotic 
resistance.1, 7 
The biofilm phenotype is omnipresent and implicated in a number of 
illnesses such as diabetic foot ulcers, dental plaque, chronic sinusitis, 





fibrosis, and medical devices and implants.8, 9 The consequences of biofouling, 
unwanted deposits of biotic substances on surface implants, are also seen in 
industry settings such as degradation of oil pipes, contamination of drinking water, 
food processing industry, ship hulls, damaging of the heat exchanging equipment, 
dairy industry, cooling water plants, and the paper industry. The wet surfaces and 
nutrient–rich resources in the aforementioned industrial settings promote the 
formation and fast growth of biofilm.10, 11, 12 The detrimental biofouling 
consequences are enormous and cause an estimated financial burden of US$ 200 
billion per year to the US alone. Biofilms are responsible for two million chronic 
infections annually across the globe and result in an estimated health care cost of 
US $11 billion.13 
 
Treatment 
 Traditional antibiotics are effective in treating acute infections caused by 
planktonic bacteria. As is evident that the biofilm phenotype is the most preferred 
mode of living by most bacteria, biofilms are commonly seen in a vast number of 
clinical settings. For many years, the perception of diagnosis and treatment of 
biofilm–related infections were done in the wrong way. Clinicians have tried to treat 
biofilm–related infection by prescribing regular high doses of antibiotics. 
Unfortunately, the high doses of administered antibiotics were successful in 
weakening the biofilm temporarily but failed to destroy the biofilm permanently. As 
a result, some survival bacteria called “persister cells” are capable of regenerating 
biofilm by efficiently transferring the acquired resistance to other bacteria.19 The 





biofilm to destroy. Till today, there are no known clinical antibiotics developed 
specifically for biofilms, whereas the use of chemical bactericidal agents for 
treating biofouling in industry settings are bleach and glutaraldehyde, which can 
kill the bacteria but fail to disrupt the biofilm. 18 The undispersed EPS material will 
act as the nutrient rich source for the development of new bacterial colonies 
(biofilm). 14 
Given the implications of biofilm phenotype of different bacteria in industry 
and healthcare, there is a pressing need to develop new chemical entities (NCE) 
targeting different phases of biofilm life cycle, like compounds focused on inhibition 
or dispersion of biofilm formation or disrupting the biofilm and killing the bacteria 
residing in the biofilm.14, 15, 16 
 
Targeting the biofilm phenotype 
In vitro studies have demonstrated that it is very easy to treat young biofilms 
using existing regular antibiotic regimen in contrast with matured biofilm.17 
Therefore, early diagnosis and an aggressive antibiotic prescription are preferred 
to treat biofilm infections. However, early diagnosis of biofilms is a challenging 
task, as most of the chronic infections are rooted to a matured biofilm phenotype, 
which is difficult to treat with existing antibiotics. The two popular, viable targets for 
the control of biofilm infections are: A) the EPS consisting of poly–anionic 
polysaccharide alignment; B) The other being “quorum sensing” used by bacteria 
in biofilms to communicate with each other.18, 19 
Very little is known and pursued in the field of developing antibiofilm 





their pivotal studies, they showed that the biogenetic polyamines such as 
spermidine, and norspermidine are capable of inhibiting biofilm formation. These 
polyamines are produced at high concentrations (50–80 M) inside matured 
biofilms, in response to nutrient gradient and toxic waste accumulation and results 
in biofilm dispersal. Norspermidine is a better natural inhibitor of biofilm formation 
with MBIC= ~25 M (minimum biofilm inhibitory concentration) compared to 
spermidine MBIC= ~1 mM. In addition, subtle changes in the structure of 
polyamines (additional methylene unit in spermidine compared to norspermidine) 
can have a radical impact on activity in biofilm regulation. Further, they have also 
shown that the addition of exogenous norspermidine has resulted in inhibition of 
biofilm formation in different bacterial species (B. subtilis, E. coli, and S. aureus). 
More importantly, this activity difference prompted the possibility of polyamine’s 
role in biofilm functioning. However, the findings from Losick, Clardy et al. are in 
complete contradiction to the initial reports of Watnick and co–workers, on the role 
of polyamines in quorum sensing and biofilm physiology.20, 21, 22 Key findings from 
their study on Vibrio Cholera reveals that protein NspS, a polyamine sensor, 
regulates the biofilm functioning in V. Cholera by sensing the presence of 
norspermidine in particular. Based on their reports norspermidine promotes biofilm 
formation at lower concentration (10 M) than spermidine (1mM). 23  
While the role of polyamines in formation or disintegration of the biofilms 
remain ambiguous, identification of potent antimicrobial agents possessing 
polyamine motifs in their structures (e.g., squalamine and spermine–squalamine 





molecules focused on biofilm control.20, 21, 22 Inspirations for our rational design of 
polyamine antibiotics stems from structural observations of polyamine frameworks 
in broad spectrum antimicrobials cationic antimicrobial peptides (AMPs such as 
meganin, pexiganin, and polymixin B), the ceragenins (cationic steroidal antibiotics 
such as CSA–13). However, the in vivo applications of these small molecules are 
limited due to their hemolytic properties and cytotoxicity (lack of selectivity for 
mammalian cell membranes over bacterial cell membranes).24, 25. 
 
Design and Synthesis of First Generation  
Antibiofilm Antibiotics 
 Acknowledging the significance of polyamines (hydrophilic) attached to a 
hydrophobic backbone, the Looper group designed and developed compounds by 
merging these two characteristics. Our hypothesis in the rational design of 
polyamine containing hydrophobic frameworks attributes to combine the 2–fold 
“kill” and the “dispersal” properties in a single entity to eradicate biofilms 
completely. The initial set of compounds has polyamines (charged termini) 
attached to an aryl (phenyl) hydrophobic backbone. Interesting conclusions can be 
drawn from the SAR studies carried out on monoaryl polyamine derivatives. 
Compounds containing a tri–amine separated by three carbons as in 
norspermidine as a cationic tail are more active than others. In vitro activity of some 
of these compounds against MRSA (methicillin–resistant staphylococcus aureus) 
is shown in Figure 5.5. The compound CZ–01–052 (MIC = 4.5 g/mL) with three 
norspermidine chains attached off of the benzene ring at 1, 3, 5 positions is more 





positions, which in turn is more active than CZ–01–007 (MIC = >800 g/mL) 
consisting of just one norspermidine moiety.26  
   The compounds in the first generation were synthesized using commercially 
available aldehydes, such as benzaldehyde, substituted benzaldehyde, 
isopthaladehyde, and benzene–1,3,5–tricarboxaldehyde. Further SAR on the 
monophenyl backbone is limited by the availability of feed stock chemicals. In 
future endeavors, we sought to access diversified hydrophobic backbones through 
chemical synthesis and work out an SAR with identified potent polyamine 
norspermidine and N–alkyl–norspermidine. 
 
Design and Synthesis of Second Generation  
Antibiofilm Antibiotics 
 Although, the first generation analogs are simple in structure, easy to 
prepare, and cost effective, the biological activity profile was modest. Further 
modifications are required to develop these compounds as potent antibiofilm 
antibiotics. The synthetic procedures involved in first generation analogs 
preparation lack diversity. To explore further SAR possibilities, we needed a 
synthetic handle for diversification. In the design of second generation analogs, we 
intend to maintain the optimal ratio of hydrophilic and hydrophobic properties 
(charge to grease ratio) in our compounds. To access branched aldehydes, we 
plan to deploy a Suzuki–Miyaura cross–coupling reaction of 5–
bromoisopthaladehyde and a variety of commercially available boronic acids.  
We began our efforts to synthesize branched aldehydes by synthesizing 5–





reported protocol in the literature.26 Aromatic m–bromination of isopthalaldehyde 
using Sulfuric acid and NBS resulted in 5–bromo–isophthalaldehyde 2. The 
resultant aryl bromide was reacted with phenyl boronic acid under optimized 
Suzuki–Miyaura cross–coupling conditions to yield 5–Phenyl–isopthalaldehyde 
3.27, 28 Subsequently, bi–aryl–bis–aldehyde was reductively aminated using Boc–
norspermidine to form an alkylated bi–aryal amine. Further, Boc deprotection using 
Methanolic HCl affords the final compound CZ–01–058 as the Hydrochloride salt 
(Scheme 5.1). 
Using the optimized sp2–sp2 cross–coupling protocol we were able to 
synthesize a variety of branched aldehydes as shown in Figure 5.6.   
The aldehydes synthesized were further used in reductive amination with 
Boc–norspermidine and N–alkyl norspermidines to result in biaryl polyamines. 
Deprotection of resultant Boc–protected polyamines yielded series of analogs 
(Figure 5.7) synthesized using a protocol similar to CZ–01–058 (Scheme 5.1).  
 
Assessment of potency of CZ–01 series of compounds 
The potency against planktonic and bacteria in biofilm phenotype (biofilm 
killing ability) of CZ–01 series of compounds is evaluated using the following 
methods: 
a) Minimum Inhibitory Concentration (MIC) against planktonic bacteria is 
measured as the concentration of the antimicrobial required to attain a 3-log 
reduction from 105 colonies–forming units (CFU)/mL to 102 CFU/mL over a 24–





b) Minimum Biofilm Eradication Concentration (MBEC) against moderate 
biofilms (103–105) CFU is measured as the concentration of the antimicrobial 
required to attain a three log reduction from 105 CFU/peg to 102 CFU/peg for Gram 
(-) bacteria or one log reduction from 103 CFU/peg to 102 CFU/peg for Gram (+) 
bacteria in an MBEC system developed by Innovotech. 
c) Effective Biofilm Eradication Concentration (EBEC) against heavy 
biofilms (109 CFU) is measured as the concentration required producing a 7-log 
reduction in the number of biofilm bacteria, grown on the surface of polycarbonate 
coupons in a CDC biofilm reactor, in 24h. 
The compounds synthesized were screened for antimicrobial activity. As 
shown in Table 5.1, all these bi–aryl polyamines, in particular, CZ–01–058, 62, 65, 
66, have better activity than the first generation analogs, which supports our 
hypothesis of adding hydrophobic character to the polyamine tail to increase 
potency. CZ–01–062 / 63 with three norspermidine cationic residues on a biphenyl 
system is more active compared to CZ–01–058 with two norspermidine chains. It 
is to be noted that all the four active analogs have three norspermidine chains 
except CZ–01–058. The best among the top four compounds is CZ–01–065, with 
one of the three norspermidines attached at the para position. However, none of 
these compounds showed notable activity (clinical standard) to be selected as a 
lead compound. Another important thing we observed is, too much hydrophobic 
character with these compounds does not benefit a great deal to improve the 
efficacy. This can be seen with analog CZ–01–070 with two CF3 groups almost 





Given the better activity of para–substituted analog, we thought to provide 
more degrees of freedom for norspermidine chains on both aryl rings.  In order to 
do this, we prepared bi–aryl ether, and alkyl aryl ethereal bis–aldehydes and 
generate analogs off of these aldehydes. The synthesis of bis–aldehyde biphenyl 
ether was achieved via a copper acetate mediated oxidative Chan–Lam coupling 
reaction of 5–Hydroxy–dimethyl isopthalate 4 with phenyl boronic acid followed by 
a Red–Al reduction of bis–ester 5 to bis–aldehyde 6 as illustrated in Scheme 5.2.29 
On the other hand, the alkyl–aryl ethereal bis–aldehyde was generated by 
a nucleophilic substitution reaction (SN2 reaction) of phenoxide generated from 
dimethyl–5–hydroxy isopthalate 4 onto benzyl bromide, followed by the Red–Al 
reduction of resultant ester 7 to aldehyde 8. The two ethereal bis–aldehydes 
prepared were treated with Boc–norspermidine under reductive amination 
conditions to afford protected polyamine derivatives. The final Boc deprotections 
resulted in polyamines as hydrochloride slats (shown above in Scheme 5.2). 
The biological activity of these polyamines with the ether backbone were 
less potent than the existing analogs. They did slightly better against Gram (–) 
bacteria compared to their counterpart CZ–01–058 (Table 5.2). We have made 
various aryl–alkyl ethereal polyamines with different substitution patterns, but none 
of them showed a promising enough biological profile. Further, these compounds 
involve a tedious synthetic procedure compared to the di aryl analogs which makes 
it difficult to further pursue this series of compounds. We then focused on 
increasing the hydrophobic nature of these ployamines by adding substitutions off 





derivatives with substitution on the terminal amine of norspermidine at either end. 
At the beginning, we started accessing the bis–N3–alkylated polyamines via 
a selective reductive amination of terminal 1o amine of the free bases of final 
compounds with different aldehydes (e.g., shown in Scheme 5.3A).  We observed 
inconsistencies in biological evaluation with respect to different batches of the 
synthesized analogs. We attribute this anomaly in biological activity to the 
impurities formed under the reaction conditions (<5 % –imperceptible through 
NMR) in synthetic sequence. The issue was addressed by optimizing a linear 
synthetic route for the side chains used in the preparation of CZ–01 compounds 
as shown in Scheme 5.3B. 
The side chain synthesis began with reductive amination of amino propanol 
9 with isobutaraldehyde to afford N–isobutyl amino propanol 10. The alcohol in 10 
was activated to bromide 11 followed by an SN2 reaction with 1,3–diaminopropane 
resulted in pure N1–isobutyl norspermidine 12 after the excess 1,3–
diaminopropane was distilled under vacuum. The final CZ compounds were 
prepared by using the alkylated norspermidines synthesized by the above protocol, 
resulting in better purity and fewer byproducts (Scheme 5.3C). 
 Analogs pertaining to CZ–01–058 series were synthesized using different 
alkylated norspermidines by employing similar reaction sequence mentioned 
above in Scheme 5.3B and 5.3C. Interesting biological activity profiles were 
observed when the synthesized bis–N3–alkylated polyamines were screened for 
their proposed antibiotic activity. All these compounds did well against MRSA with 





(hydrophobic with extra methyls) with MIC’s >10 g/mL. All of these N–alkylated 
polyamine containing compounds were more active against Gram (–) bacteria 
compared to their unsubstituted counterpart CZ–01–058 analog.  
Having seen their biological activity (Table 5.3), we were excited to see the 
activity profiles of tris–aldehydes with three substituted norspermidines. We 
synthesized the CZ–02–062 series of compounds with three substituted 
norspermidine chains on bi–aryl backbone.  
 The bi–aryl polyamines substituted with three units of N–alkylated 
norspermidine have shown impressive activity profiles, particularly CZ–01–122 
with N–octyl norspermidine which showed broad spectrum activity with MIC’s of 2 
µg/mL aginst Gram (+) MRSA and 3.5 µg/mL against Gram (–) P. aeruginosa.  
Analogs with CZ–01–140 / 127 have better activity against MRSA compared to P. 
aeruginosa. CZ–01–099 with N–isobutyl norspermidine cation linker is not active 
against Gram (–) bacteria, and shows moderate efficacy against MRSA as 
depicted in Table 5.4.26 
The notable clinically relevant broad–spectrum activity of some of these 
compounds has prompted us to pursue further biological profiling. ADME–toxicity 
studies of these compounds using the international standard ISO 10993 L929 
fibroblast cell lysis assay confirmed the in vitro efficacy of these compounds is 
related to their associated cytotoxicity. The potency and cytotoxicity are often 
associated with the hydrophobicity (increased cLogP) of the compounds. Also, 
polyamines are notoriously responsible for causing hemolysis and toxicity. 





is possibly more potent as well as cytotoxic by virtue of its higher cLogP (polarity; 
hydrophilicity and hydrophobicity of the compounds, calculated theoretically from 
the structures using maestro–11 Schrödinger software and Chemdraw software). 
All the three compounds except CZ–01–099 scores a score of 4 at 12.5 µg/mL or 
50 µg/mL (score of 0, 1, or 2 is a pass, and 3, or 4 is a fail). Surprisingly, CZ–01–
099 shown to be noncytotoxic (score of 0 even at 1000 µg/mL), thus translating to 
a therapeutic window of ~500. 
Since the beginning of the synthesis of bi–aryl polyamines, we wanted to 
synthesize the derivatives using tetra–aldehyde. Our Initial attempt to access the 
bi–phenyl tetra–aldehyde failed, and ended up isolating the proto–de–boralated / 
proto–de–brominated by product (i.e., isopthalaldehyde, 30%) from the reaction 
mixture. We might have lost the desired product in column purification in the first 
attempt, owing to its insoluble nature (insoluble in any known solvent). Taking into 
account the therapeutic index of CZ–01–099, and with intent to synthesize tetra–
substituted version of CZ–01–099, we revisited the reaction sequence and 
accomplished the synthesis of CZ–01–189, tetra–aldehyde and eventually bi–
phenyl derivative with four isobutyl norspermidine chains attached. 
The pursuit began with the conversion of 5–bromoisopthalaldehyde to 
pinacol boronate ester, followed by a Suzuki–Miyaura cross–coupling with 
resultant boronate ester and 5–bromoisopthalaldehyde gave bi–phenyl tetra–
aldehyde. The solid crashed out in the reaction mixture was filtered and washed 
with water and subsequently with ethyl acetate, to remove organic and inorganic 





and reacted under reductive amination conditions with isobutyl norspermidine to 
give the final product CZ–01–189 as hydrochloride salt upon treatment with 
Methanolic HCl as depicted in Scheme 5.4. When tested for biological activity, CZ–
01–189 had comparable MIC’s with CZ–01–099. However, it was shown to be 
cytotoxic.  
 
Biological Profiling of CZ–01–099 
 The selectivity index of CZ–01–099 has opened new avenues for this 
project. Efforts were focused on further modifications of side chain substitutions 
and the bi–phenyl backbone itself. Further, it also inspired the synthesis of 
terphenyl, and tri–aromatic systems and their amine conjugates with various 
substituted polyamines. As further SAR studies on CZ–01–099 series is in 
progress, we carried out detailed biological profiling of CZ–01–099. 
  
Biofilm dispersal abilities of CZ–01–099 
When screened against various Gram (+) and Gram (–) planktonic as well 
as biofilm phenotype, CZ–01–099 showed appreciable activity against Gram (+) 
bacteria (MRSA, B. subtilus, S. aureus, L. monocytogenes) except M. tuberculosis, 
and not active against gram (–) ve bacteria. Further, in qualitative biofilm dispersal 
assays, CZ–01–099 is tested in comparison with glutaraldehyde, and vancomycin 
for its ability to disperse well established biofilm grown on stainless steel titanium 
plates. It was confirmed through scanning electron microscopy (SEM) imaging 
technique that the CZ–01–099 is a more effective biofilm disperser compared to 





vancomycin (a known first line antibiotic commonly used in treating MRSA related 
infections), and the existing biocidal agent glutaraldehyde (as positive control, 
ineffective in dispersing the biofilms) as seen in Figure 5.10. 
 
Applications of CZ–01–099 as topical medication 
Considering the biofilm dispersal abilities of CZ–01–099, and its lack of 
cytotoxicity, we advanced to investigate its in vivo biocidal efficacy profile in a 
topical wound model using Yorkshire pigs. Using 1 cm biopsy punch a total 24 (12 
each side and in 4 sections of 6) second degree burn wounds were created on a 
pig back. Twelve wounds on one side were inoculated with MRSA planktonic 
bacteria, and the twelve wounds on the other side with well–established MRSA 
biofilm phenotype. After elevn days of infection development, the two sections of 
wounds (six wounds with planktonic MRSA and six wounds with MRSA biofilm) 
were left untreated, and the other two sections were treated with 2% of CZ–01–
099 along with 200 ppm AgNO3 for 14–day period. The pig was mercy killed after 
the treatment period, and the culture swabs from each wound were streaked on 
CHROM–agar (used to diagnose MRSA) plates (Figure 5.10).  
 As can be seen in Figure 5.10, the wounds inoculated with planktonic MRSA 
both treated with CZ–01–099 (top right), and untreated (top left) do not show the 
growth of MRSA in agar plates. This means CZ–01–099 can kill planktonic MRSA, 
and similarly pigs’ immune system can take care of infections related to planktonic 
MRSA, whereas, the MRSA growth can be seen (bottom left) in the plates streaked 
with culture swabs of MRSA biofilm related wounds, but not from the wound treated 





01–099+AgNO3 had re–epithelialized by day 25. In contrast, the untreated wounds 
inoculated with established biofilms have developed signs of chronic infection such 
as irregular wound borders and early growth of necrotic tissue. This topical wound 
study clearly demonstrates the ability of CZ–01–099 to kill the bacteria in biofilm 
phenotype. 
 
Resistance development assay 
 One of the serious global health threats in the present–day world is 
antibiotic resistance. Bacteria have come up with strategies to combat the current 
antibiotic regimen. Bacteria develop drug resistance to all the available antibiotics 
over a period, but a lower frequency of mutation is an ideal characteristic of a 
promising lead compound. The clinical isolates of MRSA were subjected to sub-
MIC levels of CZ–01–099, and the persisting cells were grown in fresh media and 
resubjected to sub–MIC levels. This process was repeated, and the MRSA isolates 
were passed through a series of 19 passages. The MIC and MBC of CZ–01–099 
was consistent at 6 g/mL throughout 19 passages albeit with minimal changes. 
In fact, the isolates after the 15th passage started growing at a slower rate on an 
agar plate, indicative of the ability of CZ–01–099 to weaken the isolates of MRSA. 
On the other hand, MIC stayed constant, but MBC of vancomycin faded after the 
12th passage. The cultures were withdrawn and disposed of fearing a danger of 









 Through the synthesis second generation analog aimed at modifying the 
hydrophobic backbone of poly cationic amines, we developed a novel class of anti–
biofilm antibiotics. We identified CZ–01–099 as a potential lead and further 
biological profiling under progress. This series of compounds has demonstrated 
broad spectrum activity, and biofilm dispersal properties. Further SAR on CZ–01–








Scheme 5.1 Synthesis of CZ–01–058 
 
Scheme 5.2 Synthesis of compounds with aryl–alkyl etherial linkage.  
A) Synthesis of biphenyl bis–aldehyde. B) Synthesis of benzyl phenyl bis–






Scheme 5.3 Optimized protocol for the synthesis of CZ–01–086. (A) Initial 
protocol for the synthesis of CZ–01–086. (B) Reaction sequence for the 
preparation of Isobutyl norspermidine side chain. (C) Reductive amination of bis–













Table 5.1 In vitro antibacterial activity of CZ–01 series second generation 
analogs against MRSA and pseudomonas aeruginosa. 
 
Compound MIC–MRSA (µg/mL) MIC– P. aeruginosa (µg/mL) 
CZ–01–058 7.3 (n=9) 50 
CZ–01–062 4.64 18 
CZ–01–065 2 14.5 
CZ–01–066 5.1 19.3 
CZ–01–067 NT NT 
CZ–01–069 >10 >20 
CZ–01–070 >5 20 
CZ–01–071 >5 20 
 
Table 5.2 Comparison of antibacterial activity of CZ–01–074 and CZ–01–095 to 
their counterpart CZ–01–058 
 
Compound MIC–MRSA (µg/mL) MIC– P. aeruginosa (µg/mL) 
CZ–01–058 7.3 (n=9) 50 
CZ–01–074 8 >25 








Table 5.3 Comparison of antibacterial activity of N–alkylated derivatives of CZ–
01–058 series of analogs 
 
Compound MIC–MRSA (µg/mL) MIC– P. aeruginosa (µg/mL) 
CZ–01–058 7.3 (n=9) 50 
CZ–01–086 8.1±4.1 (n=10) 25 
CZ–01–092 2 10.0 
CZ–01–096 2 30 
CZ–01–111 5 10 
CZ–01–112 10 >30 
CZ–01–114 1 10 
CZ–01–118 1 10 
 
Table 5.4 Comparison of antibacterial activity of N–alkylated derivatives of CZ–




MIC– P. aeruginosa 
(µg/mL) 
cLogP 
CZ–01–065          2 14.5 1.01 
CZ–01–099        5.8 200 7.29 
CZ–01–127         3 18 10.9 
CZ–01–128         2 3.5 14.0 









Figure 5.1 Cryo–scanning electron microscope images of planktonic bacteria and 
biofilm phenotype4–5 
 
Figure 5.2 Life cycle of a biofilm: 1) Attachment of planktonic bacteria to a 
surface 2) EPS secretion and irreversible attachment 3 and 4) Formation of a 
matured biofilm 5) Biofilm disintegration and release of bacteria 6) Planktonic 







Figure 5.3 Compounds with polyamine tail attached to a hydrophobic backbone. 
(a) Squalamine with spermidine polyamine tail attached to a steroidal backbone 
(b) Cationic steroidal antibiotic aka. Ceragenin’s – CSA–13 







Figure 5.4 Design and antibacterial activity of CZ–01–analogs 
 
 























Figure 5.8 CZ–01–062 series of compounds with N–substituted norspermidine 
 






Figure 5.10 Topical wound model, swab cultures grown on CHROM–agar plates 
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